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Abstract:  
Solid tumours display vast heterogeneity in oxygen tension as a consequence 
of poor vascularization and increased proliferation. Tumour hypoxia (low 
oxygen) is associated with poor prognosis as cells within this harsh 
microenvironment are viable and often resistant to chemotherapy and 
radiotherapy. The cellular response to hypoxia is regulated by transcription 
factors called hypoxia inducible factor (HIF). HIF is a heterodimeric protein 
consisting of an O2-labile subunit (HIF-1α, HIF-2α and HIF-3α) and a beta 
subunit (HIF-1β). Expression of either HIF-1α or HIF-2α often correlates with 
poor prognosis. HIFα is degraded by a well characterized pathway, however 
numerous studies have shown multiple novel regulators that also effect HIF 
activity and stability. Such novel regulators could therefore represent new 
therapeutic targets for the development of novel anti-cancer therapies for those 
tumours with high levels of hypoxia. 
 
In order to identify novel regulators of HIF, we undertook an unbiased 
approached and performed an RNAi kinome screen. Through this, we identified 
the bifunctional enzyme Coenzyme A synthase (CoAsy) as a novel negative 
regulator of HIF-1 transcriptional activity. Knockdown of CoAsy stabilizes both 
HIF-1α and HIF-2α in normoxia and hypoxia with no change in HIF-1β protein 
levels. Overexpression of PANK1, the rate limiting step in CoA biosynthesis, 
resulted in reduced HIFα expression thereby highlighting a role of Coenzyme 
A in regulating HIF stability. Analysis of breast cancer patients shows reduced 
COASY mRNA expression in the tumour compared to surrounding tissue and 
furthermore lower CoAsy expression is often found in triple negative breast 
cancer tumours compared to hormone sensitive tumours. 
 
These data indicate that CoAsy is a novel negative regulator of HIFs and 
highlights a novel link between Coenzyme A biosynthesis and cellular hypoxic 
response.    
    
    
5 
 
    
    
Acknowledgements: 
 
First and foremost I would like to thank Professor Tyson Sharp, for giving me 
the opportunity to work in his lab. Tyson has always been an endless supply of 
energy and enthusiasm. This project is very much a product of many ‘What 
about this?!’ and ‘Have you thought about trying this?’ moments, even though 
the project has nothing to do with LIMD1!  
 
I would also like to thank the fantastic collaborators throughout this project. 
Professor Ivan Gout for providing key reagents and sharing his knowledge of 
CoA biology. To Dr. Ian Spendlove for aiding me in the IHC staining and 
analysing the samples and finally to Dr. Daniel Tennant, for his metabolomics 
expertise and valuable insight in hypoxic cell metabolism. Also Katiuscia, 
Gyorgy, Susana and everyone else who has helped throughout the project.  
 
I would also like to thank all the ‘Sharpies’ that I have had the pleasure of 
sharing a bay with over the years. In particular the fantastic post-docs who have 
taught me so much over the years. Dan, who taught me almost every technique 
I know and use today. Katherine, who really taught me how to think like a 
scientist, and question data properly. Kunal, for his depth of knowledge in 
technical assays and for tolerating my ‘jokes’ so patiently for years. And finally 
John, who is always there when times are tough for a motivational pep talk over 
a beer or two. Also the PhD students; Katy, Yigen and Paul. We have shared 
many hours in the lab together, but they would have felt so much longer without 
the constant jokes and banter between us.  
 
Finally to my family and friends, there are too many of you to mention by name, 
but your constant love and support has helped me throughout this project. For 
that I am, and always will be, eternally grateful.  
 
 
 
6 
 
Abbreviations 
2-HG   2-hydroxygluturate 
Ab  Antibody 
a-KG  Alpha-ketogluturate  
bHLH  Basic helix-loop-helix  
ccRCC Clear cell renal cell carcinoma 
CDK  Cyclin-dependent kinase 
cDNA  Complimentary deoxyribonucleic acid 
CDS  Coding sequence 
CoA  Coenzyme A 
COASY Coenzyme A Synthase 
DCIS  Ductal Carcinoma in situ 
DLL3  Delta like canonical notch ligand 3 
DMEM Dulbecco’s modified eagle medium 
DNA  Deoxyribonucleic acid 
DPCK   Dephospho-CoA Kinase 
E2F  Eukaroytic transcription factor 
eGFP  Enhanced green fluorescent protein 
EGFR  Epidermal growth factor receptor 
EMT  Epithelial to mesenchymal transition 
ER  Oestrogen receptor 
FDA  Federal drug association 
FIH  Factor-inhibiting HIF 
FISH  Fluorescent in situ hybridisation 
GFP  Green fluorescent protein 
GST  Glutathione-S-transferase 
HDAC  Histone deactylase 
HER2  Human epidermal growth factor receptor 2 
HIF  Hypoxia-inducible factor 
HRE  Hypoxic responsive element 
HSP70 Heat shock protein 70 kDa 
IDH  Isocitrate dehydrogenase 
kDa        Kilodalton 
LATS1/2 Large tumour suppressor kinase 1/2 
LIMD1  LIM-domains containing protein 1 
MAPK  Mitogen activated protein kinase 
mRNA  Messenger ribonucleic acid 
MST1/2 Mammalian ste20-like protein kinase 1/2 
mTOR Mechanistic target of rapamycin 
NSCLC Non-small cell lung cancer 
ODD/ODDD Oxygen dependent degradation domain   
OXPHOS Oxidative phosphorylation 
PANK  Pantothenate Kinase 
PAS  Per-ARNT-Sim Domain 
PCR  Polymerase chain reaction 
PD-1  Programmed death receptor 1 
PDGFB Platelet derived growth factor B 
PD-L1  Programmed death ligand 1 
PHD  Prolyl-4-hydroxylase 
PPAT  Phosphopantetheine adenyltransferase 
7 
 
PPP  Pentose phosphate pathway 
PR  Progesterone receptor 
pRB  Retinoblastoma protein 
RCC  Renal cell carcinoma 
RING  Really interesting new gene 
RNA  Ribonucleic acid 
RNAi  RNA interference 
ROS  Reactive oxygen species 
RPMI  Roswell park memorial institute medium 
SCLC  Small cell lung cancer 
shRNA Short-hairpin RNA 
siRNA  Short interfering RNA 
SIRT1  Sirtuin 1 
SLC2A1 Solute carrier family 2 member 1 
TAD  Transactivation domain 
TCGA  The cancer genome atlas 
TetR  Tetracycline responsive element 
TMA  Tissue microarray 
TNBC  Triple negative breast cancer 
TSS  Transcriptional start site  
UTR  Untranslated region 
VEGF  Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VHL  Von Hippel-Lindau 
WT  Wild-type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
Table of Contents 
1. Introduction ......................................................................................................... 15 
1.1.1 The hallmarks of cancer .............................................................................. 15 
1.1.2 Lung Cancer ............................................................................................... 17 
1.1.3 Breast cancer .............................................................................................. 22 
1.2 Hypoxia in cancer .......................................................................................... 25 
1.3 Hypoxia inducible factors are responsible for cellular response to changes in 
O2 tension ............................................................................................................ 26 
1.4 O2 dependent regulation of HIFα protein stability and activity ........................ 30 
1.4.1 Prolyl-hydroxylation of the ODDD in HIFα ............................................... 30 
1.4.2 Regulation of HIF by the von Hippel-Lindau protein complex................... 32 
1.4.3 Factor-inhibiting HIF negatively regulates HIF transcriptional activity ...... 36 
1.5 HIFs in cancer................................................................................................ 37 
1.5.1 Expression of HIFα often correlates with poor patient outcome ............... 37 
1.5.2 HIF target genes in cancer ...................................................................... 38 
1.6 Non-canonical regulation of HIFs ................................................................... 47 
1.6.1 Differential regulation of HIF-1α and HIF-2α by mTOR ............................ 47 
1.6.2 Direct or indirect post-translational modifications that regulate HIFs ........ 47 
1.6.3 Emerging role of metabolites as regulators of HIFs ................................. 53 
1.7 Aims .............................................................................................................. 57 
2.1 Buffers and materials ..................................................................................... 58 
2.1.1 Materials and solutions for bacterial culture ............................................. 58 
2.1.2 Solutions for DNA agarose electrophoresis ............................................. 58 
2.1.3 Cell lysis buffers ...................................................................................... 59 
2.1.4 Solutions for SDS-Page and Western blotting ......................................... 59 
2.2 Bacterial culture ............................................................................................. 60 
2.2.1 Transformation of chemically competent cells ......................................... 60 
2.2.2 Plasmid DNA extraction from bacteria cultures ........................................ 61 
2.3 Nucleic acid techniques ................................................................................. 62 
2.3.1 Agarose gel electrophoresis of DNA ........................................................ 62 
2.3.2 Extraction of DNA from agarose gels ....................................................... 63 
2.3.3 Restriction enzyme digest of DNA ........................................................... 63 
2.3.4 Ligation of digested DNA insert into linearised vector .............................. 63 
2.3.5 DNA amplification by polymerase chain reaction (PCR) .......................... 64 
2.3.6 Site directed mutagenesis (SDM) ............................................................ 65 
2.3.7 Nucleic acid extraction from cultured cells ............................................... 65 
2.3.8 Real-time quantitative reverse transcription PCR (RT-qPCR) .................. 66 
2.4 Cell culture ..................................................................................................... 68 
9 
 
2.4.1 Culturing of cells in 2D monolayer ........................................................... 68 
2.4.2 Cell Freezing ........................................................................................... 70 
2.5 Transfection of nucleic acids to 2D cultured cells ........................................... 70 
2.5.1 Transfection of plasmid DNA with ViaFect™ ........................................... 70 
2.5.2 Transfection of siRNA with Dharmafect™................................................ 70 
2.6 Lentirviral transduction to produce stable cell lines ........................................ 71 
2.7.1 Analysis of cell proliferation using Incucyte .............................................. 72 
2.7.2 Analysis of cell proliferation using Countess II cell counter ...................... 72 
2.7.3 Clonogenic assays .................................................................................. 73 
2.7.4 Wound healing assay .............................................................................. 73 
2.8 Protein expression analysis ........................................................................... 74 
2.8.1 Sample collection and protein quantification ............................................ 74 
2.8.2 Western blot ............................................................................................ 74 
2.8.3 Immunoprecipitation assays .................................................................... 76 
2.8.4 Immunohistochemistry............................................................................. 77 
2.9 siKinome Screen ............................................................................................ 78 
2.9.1 siKinome library ....................................................................................... 78 
2.9.2 siKinome screen protocol ........................................................................ 78 
2.9.3 siKinome screen analysis ........................................................................ 79 
2.10 Labelled glucose metabolomics sample preparation .................................... 79 
2.11 FDA approved drug library screen ............................................................... 79 
3.1 Chapter aims ..................................................................................................... 82 
3.1.1 Generation of a stable HIF reporter cell line ................................................ 82 
3.1.2 Optimisation of arrayed RNAi kinome screen .............................................. 86 
3.1.2.1 Optimisation of transfection reagent ..................................................... 86 
3.1.2.2 Optimisation of cell viability reagent ...................................................... 87 
3.1.3 Primary siRNA kinome screen .................................................................... 88 
3.1.4 Secondary validation siRNA screen ............................................................ 91 
3.1.5 Coenzyme A synthase (CoAsy) .................................................................. 92 
3.1.6 Validation of CoAsy as a novel regulator of HIFs ........................................ 94 
3.1.6.1 siRNA knockdown of CoAsy ................................................................. 94 
3.1.6.2 Cloning of pLKO-tet-shRNA vector to target CoAsy .............................. 97 
3.1.6.3 Validation and optimisation of tetracycline inducible shRNA knockdown 
of CoAsy .......................................................................................................... 99 
3.1.6.4 shRNA mediated knockdown of CoAsy stabilizes HIFα protein .......... 100 
3.1.6.5 Loss of CoAsy does not alter HIF1A or HIF2A mRNA expression but 
upregulates a subset of HIF target genes ....................................................... 102 
X.1.7 Summary .................................................................................................. 104 
10 
 
4.1 Chapter aims ................................................................................................... 107 
4.2.1 Cloning of CoAsy-EGFP ........................................................................... 107 
4.2.2 Overexpression of CoAsy-EGFP does not affect HIF-1α protein levels but 
overexpression of Pank1β negatively regulates HIFα protein levels .................. 109 
4.2.3 Knockdown of enzymes that utilize CoA as a substrate ............................ 116 
4.3 CoAsy negatively regulates HIF-1α post-transcriptionally at the 30-389 and 390-
462 amino acid domains. ...................................................................................... 121 
4.4 Protein CoAlation ............................................................................................ 126 
4.4.1 Protein CoAlation in hypoxia ..................................................................... 127 
4.4.2 Direct protein CoAlation of HIF-1α ............................................................ 130 
4.4.3 Preparation of recombinant HIF-1α for in vitro CoAlation assays .............. 130 
4.4.4 Preparation of endogenous IP of HIF-1α for CoAlation analysis ................ 133 
4.4.5 Analysis of potential CoAlation on HIF-1α ................................................. 135 
4.4.6 CoAlation of members of the canonical pathway of HIF regulation ............ 136 
4.5 Analysis of cell transformation following loss of CoAsy .................................... 139 
4.5.1 Loss of CoAsy does not change cell proliferation in A549 cells ................. 139 
4.5.3 Loss of CoAsy does not affect wound closure in A549 cells ...................... 142 
4.5.4 Loss of CoAsy does not affect clonogenic potential of A549 cells .......... 144 
4.5.5 Loss of CoAsy increases clonogenic potential of T47D cells ..................... 146 
4.6 Summary ......................................................................................................... 147 
5.1 CoAsy expression in non-small cell lung cancer (NSCLC) ............................... 149 
5.1.1 Analysis of CoAsy copy number from TCGA data ..................................... 149 
5.1.2 Analysis of CoAsy mRNA expression as a prognostic marker in NSCLC .. 151 
5.1.3 Analysis of CoAsy mRNA expression as a prognostic marker using KMplot 
server ................................................................................................................ 153 
5.1.4 Optimisation of antibody to detect CoAsy in formalin fixed paraffin embedded 
tissue microarrays. ............................................................................................. 154 
5.1.5 High CoAsy expression in lung cancer results in poor patient prognosis and 
correlates with high HIF expression and VEGF expression. ............................... 157 
5.1.6 Summary .................................................................................................. 163 
5.2 CoAsy expression in breast cancer ................................................................. 164 
5.2.1 Analysis of COASY and PANK1 in an in-house dataset of breast cancer 
patients .............................................................................................................. 164 
5.2.2 CPTAC proteomics database reveals low CoAsy protein expression in ER 
and PR negative tumours .................................................................................. 167 
5.2.3 Triple negative breast cancer cell lines express low levels of CoAsy protein
 .......................................................................................................................... 168 
5.2.4 Correlation of COASY mRNA and HIF target genes from TCGA data ....... 169 
5.2.5 COASY expression is an independent prognostic biomarker in breast cancer
 .......................................................................................................................... 172 
11 
 
5.2.6 Investigating the mechanism of COASY loss in breast cancer .................. 174 
5.2.6.1 Analysis of COASY copy number in TCGA provisional dataset .......... 174 
5.2.6.2 Promoter methylation as an alternative mechanism for loss of gene 
expression ...................................................................................................... 177 
5.3 Chapter 3 conclusion ....................................................................................... 183 
6.1 Chapter aims ................................................................................................... 186 
6.1.1 Optimisation of cell viability reagent .............................................................. 187 
6.1.2 FDA library drug screen in inducible shRNA cell lines ............................... 188 
6.2 Validation of hits from drug screen .................................................................. 192 
6.2.1 Quarternary ammonium compounds ......................................................... 192 
6.3 Nicardipine HCl ............................................................................................... 196 
6.4 Future drug validation experiments ................................................................. 199 
6.5 Summary ......................................................................................................... 201 
7.1 CoAsy is a negative regulator of HIF-1 transcriptional activity ......................... 203 
7.2 Coenzyme A or a Coenzyme A derivative negatively regulates HIFα protein 
stability .................................................................................................................. 205 
7.2.1 Acetyl-CoA and HIF-1α ............................................................................. 208 
7.3 The role of CoA and CoAsy in the TCA cycle and metabolic regulators of HIFs
 .............................................................................................................................. 209 
7.4 CoAsy regulates HIF-1α stability at the 30-389 and oxygen dependent 
degradation domain (ODDD) ................................................................................. 215 
7.5 Global CoAlation in hypoxia and specific CoAlation of HIF-1α ......................... 216 
7.6 The role of CoAsy in suppressing tumour aggressiveness .............................. 218 
7.7 CoAsy expression in cancer ............................................................................ 221 
7.8 Targeting loss of CoAsy in cancer cells ........................................................... 224 
7.9 The role of CoAsy in regulating immune checkpoint blockade ......................... 225 
7.10 Concluding remarks ...................................................................................... 228 
8. Appendix ........................................................................................................... 231 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Table of figures 
 
Figure 1.1.1: The hallmarks of cancer 17 
Figure 1.1.2.1: Cell type of origin for non-small cell lung cancer. 19 
Figure 1.1.2.2: Driver mutations in Lung cancer 20 
Figure 1.1.3: The progression of breast cancer from normal breast ducts to invasive 
carcinoma. 23 
Figure 1.2: Imaging tumour hypoxia and necrosis in xenografts. 25 
Figure 1.3.1: Structure of hypoxia inducible factors 27 
Figure 1.3.2: Mechanism of HIF transcriptional activity 28 
Figure 1.4.1: Schematic of Prolyl-4-hydroxylase structure. 31 
Figure 1.4.2.1: Oxygen dependent regulation of HIFα. 34 
Figure 1.4.2.2: HIF-LIMD1 negative feedback loop 35 
Figure 1.5.2.4: The HIF mediated metabolic switch in hypoxia 46 
Figure 1.6.2.3: Hippo signaling regulates HIF-1α activity 52 
Figure 2.6: Puromycin kill curve 72 
Figure 3.1.1.1: Hypoxic responsive element driven firefly luciferase reporter 83 
Figure 3.1.1.2: Hypoxic induction of A549-HRE cells 84 
Figure 3.1.1.3: HIF isoform specificity of hypoxic responsive element. 85 
Figure 3.1.2.1: Optimisation of siRNA transfection reagent. 86 
Figure 3.1.2.2: Optimization of cell viability reagent. 88 
Figure 3.1.3.1: Primary siKinome screen for HIF transcriptional activity. 89 
Figure 3.1.3.2: String network of all the hits from primary siKinome screen 90 
Figure 3.1.4: Significant hits from secondary screen 91 
Figure 3.1.5: Schematic of CoAsy protein 93 
Figure 3.1.6.1: Knockdown of CoAsy results in stabilized HIFα protein 96 
Figure 3.1.6.2: Cloning of inducbile shRNA vector 98 
Figure 3.1.6.3: Validation of tet-shRNA system. 99 
Figure 3.1.6.4: shRNA mediated knockdown of CoAsy results in stabilized HIF-1α 101 
Figure 3.1.6.5: Analysis of HIF target gene expression in A549-tet-shRNA cell lines. 103 
Fig 4.2.1: Cloning of CoAsy-EGFP 108 
Figure 4.2.2.1: Overexpression of CoAsy does not alter HIF-1α expression. 110 
Figure 4.2.2.2: Overexpression of Pank1β reduces HIFα protein expression. 112 
Figure 4.2.2.3: qRT-PCR analysis of HEK293-Pank1β cells and HEK293T WT 113 
Figure 4.2.2.4: siRNA knockdown of PANK1 stabilises HIF-1α 115 
Figure 4.2.3.1: Schematic of enzymatic processes involving CoA. 117 
Figure 4.2.3.2: Knockdown of enzymes that utilize CoA in A549 cells. 118 
Figure 4.2.3.3 Knockdown of enzymes that utilize CoA in A549-tet-shRNA cells 120 
Figure 4.3.1: Schematic of HA-EGFP tagged domains of HIF-1α. 122 
Figure 4.3.2: CoAsy negatively regulates 30-389 and the ODDD of HIF-1α 123 
Figure 4.3.3: Identified post translational modifications in HIF-1α. 124 
Figure 4.4: Protein CoAlation. 126 
Figure 4.4.1: Menadione induced CoAlation in HEK293-Pank1β cells 128 
Figure 4.4.2: H2O2 induced CoAlation in HEK293-Pank1β cells 129 
Figure 4.4.3.1: Recombinant expression of GST-HIF-1α fusion from multiple DNA 
plasmid clones. 131 
Figure 4.4.3.2: Bacterial expression of recombinant HIF-1α GST fusion protein for in 
vitro CoAlation analysis 132 
Figure 4.4.4: Optimisation of HIF-1α IP from HEK293T cells. 133 
Figure 4.4.5: Immunoprecipitation of HIF-1α from HEK293T cells. 134 
Figure 4.4.5: CoAlation analysis of HIF-1α samples. 135 
Figure 4.4.6: IP to assess CoAlation of HIF-1α and O2-depdenedent regulators of HIF-1α
 137 
Figure 4.5.1.1: Loss of Coasy does not alter cell proliferation in A549 cells 140 
Figure 4.5.1.2: Analysis of cell proliferation of A549-tet-shRNA cells using incucyte 141 
Figure 4.5.3: Loss of CoAsy does not affect wound healing in A549 cells. 143 
Figure 4.5.4: CoAsy does not alter clonogenic potential of A549 cells 145 
Figure 4.5.5: Loss of CoAsy increases clonogenic potential of T47D cells 146 
Figure 5.1.1.1: Copy number analysis of COASY  in lung cancer 150 
13 
 
Figure 5.1.2: COASY expression does not correlate with patient survival in lung TCGA 
datasets. 152 
Figure 5.1.3: High COASY 153 
Figure 5.1.4: Optimisation of anti-CoAsy antibody for IHC. 156 
Figure 5.1.5.1: H-scores from CoAsy stained lung TMA 158 
Figure 5.1.5.2: Kaplan-Meier plot of lung cancer patient survival stratified by CoAsy 
protein expression. 159 
Figure 5.2.1.1: RNA-seq data of COASY and PANK1 165 
Figure 5.2.1.2: COASY expression from in-house cohort stratified by receptor status
 166 
Figure 5.2.2: CoAsy protein expression from CPTAC data stratified by ER and PR 
status 167 
Figure 5.2.3: CoAsy protein and mRNA expression in breast cancer cell lines 168 
Figure 5.2.4: Correlation of COASY mRNA expression and HIF target genes 170 
Figure 5.2.5: COASY mRNA expression correlates with poor patient outcome. 173 
Figure 5.2.6.1.1: COASY copy number correlates with mRNA expression 175 
Figure 5.2.6.1.2: COASY is deleted in over 33% of breast cancer patients. 176 
Figure 5.2.6.2: The promoter of COASY gene is hypermethylated in cancer 178 
Figure 5.2.6.3: COASY mRNA expression correlates with promoter methylation 179 
Figure 5.2.6.4: 5’-Azadeoxycytidine reduces COASY expression in MDA-MB231 and 
HCC1143 cells 180 
Figure 5.2.6.5: COASY promoter methylation in breast cancer cell lines. 182 
Figure 6.1: Synthetic lethality 186 
Figure 6.1.1: Optimisation of cell viability reagent for drug screen. 187 
Figure 6.1.2.1: protocol for FDA-approved library screen. 189 
Figure 6.1.2.2: Drug screen of FDA approved compounds 190 
Figure 6.2.1: Top 10 hits from drug screen in MCF10A-tet-shRNA cells. 192 
Figure 6.2.2: Quaternary ammonium compounds. 193 
Figure 6.2.3: Dose response curves for quarternary ammonium compounds in 
inducible shRNA lines. 194 
Figure 6.3.1: Nicardipine HCl was selective for CoAsy deficient cells in primary screen
 196 
Figure 6.3.2: Loss of CoAsy sensitizes A549 cells to Nicardipine HCl 197 
Figure 6.3.3: Nicardipine HCl treatment of A549-tet-shRNA cells. 198 
Figure 6.3.4: Treatment of A549-tet-shRNA cells with Nicardipine HCl from two different 
suppliers 199 
Figure 6.4: Top hits from T47D screen 200 
Figure 7.1: IP of CoAsy-EGFP and EGFP in HEK293T. 204 
Figure 7.2.1: Reporter assay of HIF activity in A549-tet-shRNA cells following 
knockdown of ACSS1, ACSS2 and OGDH 206 
Figure 7.2.2: Transfection of A549-tet-shRNA cells with Coenzyme-A. 207 
Figure 7.3.1: Steady state levels of metabolites from A549 cells 210 
Figure 7.3.2: Mass isotopomer peaks for indicated metabolite as measured by mass 
spectrometry 211 
Figure 7.3.3: The contribution of glucose to alanine and pyruvate pools in A549 cells 
following loss of CoAsy 212 
Figure 7.3.4: Loss of CoAsy does not alter HIF-1α hydroxylation. 214 
Figure 7.5: HIF-1α contains exposed cysteine residues in the 30-389 region. 218 
Figure 7.6: Loss of CoAsy increases cell migration through matrigel. 220 
Figure 7.7: COASY and CoA is lost in ccRCC 223 
Figure 7.9.1: CoAsy may immune checkpoint blockade 226 
Figure 7.9.2: CoAsy expression is higher in infiltrating lymphocytes. 227 
Figure 8.1: Knockdown of CoAsy in A549-tet-shRNA cells 231 
Figure 8.2: qRT-PCR analysis of HIF target genes 231 
Figure 8.3: Alternative biological replicate of HEK293-Pank1β treated with H2O2 232 
Figure 8.4: Colony assay of T47D-tet-shRNA cell lines 232 
Figure 8.5.1: Steady state levels of metabolites from A549 cells 233 
Figure 8.5.2: Mass isotopomer peaks for indicated metabolite as measured by mass 
spectrometry. 234 
 
14 
 
 
 
 
 
 
 
 
Introduction 
 
The role of hypoxia and HIF signaling in cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
1. Introduction 
1.1.1 The hallmarks of cancer 
Cancer is one of the leading causes for death in the developed world. Recent 
statistics have shown that 1 in 2 people born after 1960 will be diagnosed with 
some form of cancer during their lifetime. In the UK there were over 350,000 
new cases of cancer and over 160,000 deaths from cancer in 2016 [1]. Current 
survival rates are 50% for over 10 years, but this does not represent all cancers 
as almost half of all cancer deaths in 2016 were from cancers of the breast, 
prostate, bowel and lung. Globally, the cancer burden is estimated to be 9.6 
million deaths in 2018 and 1 in 6 people dying of cancer [2]. This staggering 
disease burden has resulted in decades of research to further understand the 
pathogenesis, progression and ultimately treatment of disease.  
 
Cancer is a heterogeneous disease, with each cancer type containing many 
other subgroups. Cancers cannot be defined by a singular source of rapidly 
proliferating cells; instead tumors are a complex tissue formed of multiple cell 
types and mutations resulting in a varied microenvironment. Despite this 
complexity a seminal paper by Hanahan and Weinberg defined common traits 
shared across all cancer types. These are referred to as the “Hallmarks of 
cancer.”[3, 4] The hallmarks describe cancer cell traits such as sustained 
proliferative signaling often arising from a gain in self-sufficiency of growth 
signaling pathways, such as activating mutations in epidermal growth factor 
receptor (EGFR) which results in sustained signaling without ligand induced 
stimulation [5]. Conversely, cancer cells display insensitivity to anti-proliferative 
signals, one such example is the well-characterized tumour suppressor protein 
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pRB, functional pRB binds to E2F and blocks transcriptional activity thereby 
blocking cells from progressing through G1 phase and continuation of cell cycle 
[6]. Furthermore for cancer cells to continue proliferative signaling, the 
mechanism of programmed cell death (apoptosis) is inhibited, this can be seen 
through upregulation of the oncogenes such as BCL2 [7]. To allow cells to 
maintain unrestrained replication telomerase activity is reactivated in cancer 
cells thereby enabling replicative immortality [8]. Cancer cells further alter the 
surrounding environment through activation of angiogenesis, the formation of 
new blood vessels through upregulation of activating factors such as VEGF-A 
[9]. Finally, cancer cells invade and metastasise to distal sites forming new 
colonies, this can occur by multiple processes, however one well established 
model is through epithelial-mesenchymal transition that is typified by altered 
cellular junctions such as loss of E-cadherin [10]. These six highlighted points 
are the initial hallmarks, the list was further expanded to include: deregulating 
cellular energetics, genome instability and mutation, avoiding immune 
destruction and tumour-promoting inflammation (Fig. 1.1.1) [4].  These 
hallmarks and emerging hallmarks give a simple overview to shared 
characteristics to the majority of human cancers, however cancer is a very 
heterogeneous disease with each type displaying a diverse set of molecular 
drivers. 
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Figure 1.1.1: The hallmarks of cancer. The hallmarks of cancer and the next 
generation of hallmarks as termed by Hanahan and Weinberg, these are traits 
common to the majority of cancers [4]. Figure adapted from Hanahan and Weinberg 
 
1.1.2 Lung Cancer 
Lung cancer is currently the most common cancer worldwide and accountable 
for over 21% of UK cancer deaths in 2016 [11]. Patient survival has not seen 
much improvement in the last 40 years in the UK with only 5% of patients 
diagnosed live for ten years or more. These statistics represent a clear unmet 
medical need, therefore we utilized lung cancer as one of the disease models 
used throughout this project.  
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Lung cancer is broadly divided into two categories non-small cell lung cancers 
(NSCLC) that accounts for 85% of lung cancers, the remaining 15% of lung 
cancers are small-cell lung cancers (SCLC). NSCLC is broadly divided into 
three subtypes: adenocarcinoma, large cell carcinoma and squamous cell 
carcinoma. Even within these subtypes, there is great mutational diversity and 
further postulated subtypes, however for simplicity we will focus on the broader 
definitions [12]. Small-cell lung cancers are primarily found in heavy smokers, 
these tumours arise from pulmonary neuroendocrine cells [13]. Squamous cells 
primarily originate from the first four branchings of the bronchus and are thought 
to originate from the basal progenitor cells located here, however 
adenocarcinomas originate from alveolar type II cells; although this is still 
debated due to the plasticity observed between alveolar type I and type II cells 
[14]. Furthermore recent evidence has shown that tumour recurrence following 
EGFR inhibitor resistance appears as SCLC despite initial NSCLC tumours, the 
current theory behind this phenomenon is that alveolar type II cells can also 
give rise to SCLC [15]. 
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Figure 1.1.2.1: Cell type of origin for non-small cell lung cancer.  Schematic 
diagram of cell type of origin in lung cancer. Image highlights squamous cell arising 
from the branching of the bronchus whereas adenocarcinoma develop from the 
alveolar cells, the cell type of origin is thought to be AT2 cells derived from Clara cells. 
Small-cell lung cancer, not pictured here, arises from neuroendocrine cells found in 
the columnar epithelium. Figure adapted from Chen et al., [16] 
 
There are various genetic drivers of lung cancer; EGFR mutations are common 
in NSCLC and are predicted to be an early driver mutation, particularly in 
adenocarcinoma. Screening for EGFR mutations in a large cohort of lung 
cancer patients identified that they occurred in 16.6% of patients, particularly 
exon 19 deletions of L858R mutation, both resulting in constitutively active 
EGFR [17], however this figure is higher in Asia, however the reason for this is 
unclear [18]. EGFR inhibitors such as erlotinib and gerfitinib have shown some 
efficacy with partial responses in around 10% of NSCLC patients [12]. KRAS 
mutations are also prevalent in NSCLC, particularly in smokers. Often these 
mutations effect codons 12 or 13 and lead to a loss of Kras GTPase activity, 
thereby rendering a constitutively active Ras-Raf-Mek-Erk kinase pathway, 
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resulting in sustained cellular proliferation [19]. These are just some of the 
driver mutations associated with lung cancer, however as previously mentioned 
each subtype is largely heterogeneous and multiple other drivers have been 
identified, a summary of which can be found in Fig 1.1.2.2.   
 
 
Figure 1.1.2.2: Driver mutations in Lung cancer. Known driver mutations in lung 
adenocarcinoma, squamous cell carcinoma and small-cell lung cancer. Driver 
mutations identified from [20-22]. 
 
Targeting these driver mutations is of significant clinical interest. Current 
therapies include targeting mutant EGFR using gerfitinib or erlotinib, due to the 
increased activity of EGFR, these patients show increased response to EGFR 
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therapy [13]. ALK and ROS1 fusions are another form of driver mutations that 
has been exploited for therapeutic targeting in adenocarcinoma, indeed the 
ALK-ROS1 fusion results in a pseudo-dimerization of each kinase resulting in 
hyperactive fusion enzymes. Phase III trials with the ALK-ROS fusion inhibitor, 
crizotinib, showed a significant increase in progression-free survival compared 
to chemotherapy as well as a greater improvement in quality of life [23]. The 
emerging role of immunotherapy in targeted therapies has transformed cancer 
research in recent years. Using inhibitors of immune checkpoint, the 
mechanism how cancer cells evade immune destruction, it is possible to re-
sensitize tumour cells to immune destruction. Large scale trials targeting the 
PD-1/PD-L1 axis has resulted in successful trials showing increased patient 
survival both as first line treatment and with adjuvant chemotherapy [24-26]. 
 
In comparison to these successes in targeted therapies in NSCLC, there are 
currently no targeted therapies for patients with small cell lung cancer. Recent 
trials with a monoclonal antibody targeting DLL3, an oncoprotein that activates 
Notch signaling in small cell lung cancer, showed early response to reducing 
tumour burden however they failed to elicit significant changes in overall 
survival or progression free survival [27]. 
 
Whilst there have been great advances in development of targeted therapies of 
lung cancer, either through small molecule inhibitors or immunotherapy, it is still 
an area of clear unmet need as can be seen by the large disease burden. The 
plethora of molecular drivers results in a complex situation where it is unlikely 
that a single targeted therapy will be effective for all patients, therefore we 
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hypothesize through identification of novel drivers that may act as therapeutic 
targets, will help expand the current ‘toolbox’ of treatment options. 
 
1.1.3 Breast cancer 
In 2015 there were over 55,000 new cases of breast cancer in the UK, leading 
to over 11,500 deaths [28]. In fact, breast cancer remains the largest cause of 
cancer-related death in women world-wide [29].  
 
Breast cancer has clearly defined subtypes depending on cell types of origin 
and expression of various molecular drivers. The majority of breast cancer 
cases arise from cells lining the milk ducts. Cancerous cells progress to form a 
pre-invasive lesion termed ductal carcinoma in situ (DCIS) before becoming 
invasive and finally presenting as metastatic disease [29].  
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Figure 1.1.3: The progression of breast cancer from normal breast ducts to 
invasive carcinoma. Schematic diagrams and IHC from breast cancer patients 
showing pre-cancerous duct, which develops in to ductal carcinoma in situ before 
invading and presenting as metastatic disease. Staining in IHC is CK5/6, a marker of 
myoepithelial cells Figure adapted from Allen et al., [30] 
 
Breast cancer is broadly separated in to four categories: luminal A, luminal B, 
HER2 positive and basal-like breast cancer [31]. Currently targeted therapy and 
treatment options is decided upon following analysis of molecular signatures 
and analysis of each subtype. Both Luminal A and Luminal B are hormone 
receptor positive, this means they are estrogen receptor (ER) and progesterone 
receptor positive (PR) therefore first line treatment is endocrine therapy for 
these patients [32]. Luminal A and B subtypes differ by Ki-67 expression, with 
luminal B patients expressing higher levels of Ki-67. Ki-67 is a well-established 
marker of cell proliferation therefore unsurprisingly luminal B tumours are 
known to grow faster and correlate with poor survival compared to luminal A 
[33]. HER2 positive cancers are so named due to high expression of the HER2 
receptor, which is encoded by the ERBB2 gene. This occurs primarily through 
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increased copy number with overexpressing cells expressing between 25-50 
copies of the gene as identified through FISH [34]. This high level of HER2 
expression makes these cells susceptible to treatment with Herceptin (trade-
name: trastuzamab), due to increased dependence on HER2 signaling. The 
final group is triple-negative breast cancer/basal-like carcinoma, this group 
lacks expression of the aforementioned receptors which results in limited 
targeted therapeutic options. The basal-like carcinomas differ from triple-
negative breast cancer (TNBC) tumours due to high expression of basal 
markers such as cytokeratin 5,6 and 17 [35, 36]. 
 
Like lung cancer, breast cancer is a highly heterogeneous disease, however 
there are strong familial links with germline mutations in BRCA1 and/or BRCA2 
mutations. These mutations are well characterized and form screening 
practices employed today, however large scale analysis of 560 breast cancer 
patients identified that 90/560 contained these mutations, indicating that this 
risk factor only accounts for a small proportion of patients [37]. Instead, there 
are a number of lower penetrance mutations or molecular drivers that will 
account for the majority of breast cancer patients. Through identification of 
these alternative drivers it will allow for novel targeted therapies which are of 
particular clinical importance to the basal-like and TNBC patients. 
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1.2 Hypoxia in cancer 
It has long been recognized that oxygen tensions vary greatly throughout solid 
tumours [38]. This phenomenon arises from rapid proliferation in growing 
tumors and aberrant vasculature resulting in an imbalance of oxygen supply 
and consumption. This imbalance leads to great O2 heterogeneity with ranges 
in partial oxygen pressure (pO2) from 40 mmHg (approximately 11% O2) down 
to below 2.5 mmHg (below 1% O2). These regions of sub 1% oxygen 
concentration are referred to as hypoxic [39]. Within these hypoxic regions, 
there is often substantial necrosis, uncontrolled cell death, but despite this 
harsh tumour microenvironment, a small subset of cancer and normal cells 
remains viable [40].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Imaging tumour hypoxia and necrosis in xenografts.  
Immunofluorescence of head and neck cancer xenograft stained for pimonidazole 
(green), HIF-1α (red) and blood vessels (blue). N indicates necrotic regions. This figure 
shows hypoxic regions stained in green, at the center of these regions there is an area 
of cell necrosis. This figure further shows the diffusion of tissue oxygenation away from 
blood vessels (blue). Figure adapted from Meijer et al.,  
 
Early studies in head and neck tumors displayed that hypoxic in metastatic 
lesions correlated with poor survival following radiotherapy treatment [41]. This 
association of poor prognosis on disease-free and overall survival with tumor 
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hypoxia has also been reported in cervical cancer [42]. Tumour hypoxia still 
occurs in well oxygenated tissues such as the lungs, due to the poorly formed 
vascular surrounding tissues. Furthermore this tumour hypoxia correlates with 
poor patient survival; two studies with different imaging techniques to detect 
tumor hypoxia showed that hypoxia was a predictive indicator of tumor 
response to therapy and overall patient survival [43, 44]. 
 
1.3 Hypoxia inducible factors are responsible for cellular response to 
changes in O2 tension 
The cellular response to hypoxia is regulated by the hypoxia inducible factors 
(HIFs). HIFs are heterodimeric proteins consisting of an O2 labile subunit (HIFα) 
and a beta subunit (HIF-1β). In low oxygen concentration, the subunits 
translocate to the nucleus, dimerize and initiate the transcription of target genes 
[45]. These target genes allow for response and adaptation to low oxygen 
tension, including those related to altering cellular metabolism, angiogenesis 
and cell cycle progression [46]. The general structure of HIFs (Fig. 1.3.1) 
consists of an N-terminal basic helix-loop-helix (bHLH) domain that facilitates 
DNA binding, a PER-ARNT-SIM (PAS) domain, that allows for dimerization and 
two transactivation domains (N-TAD and C-TAD) for transcriptional activity. In 
addition to these, the HIF alpha subunits contain an oxygen dependent 
degradation domain (ODD) that is essential for protein degradation in the 
presence of molecular oxygen. 
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Figure 1.3.1: Structure of hypoxia inducible factors. Schematic of HIF isoform 
structures. Each subunit contains bHLH domains, PAS domains and two TAD 
domains. ODDD domains are only found in α subunits 
 
There are three mammalian HIFα subunits; HIF-1α and HIF-2α are the two most 
well studied, less is known about the third subunit, HIF-3α, although this is a 
fast developing field. They each share the common motifs, such as the bHLH 
domain, PAS domain and TAD domain, but differ in sequence and length with 
approximately 48% amino-acid sequence homology [46]. Expression of HIF-1α 
is widespread and found in almost all tissue and cell types; initially it was 
thought that HIF-2α was exclusively found in the vasculature [47], until 
immunohistochemical analysis of mice following hypoxic exposure revealed 
HIF-2α expression in a variety of tissue types, although expression was still not 
ubiquitous as is observed with HIF-1α [48]. HIF-3α differs to HIF-1/2, as there 
are numerous splice variants that have been identified [49]. There are 
conflicting reports on the function of HIF-3α, it has been suggested that HIF-3α 
acts as a dominant-negative regulator of HIF-1/2 and has no activity as a 
transcriptional activator [50]. This does not hold true of all splice variants as 
Zhang et al., showed that human HIF-3α splice variants HIF-3α-1 and HIF-3α-
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9 are able to upregulate target genes following identification of homologous 
splice variants in zebrafish [51]. Therefore, the biology and activity of HIF-3α 
largely depends on which splice variant is being expressed and the cellular 
context in which they are expressed, as these differences are not well 
characterized or fully understood we will focus on HIF-1α and HIF-2α 
 
 
 
Figure 1.3.2: Mechanism of HIF transcriptional activity Schematic of HIF 
transcriptional activity. In low O2 conditions the HIFα subunit is stabilised (A) and forms 
a heterodimer with the β subunit (B) before translocating to the nucleus and binding to 
hypoxic responsive elements and upregulating target genes. 
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HIF activity occurs when the alpha subunit becomes stabilized (Fig. 1.3.2A), 
binds to the constitutively expressed β-subunit (Fig. 1.3.2B) before 
translocating to the nucleus where it binds to consensus motifs (5’-RCGTG-3’ 
[52]), termed hypoxic responsive elements (HREs) in DNA before initiating 
transcription (Fig. 1.3.2C). Despite numerous canonical HIF-binding motifs 
throughout the genome, not all of these are functional; ChIP-seq analysis in a 
breast cancer cell line (MCF-7), revealed over 500 HIF binding sites, with 400 
for HIF-1α and 425 for HIF-2α (of which 356 and 301 overlapped with HIF-1β 
peaks for HIF-1α and HIF-2α respectively), whilst there was significant overlap 
in binding sites, others were distinct indicating different rolls for HIF subunit 
activity in response to hypoxia, furthermore this dataset showed that the HIF-
1α binds more closely to transcriptional start sites (TSS) than HIF-2α with ~40% 
of HIF-1α binding sites within 2.5 kb from TSS compared to ~20% for HIF-2α 
[53]. This overlap of HIF-1α and HIF-2α target genes has also been noted in 
renal cell carcinoma [54, 55]. The specificity of HIFα subunit target genes has 
been mapped to the N-terminal transactivation domain, as overexpression 
experiments with mutant HIF-1α with the HIF-2α N-TAD was able to induce 
expression of HIF-2α specific target genes, and vice versa with mutant HIF-2α 
[54].  
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1.4 O2 dependent regulation of HIFα protein stability and activity 
1.4.1 Prolyl-hydroxylation of the ODDD in HIFα 
How cells adapt to and sense changes in oxygen was unknown at the time HIF-
1 was first discovered, instead it was just known that HIF-1 is stabilized in low 
oxygen tensions. A series of papers first identified the interaction between HIF-
1α and pVHL (to be discussed later in 1.4.2) required prolyl-hydroxylation at 
P565 residue, this hydroxylation event was further shown to be dependent of 
O2, ascorbate, Fe2+ and 2-oxogluturate [56, 57]. Later, work in C. Elegans first 
identified the nematode homologue of HIFα before identifying Egl-9 as the 
hydroxylase that is functional. The human homologue was identified as a series 
of proteins now termed HIF-prolyl-4-hydroxylases (PHDs) [58]. Furthermore an 
additional hydroxylation site was further confirmed corresponding to P402 in 
HIF-1α, this was further shown to be critical for HIF-1α regulation both in vitro 
and in cellulo [59]. 
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Figure 1.4.1: Schematic of Prolyl-4-hydroxylase structure. Schematic diagrams of 
prolyl-hydroxylase protein structures. Each isoform contains a C-terminal hydroxylase 
domain where the co-factors and active site are located. Between each isoform there 
is ~60% amino-acid sequence homology. PHD2 differs from the other isoforms as it 
contains an additional MYND domain. 
 
There are 3 members of this family: PHD1, PHD2 and PHD3. Through siRNA 
mediated knockdown experiments it was shown that PHD2 is the isoform that 
is critical for HIF hydroxylation as knockdown of PHD1 or PHD3 had lesser 
effects on HIF stabilization in normoxia [60]. The PHD enzymes each contain a 
C-terminal hydroxylase domain that contains the catalytic residues and all 
required co-factor binding sites. PHD1 and PHD2 have extended N-terminal 
regions, the function of which is not known. Germline mutations in EGLN1, 
causing a D4E and C127S substitutions in mature protein, have been found in 
the Tibetan population and are associated with adaptation to high altitude, it 
has been further postulated this occurs through a reduction of binding from 
PHD2 and p23, a co-factor facilitating PHD2 and HIF interaction [61]. All three 
PHD isoforms are capable of hydroxylating HIF-1α with varying affinities [62, 
63], however each enzyme displays a Km for O2 at ranges above physiological 
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oxygen levels. As a result of this, the prolyl-4-hydroxylase enzymes are able to 
sense subtle changes in oxygen tension and hydroxylate HIF when O2 
concentrations are sufficient.  
 
1.4.2 Regulation of HIF by the von Hippel-Lindau protein complex 
In 1996, it was noted that a number of hypoxia-inducible genes were also 
negatively regulated by the tumour suppressor protein von Hippel-Lindau 
protein (pvHL), as renal carcinoma cells lacking wild-type pVHL expressed 
higher levels of SLC2A1, VEGFA and PDGFB mRNA irrespective of oxygen 
tension, which was reversed upon addition of reintroduction of wild-type pVHL 
[64]. It was later discovered that these cells display stabilized HIF-1α and HIF-
2α and that pVHL co-immunoprecipitates with each HIFα subunit in an iron 
dependent manner. These findings in combination with those discussed in 1.4.1 
highlighted an axis where HIFα is hydroxylated by the PHD enzymes which 
allows binding of pVHL and subsequent degradation. The degradation pathway 
was later characterized in 2000 by Cockman et al., who showed that the 
pVHL/HIFα interaction was required for HIF ubiquitylation and subsequent 
degradation via the proteasome [65].  
 
pVHL exists in two isoforms, a 30 kDa isoform (p30) and 19 kDa isoform (p19), 
this second shorter isoform arises as a consequence of an internal translation 
start site resulting in a truncated product lacking the N-terminal sequence. Re-
expression of the p19 isoform in renal cell carcinoma cell lines with mutated 
pVHL resulted in a reduction of HIF target gene expression and a reduction in 
tumour burden suggesting that the tumour suppressor properties of pVHL are 
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conferred by both isoforms [66]. pVHL forms part of a protein complex with 
Elongin B and Elongin C; the crystal structure of this complex has been 
resolved with a short fragment of hydroxylated HIF-1α, which shows how the 
binding pocket of pVHL contains multiple serine and histidine residues that 
interact with the hydroxylated proline residue and stabilise the protein-protein 
interaction, furthermore this binding pocket contains multiple frequently 
oncogenic mutated residues which destabilize this interaction [67, 68].  This 
pVHL-Enlongin B-Elongin C (VBC) complex acts as a recognition motif for Cul2, 
a scaffold protein that further recruits Rbx1, a RING structure that combined 
form a canonical Cullin-RING E3 ubiquitin ligase complex [69-71]. The E3-
ubiquitin ligase complex polyubiquitinates HIFα, which signals HIFα for 
destruction via the 26S proteasome system [72]. 
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Figure 1.4.2.1: Oxygen dependent regulation of HIFα. O2-dependent regulation of 
HIFα protein stability. PHD enzymes hydroxylate conserved proline residues in the 
ODDD that allows pVHL to bind. pVHL acts as a recognition sequence for E3-ubiquitin 
ligase complex (not pictured) that polyubiquitinates HIFα thus signaling it for 
degradation via the 26S proteasome. LIMD1 scaffolds this process, focusing 
enzymatic activity and enhancing degradation rate. 
 
To summarise the oxygen dependent degradation of HIFα protein; the prolyl-
hydroxylase enzymes hydroxylate proline residues in the oxygen dependent 
degradation domain of HIFα proteins in a reaction that requires O2, Fe2+, 2-
oxogluturate and ascorbate. This hydroxylation event allows binding of pVHL 
in complex with Elongin B and C. pVHL acts as a recognition motif for the Cul2-
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Rbx1 E3-ubiquitin ligase complex that polyubiquitinates HIF that signals the 
protein for degradation via the 26S proteasome. This process ensures that in 
cells with sufficient oxygenation, HIFα protein is rapidly degraded before 
eliciting a transcriptional response. The tumour suppressor protein LIM 
domains containing protein 1 (LIMD1) and related family members (Ajuba and 
WTIP) act as molecular scaffolds for PHDs and pVHL, thereby focusing 
enzymatic activity and increasing efficiency of HIF degradation [73] (Fig. 
1.4.2.1). LIMD1 itself is a hypoxic responsive gene, like PHD2 and PHD3 [60, 
74], ablation of the hypoxic response element in the promoter of LIMD1 alters 
the negative feedback loop of HIF regulation resulting in larger and more 
vascular tumour xenografts (Fig.1.4.2.2) [75]. This work highlights the 
biological significance of this degradation mechanism, as subtle changes in the 
efficiency of this process have profound implications on tumour progression. 
 
 
 
 
 
 
 
 
Figure 1.4.2.2: HIF-LIMD1 negative feedback loop. Schematic diagram representing 
negative feedback loop whereby HIF-1 promotes hypoxic expression of LIMD1, which 
in turn increases turnover of HIF-1α protein. Figure used with kind permission of Dr. 
Katherine Bridge. 
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1.4.3 Factor-inhibiting HIF negatively regulates HIF transcriptional activity 
Factor inhibiting HIF (FIH-1)  is another 2-oxogluturate dependent dioxygenase, 
that hydroxylates the C-terminus of HIF-1α and subsequently blocks 
transcriptional activity [76]. Unlike the PHD enzymes, FIH-1 hydroxylates HIF 
at an asparagine residue (asparagine 803 in HIF-1α) [77]. This hydroxylation 
event in the C-TAD blocks transcriptional activity through blocking the 
recruitment of transcriptional co-activators such as p300/CBP, this occurs due 
to disruption of hydrophobic interactions in the α-helix at the binding interface 
between HIFα and p300 [77-79]. It is important to note that unlike the previous 
mechanism of HIF regulation, this does not alter HIF protein stability instead 
blocks activity, as a consequence of this it means that just because HIF protein 
is present does not necessarily imply that there will be transcriptional activity. 
Analysis of the affinity of the PHD hydroxylases and FIH-1 for oxygen highlights 
a difference between the two groups, whilst the prolyl-hydroxylases display a 
higher Km for O2 than FIH-1, this means FIH-1 will remain functional at lower 
oxygen tensions than the PHDs [80]. As a result of this there will be a window 
where HIF protein is stabilized due to lack of activities from PHDs but activity 
will be inhibited due to still functional FIH-1. As FIH-1 hydroxylation occurs at 
the C-TAD residual functionality is still maintained through activity through the 
N-TAD, however a different subset of genes will be activated. Through both 
overexpression and shRNA mediated knockdown of FIH these target genes 
were characterized in HeLa cells and separated in to ‘FIH-inhibited genes’ and 
‘Non-FIH-inhibited genes’. Between these two groups, the FIH-inhibited genes 
displayed a significant increase in hypoxic induction when placed in 0.2% O2 
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as opposed to 3% O2 whereas the ‘non-FIH-inhibted genes’ had a lesser 
difference between the two oxygen tensions [81]. 
 
1.5 HIFs in cancer 
1.5.1 Expression of HIFα often correlates with poor patient outcome 
It has been observed that there is an increased expression of HIF-1α and HIF-
2α across a variety of cancer types. Immunohistochemical analysis of patients 
with NSCLC showed that increased expression of either HIF-1α or HIF-2α 
correlated with decreased overall survival [82].  Overexpression of HIF-1α and 
HIF-2α has also been linked to poor patient outcome in prostate, ovarian and 
colorectal cancer as well as many others [83-85]. In breast cancer there are 
two reports that individually identify HIF-1α and HIF-2α expression as 
independent biomarkers of patient outcome [86, 87], recent work identified that 
of the breast cancer subtypes, there is an upregulated hypoxic signature 
observed with TNBC tumours compared to receptor positive tumours [88]. 
Mutations in VHL or loss of 3p and subsequent loss of VHL was the only truncal 
event found in large scale genetic analysis in clear cell renal cell carcinoma 
(ccRCC), indicating that this event happens early on in ccRCC development 
[89]. Unsurprisingly, as a consequence of loss of pVHL functionality, HIFα 
isoforms are often found upregulated in renal cell carcinoma. However in this 
cancer type there is isoform specificity in terms of tumorigenicity. Analysis of 
HIF-1α protein expression by western blot in 93 patients with RCC highlighted 
that high HIF-1α expression was favourable, and in contrary to other cancer 
types correlated with improved patient outcome [90]. However, IHC analysis of 
a larger TMA of 357 RCC patients indicated that HIF-1α in fact correlates with 
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poor patient outcome [91]. Overexpression of HIF-2α with mutated ODDD 
proline residues to ensure normoxic expression was sufficient to overcome VHL 
tumour suppression in ccRCC cell lines and xenografts [92], however a 
separate study demonstrated that no such effect was observed following 
normoxic expression of HIF-1α indicating that indeed HIF-2α is the isoform 
driving tumourigenesis in RCC [93]. Further studies identify that loss of 14q, the 
chromosome arm that contains HIF1A gene, occurs at high frequency in 
advanced kidney cancers, furthermore shRNA mediated knockdown of HIF1A 
resulted in larger tumour xenografts suggesting that HIF-1α inhibits cell 
proliferation [94]. The differential role of the HIF isoforms in renal cell carcinoma 
could be explained by work by Raval et al., which showed that protumorigenic 
genes were exclusively upregulated by HIF-2 in RCC and not HIF-1, 
furthermore that HIF-1α suppresses HIF-2α and vice-versa [95]. This highlights 
the context specificity behind HIF activity and function, however it can be said 
that in the majority of cases expression of HIFα is not favourable for patient 
outcome. 
 
1.5.2 HIF target genes in cancer 
HIFs upregulate a number of target genes in normal tissues as an acute 
response to fluctuations in oxygen homeostasis. However cancer cells hijack 
these mechanisms to promote tumorigenesis. Whilst HIF target genes vary 
between cell types, thus highlighting the importance of cell context when 
considering HIF signaling, a number of traits remain consistent when studied 
across cancer cells. A number of these pro-tumourigenic mechanisms will be 
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discussed below, with a particular focus of HIF signaling within cancer cells as 
opposed to peripheral cells in the surrounding microenvironment. 
  
1.5.2.1 Angiogenesis 
The formation of new blood vessels is a crucial event in tumour progression as 
after rapid expansion and proliferation the nutrient and oxygen demand of the 
proliferating cells exceeds the pre-existing vasculature. Furthermore 
angiogenesis serves as an avenue for cancer cells to invade and metastasize 
through thereby driving cancer progression [96]. Therefore significant research 
work has been performed to develop antiangiogenic therapies.  
 
HIF drives angiogenesis through multiple mechanisms. The vascular 
endothelial growth factor (VEGF) family comprises 4 secreted ligands that bind 
to tyrosine kinase receptors on vascular endothelial cells, stimulating migration 
(VEGFR-1 and VEGFR-2). VEGF-A is the ligand that primarily drives the 
angiogenic switch [97, 98]. Early work displayed that VEGFA mRNA expression 
was induced by hypoxia and contains a canonical HIF-1 HRE sequence [98, 
99], the secreted VEGF-A protein creates a gradient of expression around 
areas of low oxygen tension which endothelial tip cells grow towards from 
blood-vessel sprouts [100]. Angiopoieten-2 (Ang-2) is an antagonistic ligand for 
Tie2 receptor expressed on sprouting cells, which upon binding works to 
promote new vascularization to be formed [101]. Like VEGFA, the ANGPT2 
gene (that encodes Ang-2) also contains a functioning HRE and is a HIF 
responsive gene [102]. This result shows how HIF drives new blood vessel 
formation through the VEGF-Ang2 axis; a number of inhibitors have been 
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developed to target this axis. One such inhibitor is axitinib (related compounds 
include cabozantinib and pazopanib), a tyrosine-kinase inhibitor that targets 
multiple targets including VEGFR-1-3, which is currently approved for second 
line treatment of advanced renal cell carcinoma [103, 104].  
 
HIFs further propagate angiogenesis through alteration of the platelet derived 
growth factor (PDGF) pathway. The endothelial cell receptor for this pathway 
activates the same kinase cascade as VEGFR-1 signaling following activation 
by PDGF ligand binding [105]. As with VEGFA, one of the PDGFR ligands, 
PDGFB, is a hypoxic responsive gene and contains a functional HRE in the 5’ 
UTR [106]. In addition to this mechanism, the PDGFR-β receptor is hyper-
phosphorylated in hypoxia in a HIF dependent manner. This hyper-
phosphorylation indicates activity of the tyrosine kinase domain of PDGFR. This 
occurs through a HIF-dependent downregulation of a number of protein 
tyrosine phosphatases that dephosphorylate PDGFR [107]. This axis provides 
another mechanism how HIFs can regulate new blood vessel formation at both 
the receptor and ligand of the signaling pathway. 
 
1.5.2.2 Hypoxia and HIFs in the development of resistance to radiotherapy 
and chemotherapy 
Whilst we have primarily focused on targeted therapy through inhibition with 
small-molecules or monoclonal antibodies as a treatment strategy, 
radiotherapy remains a crucial tool in treating multiple cancer types. Tumour 
hypoxia has long been associated with radiotherapy resistance; this largely 
arises as a result of a HIF-independent mechanism termed ‘the oxygen effect’. 
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Radiotherapy induces cell death through high-powered ionizing radiation 
inducing intracellular free radical formation and further radical propagation 
through ROS induction. These free radicals induce widespread DNA damage; 
the presence of molecular oxygen (O2) ‘fixes’ the DNA maintains DNA in the 
damaged state thereby inducing cell death [108, 109].  
 
HIF signaling can further induce radiotherapy resistance through modulation of 
cellular metabolism; further details on how HIF modulates cell metabolism will 
be discussed in more depth in 1.5.2.4. Briefly, through HIF-dependent changes 
in metabolism, the antioxidant capacity of tumour cells is increased within the 
cancer cells as a result of increased flux through the pentose phosphate 
pathway that maintains glutathione in the reduced state [110]. Furthermore, 
lactate production has been linked to radioresistance through the ability of 
lactate to scavenge free radicals, this increased levels of lactate is a common 
hallmark of the glycolytic switch that occurs in hypoxic cancer cells as a 
consequence of increased HIF activity [111-114]. The role of HIF-1α in 
radiotherapy resistance was confirmed in a mouse model of soft tissue sarcoma 
with deleted HIF1A, where loss of HIF1A re-sensitised tumours to ionizing 
radiation. Levels of DNA damage repair and autophagy were similar between 
the HIF1A null and positive groups however there were significant 
mitochondrial defects, which possibly contributed to radiotherapy resistance 
[112]. 
 
Resistance to therapy is a major clinical problem with tumours either acquiring 
resistance as a result of treatment or presenting with innate resistance due to 
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the surrounding microenvironment. Through understanding these mechanisms 
there is the possibility to circumvent the problems and resensitise tumours to 
therapy. Early reports highlighted the importance of HIF-1α in promoting 
resistance to therapy as mouse embryonic fibroblasts knocked out for HIF-1α 
displayed increased sensitivity to treatment with carboplatin in both normoxia 
and hypoxia [115]. One mechanism behind HIF-mediated drug resistance is 
through increased expression of drug efflux pumps. Knockdown of HIF-1α in 
glioma cell lines reduced expression of multidrug resistance-associated protein 
1 (MRP1) at both the protein and mRNA levels [116], this was later found to be 
due to a functional HRE that was found to be active in colorectal cancer lines 
[117]. Expression of this efflux pump increases export of drugs from the cell 
such that the concentration falls below sub-lethal levels [118]. P-glycoprotein 
(P-gp, also known as multidrug resistance protein 1, MDR1) is another HIF 
target gene that acts as a drug efflux pump, upregulation of P-gp has been 
reported in a number of cancer types such as breast cancer, gastric cancer and 
glioblastoma [119-121]. 
 
Recent work in pancreatic cancer cell lines and mouse models identified 
rewired glucose metabolism in gemcitabine resistant samples. Cell lines were 
cultured in increasing doses of gemcitabine to generate acquired resistance to 
gemcitabine (Gem-R). These lines have increased glucose uptake and 
displayed increased flux of glucose through non-oxidative pentose phosphate 
pathway compared to wild type cell lines. This increased flux through non-
oxidative PPP resulted in increased pyrimidine biosynthesis, as gemcitabine is 
a nucleoside analog the efficacy of gemcitabine is inhibited upon increased de 
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novo nucleoside synthesis. This switch to increased glucose uptake and 
nucleoside synthesis is mediated through HIF-1α; pharmalogical inhibition of 
HIF-1α resulted in resensitisation to gemcitabine. This seminal work highlights 
how metabolic rewiring mediated by HIF-1α can confer acquired resistance to 
chemotherapy treatment [122]. 
 
1.5.2.3 HIF transcriptional activity drives EMT switch to promote 
metastasis 
For the majority of cancer cases, the leading cause of death arises from 
metastasis. Therefore significant interest and research has gone in to further 
understanding the molecular drivers of metastasis. As previously mentioned in 
section 1.5.2.1 an early event in metastasis is the formation of vasculature to 
provide an avenue for cells to extrude through. Secondly, epithelial derived 
cancer cells undergo a process termed epithelial-to-mesenchymal transition 
(EMT). Through this process, cells lose E-cadherin which disrupts and cell-to-
cell adhesion and acquire mesenchymal proteins such as vimentin which 
regulates cell shape and motility as well as multiple other changes [123]. The 
switch between these two cell states is driven by a number of transcription 
factors. TCF3, ZFHX1A and ZFHX1B are all transcription factors that repress 
expression of E-cadherin, each of these are HIF-1 target genes therefore active 
HIF-1 will drive expression of each and subsequently repress expression of E-
cadherin [124]. TWIST1 is another transcription factor that mediates the EMT 
switch in cancer cells [125], the TWIST1 gene is a hypoxic responsive gene 
that is activated in a HIF-2 dependent manner in HEK293T cells [126]. Further 
studies have shown that in some cellular contexts TWIST1 is upregulated by 
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HIF-1, furthermore knockdown of TWIST1 in HIF-1α overexpressing cells 
resulted in a reversal of the EMT/metastatic phenotype thereby indicating that 
the HIF-1 upregulation of TWIST1 is a key mediator of hypoxia induced 
metastasis [127].  
 
Following EMT cancer cells invade surrounding tissues, in order to do so the 
cells need to degrade the extracellular matrix surrounding the tissue. This 
occurs through secretion of matrix metallo-proteases (MMPs) [128]. A number 
of these MMPs have been identified as HIF responsive genes [129-131], 
therefore as the cancer cells undergo EMT, HIF will continue to upregulate 
expression of MMPs thereby degrading extracellular matrix and allowing cancer 
cells to migrate through. 
 
1.5.2.4 HIFs promote the glycolytic switch in cancer cells 
In 1925, Otto Warburg first described the phenomena whereby the cellular 
metabolism in cancer increases glucose consumption and lactate secretion 
even with functioning mitochondria and sufficient oxygenation [132]. This was 
paradoxical at the time as lactate production is a product of anaerobic 
metabolism, therefore the term aerobic glycolysis was coined, and this refers 
to the shift from full oxidation of glucose through mitochondrial processes such 
as TCA cycle and subsequent oxidative phosphorylation (OXPHOS) to the 
cytoplasmic glycolytic pathway. Whilst this switch in metabolism appears to be 
an inefficient system for ATP production, it has been hypothesized that this 
occurs as a mechanism to sustain biosynthesis of other molecules such as 
nucleosides and lipids to maintain cell proliferation [133].   
45 
 
 
Hypoxia and HIFs regulates metabolism in a multitude of ways. O2 acts as the 
terminal electron acceptor during OXPHOS, therefore the electron transport 
chain (ETC) ceases to function during hypoxia. HIF signaling directs glucose 
metabolism away from mitochondrial processes at multiple stages. One such 
example is the HIF-mediated upregulation of pyruvate dehydrogenase kinase 
1 (PDK1). This enzyme phosphorylates the pyruvate dehydrogenase (PDH) 
complex at the PDH-E1α subunit, blocking the conversion of pyruvate to acetyl-
CoA [134]. This reaction utilizes Coenzyme A as a substrate to transfer two 
carbons from pyruvate into the TCA cycle. Glucose metabolism is further 
altered through the HIF-dependent induction of LDHA, the gene that produces 
lactate dehydrogenase an enzyme that catalyzes the reversible formation of 
lactate from pyruvate [135]. Lactate is secreted from the cells through the MCT4 
transporter, recent work in fasted mice has demonstrated that lung and 
pancreatic tumours can utilize circulating lactate to fuel the TCA cycle at higher 
rates than glucose [136].  
 
Glutamine addiction is a term to describe how many cancer cells rely on 
glutamine as the predominant mitochondrial substrate to maintain cellular 
function [137]. Glutamine is converted to α-ketogluturate (α-KG) which can then 
participate in the forward TCA cycle to produce ATP, however in hypoxic cells 
this α-KG is reductively carboxylated by isocitrate dehydrogenase (either IDH1 
or IDH2) to form citrate. Citrate is then used to maintain lipogenesis, which is 
required for cell proliferation and function [138-140]. This reductive 
carboxylation is HIF dependent as overexpression of HIF-1α in normoxia 
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diverts glutamine to citrate and the carboxylation is reduced following loss of 
HIF-1α. This result highlights the dependence of cancer cells to utilize 
glutamine as an alternative carbon source, this is of clinical importance as it 
has been shown that treating VHL-null RCC xenografts with glutaminase 
inhibits tumour growth [140].  
 
This section shows how HIFs drive a shift in cancer cell metabolism that has 
been a defining characteristic of cellular transformation that was first noted 
almost a century ago. Furthermore that this switch also provides inherited 
vulnerabilities as a result of glutamine dependency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.2.4: The HIF mediated metabolic switch in hypoxia. Schematic diagram 
showing how metabolism is altered during hypoxia summarizing section 1.5.2.4. 
Pyruvate dehydrogenase complex (red) is inhibited by phosphorylation by PDK1. 
Enzymes highlighted in blue are upregulated or increase in activity in low oxygen 
tensions. 
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1.6 Non-canonical regulation of HIFs 
The O2 dependent regulatory pathway maintains HIF homeostasis in normal 
cells, however multiple cancers upregulate HIF irrespective of oxygen tensions, 
this is exemplified by VHL deletions in ccRCC. There has been extensive 
research in identifying new regulators of HIFs that are often altered in cancer 
and drive tumorigenesis. 
 
1.6.1 Differential regulation of HIF-1α and HIF-2α by mTOR 
The mechanistic target of rapamycin (mTOR) is a kinase that is the core 
component of two complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) [141]. Reports have shown that HIF-1α protein 
expression and transcriptional activity is sensitive to treatment with rapamycin, 
but no changes in protein stability were observed suggesting that this is through 
the role of mTOR in regulating protein translation [142, 143]. Furthermore, in 
RCC cells HIF-1α and HIF-2α protein expression are both reduced following 
siRNA knockdown of MTOR. HIF-1α protein expression is dependent on both 
raptor (component of mTORC1) and rictor (component of mTORC2) indicating 
that both complexes regulate HIF-1α protein however only knockdown of rictor 
resulted in reduced HIF-2α protein [144].  
 
1.6.2 Direct or indirect post-translational modifications that regulate HIFs 
1.6.2.1 Ubiquitination and proteasomal degradation of HIF-1α 
The canonical mechanism of PHD-VHL dependent ubiquitination of HIF-1α is a 
well characterized process, however a number of alternative ubiquitination 
pathways also serve to negatively regulate HIFα protein stability. One such 
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example is the HSP70-CHIP axis. Through LC-MS/MS analysis of HIF 
interacting proteins both heat shock protein 70 (HSP70) and carboxyl terminus 
of Hsc70 interacting protein (CHIP) were identified. CHIP is an E3 ubiquitin 
ligase that ubiuitates HIF-1α in chronic hypoxia in the presence of HSP70. Only 
HIF-1α was subject to ubiquitination through this axis and only in sustained 
hypoxia as part of a negative feedback loop, due to the differential target genes 
between the HIFα isoforms this may regulate differential transcriptome in acute 
and chronic hypoxia [145]. 
 
Parkin is an E3 ubiqutin ligase protein that displays reduced expression in 
breast cancer and inhibits breast cancer cell proliferation in vitro [146, 147]. 
Furthermore parkin was identified as a HIF-1α interacting protein capable of 
ubiquitinating HIF-1α at Lys477 in the ODDD, an alternative residue to pVHL 
mediated ubiquitination. Through this degradation axis, parkin inhibits cancer 
cell metastasis invasion in a HIF-dependent manner [148]. Both the HSP70-
CHIP and Parkin axis show how HIF-1α is subject to further ubiquitination and 
proteasomal degradation beyond the canonical PHD-VHL axis, however 
Montagner et al. demonstrated that HIF-1α can be degraded by the proteasome 
in a ubiquitin-independent manner [149].  
 
SHARP1 (also known as Dec2) is a basic-helix-loop-helix protein that is a 
transcriptional repressor playing a role in regulating the circadian rhythm [150]. 
Co-immunoprecipitation experiments showed that SHARP1 directly interacts 
with HIF-1α and promotes interaction with the proteasome in an oxygen and 
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VHL independent manner [149]. Furthermore loss of SHARP1 increases TNBC 
cell metastasis and invasion in a HIF dependent manner.  
 
1.6.2.2 Regulation of HIF protein stability and activity by acetylation 
Protein acetylation is a major post-translational modification prevalent across a 
wide variety of targets. Acetylation occurs through an enzymatic process, 
mediated by acetyltransferases, where the acetyl group from acetyl-CoA is 
transferred to the N-terminus of proteins or lysine residues [151]. P300/CBP-
associated factor (PCAF) is a lysine acetyltransferase that acts a transcriptional 
cofactor for HIF-1α and p53 [152]. Furthermore PCAF acetylates HIF-1α at 
Lys674 that stabilizes the interaction with the transcriptional coactivator p300, 
deacetylation at this residue is catalyzed by sirtuin 1 (SIRT1) [153]. HIF-2α is 
not acetylated by PCAF, instead through CBP mediated acetylation exclusively 
from Acetyl CoA synthetase 2 (ACSS2) derived acetyl-CoA [154, 155]. SIRT1 
is still the deacetylase active for HIF-2α, however increased SIRT1 expression 
promoted HIF-2 activity, thereby indicating differential roles of SIRT1 and 
acetylation in regulating HIF-1 or HIF-2 transcriptional activity independent of 
protein stability [156].  
 
RNAi-mediated knockdown of the class II histone deactylases, HDAC4 and 
HDAC6, resulted in reduced HIF-1α protein levels and activity in a VHL-
independent manner [157]. Acetylation of HIF-1α by HDAC4 occurs at a cluster 
of lysine residues at the N-terminus (Lys-10, 11, 12, 19 and 21) that serves to 
stabilize HIF-1α as evidenced through cyclohexamide chase assay [158] . 
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These two pathways show contrasting roles of protein acetylation on HIFs as 
one axis regulates protein activity in an isoform specific manner whereas the 
second pathway discussed regulates protein stability in addition to activity.  
 
1.6.2.3 Kinase regulators of HIF 
The role of protein phosphorylation in regulating HIF was established the same 
year that HIF was first characterized, as treating cells with protease inhibitors 
reduced both HIF-1α protein expression and DNA binding capability [159]. 
Since these early experiments a number of kinases that regulate HIF stability 
and activity have been identified. A number of reviews have compiled 
comprehensive lists of these kinases [160, 161], however for brevity, here a 
number of kinases will be discussed to cover different mechanisms that kinases 
regulate HIF activity.  
 
Using an RNAi screen targeting the human kinome, Chen et al. assayed a HRE 
based reporter in HeLa cells. Through this approach they identified SMG-1 as 
a negative regulator of HIF-1 transcriptional activity, which acts through 
inhibition of MAPK [162]. Whilst the authors do not decipher how SMG-1 
regulates MAPK, this work shows that unbiased RNAi screens are an effective 
way of identifying novel regulators of HIF activity. 
 
Inhibitor of differentiation 2 (ID2) is a protein that regulates stem cell 
characteristics that is frequently upregulated in glioma, driving tumorigenesis 
and angiogenesis [163, 164]. Active ID2 binds to pVHL displacing cullin 2 and 
subsequently inhibiting HIF-2α proteasomal degradation. However the kinase 
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DYRK1 maintains ID2 in an inactive state through phosphorylation at Thr27, 
this phosphorylation event is oxygen dependent as DYRK1A and DYRK1B are 
direct targets of PHD1, PHD2 and PHD3 [165]. This work highlights a kinase 
that is required to maintain efficient HIF-2α turnover and presents a novel 
mechanism of destabilization of the pVHL-E3 ubiquitin ligase complex. 
 
Cyclin-dependent kinase 1 (CDK1) plays a crucial role in regulating cell-cycle, 
however CDK1 was identified as a kinase that directly phosphorylate HIF-1α 
[166]. This phosphorylation event occurs at Ser668, the phosphorylation 
stabilizes HIF-1α protein and enhances cell migration and invasion in vitro and 
stimulates tumour growth in vivo. However, another paper proposed a different 
mechanism behind CDK1 mediated HIF-1α stabilisation. These findings 
confirmed that there was a direct interaction between CDK1 and HIF-1α, 
however treatment with the lysosome inhibitor bafilomycin A1 negated the 
effects of CDK1 overexpression [167]. It is unclear as to which mechanism is 
true, or if different cellular context accounts for these differences. Regardless 
these two papers show that direct interaction between an active kinase and 
HIF-1α is capable of stabilising HIF-1α.  
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Figure 1.6.2.3: Hippo signaling regulates HIF-1α activity. Schematic diagram of 
HIF regulation through Hippo signaling pathway. MST1/2 phosphorylates and 
activates LATS1/2. Phosphorylated LATS then phosphorylates YAP, which blocks 
nuclear import. Upon dysregulation of this signaling cascade YAP accumulates in the 
nucleus whereby it binds to HIF-1α thus stabilizing protein and increasing 
transcriptional activity [169]. 
 
The hippo signaling pathway plays an important role in development and 
cancer [168], this pathway involves a kinase cascade where MST1/2 
phosphorylates LATS1/2 which in turn results in the phosphorylation of YAP, a 
transcription factor that is retained in the cytoplasm upon phosphorylation [169, 
170]. A non-transcriptional function of YAP in the nucleus is to directly bind to 
and stabilize HIF-1α [171], therefore deregulation of MST1/2 or LATS1/2 will 
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cause accumulation of nuclear YAP and subsequent stabilisation of HIF-1α. 
LATS2 mutations have not been identified in cancer, however the E3 ubiquitin 
ligase SIAH2 destabilises LATS2 and is found upregulated in breast cancer 
[171]. SIAH2 plays a further role in cancer as other ubiquitination and 
subsequent degradation targets of SIAH2 are the PHD1/3 proteins, therefore 
upregulation of SIAH2 will increase hypoxia signaling via multiple mechanisms 
[172]. 
 
1.6.3 Emerging role of metabolites as regulators of HIFs 
1.6.3.1 Succinate and fumarate inhibit prolyl-hydroxylases  
The TCA cycle is impaired in both hypoxia and pseudo-hypoxia through 
activation of HIFs, induction of PDK1 and phosphorylation of the pyruvate 
dehydrogenase complex as discussed in 1.5.2.4. It has been shown that 
succinate accumulates in multiple hypoxic tissues suggesting that succinate 
acts as a ‘dead-end’ in TCA cycle flux in low O2 conditions [173]. This 
accumulated succinate in the mitochondria diffuses in to the cytoplasm where 
it can inhibit PHDs thereby resulting in stabilised HIFα proteins [174, 175]. Loss-
of-function mutations in succinate dehydrogenase complex enzymes are 
prevalent in multiple cancers including renal cell carcinoma and colorectal [176, 
177].  
 
Germline mutations in fumarate hydratase (FH) predispose patients to 
developing renal cell carcinoma [178, 179]. Addition of fumarate to cells or 
siRNA mediated knockdown of FH result in stabilised HIF-1α in normoxic as a 
consequence of PHD inhibition [180]. Despite both succinate and fumarate 
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being found in non-transformed cells and acting as intermediates in TCA cycle, 
they are still considered to be oncometabolites when accumulated at high levels 
[181], in part due to inhibition of PHDs and regulation of HIFs. These results 
highlight how perturbations in TCA cycle homeostasis can drive cancer 
progression.    
 
1.6.3.2 Prolyl-hydroxylases sense intracellular changes in cysteine 
After an initial observation that TNBC cells expressed stabilised HIF-1α in 
normoxic conditions, which is degraded following the addition of fresh culture 
medium, L-glutamine was identified as a secreted molecule that stabilizes HIF-
1α through inhibition of prolyl-hydroxylase function [88]. L-glutamine was 
secreted through the xCT cystine-glutamine antiporter, which depletes 
intracellular cysteine. This depletion of intracellular cysteine is sufficient to 
inhibit prolyl-hydroxylase function and stabilise HIF-1α. This landmark paper 
provides insights in to how PHD enzymes are able to sense changes in cysteine 
as well as oxygen.  
 
1.6.3.3 IDH1/2 mutations and the role of 2-HG as an oncometabolite 
As previously discussed, cell metabolism is significantly altered in cancer. 
Rewiring of these metabolic pathways does not solely result in altered levels 
and fluxes of metabolites; certain mutations can result in formation of atypical 
metabolites, one such example of this is mutations in isocitrate dehydrogenase 
(IDH1 and IDH2). Mutations in IDH1 and IDH2 occur at high frequency in 
gliomablastoma patients with mutations always affecting the R132 codon; in a 
cohort of 445 CNS tumours over 70% of patients were positive for IDH1-R132 
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mutations [182]. Furthermore, IDH mutations have been identified, albeit less 
frequently (1.1% of NSCLC), in breast and lung cancer [183, 184]. Wild-type 
IDH catalyzes the decarboxylation of isocitrate to form α-ketogluturate (also 
known as 2-oxogluturate, αKG) in a reversible reaction that occurs both in the 
cytoplasm as well as in the mitochondria as part of the TCA cycle, however 
mutant IDH gains the ability to convert αKG into the (R)-enantiomer of 2-
hydroxygluturate (2-HG)  [185, 186].  The role of HIFs in brain tumours is 
different to other tumours as it has been reported that HIF-2α acts as a tumour 
suppressor in these cancers and that HIF-1α reduces tumour growth and brain 
penetrance in orthotopic tumour models [187, 188]. This is of importance as 2-
HG accumulates in tumours with IDH mutations and acts as a substrate for 
PHD enzymes, thereby increasing turnover of HIF-1α protein. This increased 
degradation of HIF resulted in increased proliferation and anchorage 
independent growth of astrocytes [189]. Whilst the role of HIF is reversed in 
brain tumours compared to most solid tumours, these results highlight how 
oncogenic mutations resulting in the formation of novel metabolites can 
modulate HIF pathway activity that drives cancer progression. The converse of 
this has been observed in cancer-associated fibroblasts, which display a 
reduction in IDH3α (a related homolog of IDH1 and IDH2 but performs non-
reversible reactions) following transformation from fibroblast to CAF. In these 
IDH3α deficient cells, prolyl-hydroxylase function is inhibited as a consequence 
of depleted levels of α-KG and subsequent accumulation of succinate and 
fumarate. This results in stabilised HIF-1α that helps promote pro-tumour 
functions of CAFs [190].  
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Through genetic screens in haploid cell lines, Burr et al. identified that loss of 
OGDH (the gene encoding a core component of the alpha ketogluturate 
dehydrogenase complex) and LIAS (Lipoic acid synthase, of note lipoate was 
further identified as an OGDHC inhibitor) resulted in stabilised HIF-1α in 
normoxic conditions. Disruption of this complex resulted in accumulation of L-
2-HG, an enantiomer of R-2-HG that also inhibited PHD activity [191]. 
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1.7 Aims 
This work highlights the importance of HIF signaling in driving tumourigenesis 
in multiple cancer types. HIF target genes regulate many pro-tumourigenic 
functions such as inducing metastasis, increasing resistance to treatment and 
altering cellular energetics to sustain growth. Dysregulation of HIF occurs by 
multiple mechanisms resulting in a pseudo-hypoxic phenotype and a HIF driven 
cancer progression.  
 
We aim to identify novel regulators of HIFs that may serve as therapeutic 
targets in breast and lung cancer. 
 
To achieve this we aim to:  
 Perform an unbiased screen of HIF-1 activity to identify novel 
regulators 
 Validate hits and determine mechanism behind HIF regulation 
 Determine the role of this novel regulator on cellular transformation 
 Assess the expression of this regulator in patient data and determine 
suitability for targeted therapy 
 Identify a small molecule to selectively target this novel regulator of 
HIFs in cancer cells 
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Materials and Methods 
 
2.1 Buffers and materials 
2.1.1 Materials and solutions for bacterial culture 
1. Agar plates – 3.5% (w/v) LB-Agar was dissolved in distilled water and 
autoclaved and stored at room temperature until use. To prepare plates agar 
was boiled in microwave to before allowing to cool to ~40°C. Once cool, 
appropriate dilution of antibiotic was added and solution was poured into sterile 
plates and left to set at room temperature. Plates were stored at 4°C and used 
within 4 weeks.  
2. Ampicillin – 100 mg.mL-1 stock solutions were stored at -20°C in 1 mL 
aliquots. Working concentrations of 100 µg.mL-1 were used throughout. 
3. Kanamycin – 50 mg.mL-1 stock solution of kanamycin was stored at 4°C. 
Agar plates were made at concentration of 50 µg.mL-1 and liquid cultures were 
prepared at a concentration of 33 µg.mL-1. 
 
2.1.2 Solutions for DNA agarose electrophoresis 
1. 10X DNA loading solution – 30% glycerol and 0.25% (w/v) bromophenol 
blue were dissolved in MilliQ distilled water and stored at room temperature. 
Solution was diluted to 1X with sample prior to loading. 
2. Tris-Borate EDTA buffer – 10X TBE buffer was diluted to 1X with distilled 
water to achieve final concentration of 40 mM Tris-Borate and 2 mM EDTA.   
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2.1.3 Cell lysis buffers 
1. RIPA buffer – 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 1% (v/v) IGEPAL-630 and 50 mM Tris (ph 8.0) were dissolved in MilliQ 
distilled water and stored at 4°C. 
2. Protease and phosphatase inhibitors – Pierce protease inhibitors and 
phosphatase inhibitor tablets (Thermofisher) were dissolved in 10 mL of RIPA 
buffer before storing solution in -20°C.  
 
2.1.4 Solutions for SDS-Page and Western blotting 
1. Phosphate buffered saline (PBS) – 10X PBS solutions were prepared by 
dissolving 1 sachet of PBS powder (Severn biotech) in 1 L of distilled water. 
10X solution was further diluted to 1X with distilled water to achieve final 
concentration of 137 mM NaCl, 2.7 mM KCl, 4m3 mM Na2HPO4 and 1.47 mM 
KH2PO4. 
2. PBS-T – 10X PBST solution was prepared by dissolving 1 sachet of PBS 
powder in 1 L of distilled water before adding 5 mL of Tween-20 (Sigma-
aldrich). 10X solution was further diluted to 1X with distilled water to achieve a 
final concentration of 1X PBS with 0.05% tween.  
3. Western blot blocking solution – 5% skimmed milk powder (w/v) (Sigma-
Aldrich) or 5% Bovine serum albumin (w/v) (Sigma-Aldrich) were dissolved in 
1X PBST and stored at 4°C and used within 4 days.  
4. SDS-PAGE Gel casting solutions – Resolving gel: 30% Protogel 
Acrylamide, 4X Resolving buffer (BioRad) were made up to appropriate 
concentration in distilled water. Acrylamide was set with the addition of 1:100 
of 10% Amino persulfate (Sigma-aldrich) and 1:1000 of N,N,N’,N’-
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tetramethylethylenediamide (TEMED) (Sigma-aldrich). Stacking buffer was 
made as before but with 1:200 of 10% Amino persulfate and 4X stacking buffer 
(1.0M Tris pH 6.8, 10% (w/v) SDS). 
5. SDS-PAGE Running buffer – 10X Tris glycine-SDS buffer was diluted to 
1X with distilled water to achieve a final concentration of 25 mM Tris (ph 8.3), 
0.2 M Glycine and 1% (w/v) SDS. 
6. Transfer buffer – 10X Tris glycine buffer was diluted with distilled water and 
methanol added to make final solution of 1X tris-glycine with 20% methanol. 
7. 5X SDS-PAGE loading buffer – 250 mM Tris-HCl (ph 6.8), 50% (v/v) 
glycerol, 0.05% (w/v) Bromophenol blue and 5% (w/v) SDS were dissolved in 
distilled water. For reducing conditions 5% (v/v) β-mercaptoethanol was added 
to loading buffer. Buffer was stored in 1 mL aliquots at -20°C.  
8. Coomassie Blue staining solution – 0.1% (w/v) Coomassie Brilliant Blue 
R was dissolved into a 40% Methanol, 10% acetic acid and 50% distilled water 
solution. Solution was stored at room temperature. 
9. Coomassie Blue De-staining solution – 10% (v/v) and 10% (v/v) acetic 
acid were mixed with distilled water and stored at room temperature. 
 
2.2 Bacterial culture 
2.2.1 Transformation of chemically competent cells 
DH5α chemically competent cells (New England biolabs) were removed from -
80°C and thawed on ice for 10 minutes. 2 µL of ligated DNA or 1 uL of purified 
plasmid were added to 25 uL of competent cell suspension before incubating 
on ice for 30 minutes. The cells were then heat shocked in a water bath set to 
42°C for 30 seconds before incubating on ice for a further 5 minutes. 500 µL of 
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Luria Broth (LB) was added to the cell suspension and resulting mix was 
incubated at 37°C for 1 hour with gentle agitation. 40-400 µL of the bacteria cell 
suspension was spread onto agar plates with appropriate antibiotic (Kanamycin 
at 50 µg.mL-1 and Ampicillin at 100 µg.mL-1) and left overnight at 37°C. Positive 
colonies were picked with 200 µL pipette tip and inoculated overnight in 5 mL 
of LB containing appropriate antibiotic selection. The following day 800 µL of 
bacteria suspension was mixed with 200 µL of glycerol before immediately 
storing at -80°C. Remainder of bacteria suspension was used for downstream 
analysis. 
 
2.2.2 Plasmid DNA extraction from bacteria cultures 
2.2.2.1 Mini-prep DNA extraction 
Mini-prep DNA extractions were performed using Monarch Plasmid miniprep kit 
(New England Biotech) as per manufacturers instructions. Briefly 5 mL of 
bacteria culture was inoculated overnight in LB containing appropriate antibiotic 
selection. 4 mL of the bacterial suspension was centrifuged at 5000 G to pellet 
bacteria prior to continuing the protocol. The protocol is based around the 
traditional alkaline lysis method with the RNAse added to the first suspension 
buffer to remove all bacterial RNA prior to continuing with the purification using 
a column based approach. Eluted plasmid DNA was analysed on Nanodrop to 
measure purity and concentration, 260:280 ratio of over 1.8 and 260:230 ratio 
of at least 1.9 was used as quality control of plasmid DNA. 
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2.2.2.2 Midi-prep and Maxi-prep DNA extraction 
Both Midi-prep and Maxi-prep kits were performed using kits from Qiagen as 
per manufacturers instructions. Starting cultures of 50 mL (Midi-prep) and 200 
mL (Maxi-prep) were used for plasmid isolation. Extractions were performed as 
in 2.2.2.1 but with larger reaction mixtures. The primary difference lies in an 
altered elution step that contains an additional isopropanol precipitation step. 
DNA pellets were washed 2 times with ice-cold 70% ethanol before dissolving 
in TE buffer. Quality and concentration of plasmid DNA was analysed using 
nanodrop spectrophotometer. 
 
2.3 Nucleic acid techniques 
2.3.1 Agarose gel electrophoresis of DNA 
Agarose gels (0.8-3% agarose w/v) were prepared by melting the appropriate 
amount of agarose in 1X TBE (Tris-Borate EDTA) buffer depending on DNA 
size and required resolution. Warm agarose solution was allowed to cool before 
adding either GelRed or GelGreen (Biotium) and pouring into casting station 
with suitable comb. DNA size was estimated by running GeneRuler 1Kb plus 
DNA ladder (ThermoFisher). DNA electrophoresis was performed on horizontal 
gel electrophoresis equipment at a constant voltage of 80-100V. Bands were 
visualised under UV or blue light and imaged using Amersham Imaging 
ChemiDoc 600 (GE Healthcare) or G:BOX imaging system (Syngene) and 
GeneSnap software. 
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2.3.2 Extraction of DNA from agarose gels 
DNA bands were visualised under blue light and excised from agarose using 
clean scalpel. The DNA was extracted using Monarch gel extraction kit (New 
England Biolabs) as per manufacturers instructions. DNA bands were weighed 
inside a sterile 1.5 mL eppendorf before dissolving band in 4 volumes of 
dissolving buffer at 55°C. Solutions were transferred to Monarch DNA cleanup 
columns before being washed two times with DNA wash buffer. DNA was eluted 
in elution buffer and quantified using Nanodrop. 
 
2.3.3 Restriction enzyme digest of DNA 
Restriction enzyme digest of DNA was performed with enzymes in their 
appropriate buffer (New England Biolabs). For each 1 μg of DNA to be digested, 
10 units of enzyme and 1 μL of appropriate buffer was added to nuclease free 
water to a final reaction volume of 10 μL. Reactions were heated to 37°C using 
Verity thermocycler (Applied Biosystems). 10X DNA buffer was added to stop 
reaction before separating DNA fragments by agarose gel electrophoresis. 
 
2.3.4 Ligation of digested DNA insert into linearised vector 
All digestions were performed with sticky-ends created by two distinct 
restriction endonucleases such that vector and insert had complementary 
overhanging ends to ensure correct insert orientation. Prior to ligation vector 
and insert were both digested as described in 2.3.3 and DNA was purified as 
detailed in 2.3.2. Ligations were performed with an insert to vector molar ratio 
of 3:1. A total of 25 ng of vector and the appropriate amount of insert was made 
up to a final volume of 5 μL with nuclease free water. 5 μL of 2X Instant sticky-
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end ligase master mix was added and mixed by gentle pipetting. Reactions 
were left for 5 minutes at room temperature before proceeding with bacteria 
transformation as described in 2.2.1. In parallel a second reaction was 
performed without insert to assess self-annealing of plasmid DNA. 
 
2.3.5 DNA amplification by polymerase chain reaction (PCR) 
For Amplification of DNA, the proofreading polymerase Phusion Hot Start Flex 
2X master mix (New England biolabs) was used. Forward and reverse primers 
were used at a final concentration of 0.5 µM each. DMSO is also added to the 
reaction mixtures at a final concentration of 3%, DMSO binds to cytosine 
residues making the DNA more susceptible to heat denaturation and aids in the 
amplification of G-C rich regions. Template DNA was used at a concentration 
of 2-20 ng for plasmid DNA or at least 50 ng for genomic DNA.  
 
Cycling conditions are displayed below:  
Table 2.3.5: Cycling conditions used for PCR 
Step Temperature Duration 
Initial Denaturation 98°C 30 seconds 
Cycles 98°C 5-10 seconds 
Annealing temperature 
50-72°C 
10-30 seconds 
72°C 20 seconds/kb 
Final Extension 72°C 5 minutes 
Hold 4°C Indefinitely 
 
65 
 
Number of cycles varied depending on subsequent usage, for example site 
directed mutagenesis reactions were performed with 25 cycles however 
amplification from cDNA for ligations were performed with 40 cycles. 
 
2.3.6 Site directed mutagenesis (SDM) 
Primers were designed for SDM using the online tool nebbasechanger (New 
England Biolabs). PCR reactions were performed as described in section 2.3.5 
prior to performing the KLD reaction as described by the manufacturer. The 
KLD reaction phosphorylates the PCR product to allow for the ligation prior to 
DpnI digest to degrade the template DNA (due to dam methylation which occurs 
in bacterial production of plasmid DNA). The resulting KLD mix is then 
transformed as described in section 2.2.1 before confirming successful 
mutagenesis by Sanger sequencing (Source bioscience).  
 
2.3.7 Nucleic acid extraction from cultured cells 
2.3.7.1 Genomic DNA extraction from cultured cells 
Genomic DNA was extracted from cultured cells using QuickExtract DNA 
extraction solution (EpiBio) as per manufacturer’s instructions. Briefly, cell 
pellets (~ x104 cells) were collected and washed with PBS before resuspending 
in 500 µL of extraction solution. Samples were vortexed before heating to 65°C 
for 6 minutes and then 98°C for 2 minutes. The resulting solution contains 
genomic DNA ready for PCR amplification. Samples were stored at -20°C. 
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2.3.7.2 mRNA extraction from cultured cells. 
For RNA extractions the ReliaPREP RNA Miniprep system (Promega) was 
used. This is a column based assay kit that extracts mRNA from cultured cells. 
The column has binding capacity for mRNA and other lncRNA but does not 
capture small RNA such as miRNA. For mRNA extractions the protocol was 
followed as per manufacturer’s instructions. Briefly, cell lysis is performed with 
a guanidine thiocyanate buffer supplemented with 1-thioglycerol to disrupt cell 
integrity whilst maintaining RNA integrity. After loading lysate on to the column 
and wash steps, the column is treated with DNAse I for 15 minutes to ensure 
RNA is pure following extraction. Following further washes the RNA is eluted in 
nuclease free water and concentration and purity is measured using Nanodrop 
spectrometer. 
 
2.3.8 Real-time quantitative reverse transcription PCR (RT-qPCR) 
qRT-PCR was performed using 1-Step qRT-PCR GoTaq system (Promega) as 
per manufacturer’s instructions. Briefly, 35 ng of RNA was used in a 20 µL 
reaction with 50X RT and 2X Go-Taq master mixed diluted down to 1X with 
nuclease free water. For each primer pair two wells of no template controls 
were assayed to ensure no non-specific amplification arises from potential 
contaminations of stock solutions, to ensure amplification is from cDNA derived 
from initial RNA stock reaction mixtures lacking the 50X RT were also prepared 
for each sample. QuantStudio 5 (Applied Biosystems) was used for all qRT-
PCR experiments using the in built QuantStudio software. Cycling conditions 
for qRT-PCR are listed below. Melt curve analysis was performed for each 
reaction mix to ensure only a single peak is present and amplification is specific, 
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any reactions where mixed peaks were present in sample were discarded from 
subsequent analysis.  
 
Table 2.3.8: Cycle conditions used for all qRT-PCR reactions 
Stage Temperature Time 
Hold stage 37°C 15 minutes 
95°C 10 minutes 
PCR Cycle 
(40X cycles)  
95°C 15 seconds 
60°C 45 seconds 
Melt Curve 95°C 15 seconds 
60°C 15 seconds 
95°C 1 second (0.15°C.s-1 ramp 
speed) 
 
Prior to performing experiments, primers were optimised to achieve 100% 
efficiency. To achieve this, serial dilutions of RNA were prepared with a top 
RNA volume of 50 ng was assayed against a concentration range of primer 
concentration at a set annealing temperature of 60°C. Reaction efficiencies 
were calculated by plotting Log (RNA concentration) vs Average CT value, the 
gradient of this standard curve was used in the equation below: 
𝑃𝑟𝑖𝑚𝑒𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  100 × (10
−1
(𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡−1) ) 
 
Primer concentrations that yielded efficiencies between 95-105% were used for 
subsequent reactions. For each primer pair used the final concentration was 
200 nM apart from HIF1A and HIF2A were concentrations of 250 nm were used. 
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For analysis of samples the standard curve was used to give relative mRNA 
concentrations that are then normalised to housekeeping genes such as RPII. 
 
2.4 Cell culture 
2.4.1 Culturing of cells in 2D monolayer 
Adherent cells were cultured in media indicated in the Table 2.4.1 and 
maintained in humidified incubator set to 37°C and 5% CO2. Hypoxic 
incubations were performed by incubating cells in INVIVO2 (Ruskinn) at 1% O2, 
5% CO2 and 94% N2 for specified time.  
 
For plating of cells for downstream experiments or passaging of cells; cells were 
washed in sterile PBS to remove residual medium prior to detaching cells with 
Trypsin-EDTA at 37°C. Complete media was added to neutralize trypsin. Cell 
suspension was centrifuged for 3 minutes at 1,300 rpm to form a cell pellet, 
which was subsequently washed 1x with sterile PBS before re-suspending in 
complete media. Cells were counted using TC20TM BioRad Cell Counter before 
plating at optimal cell density for each cell line and assay.  
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Table 2.4.1: Cell culture medium and additives used for culturing cell lines 
Cell line Basal Medium Serum Other Supplements 
A549 DMEM 10% FBS  
HeLa DMEM 10% FBS  
U2OS DMEM 10% FBS  
HEK293T DMEM 10% FBS  
SAEC Small airway 
medium (Lonza) 
 Kit includes: hEGF, 
epinephrine, triiodothyronine, 
transferrin, BSA, retinoic acid, 
GA-1000, Hydrocortisone, 
Insulin and BPE 
MCF10A DMEM/F12 
media 
5% Horse serum 20 ng.mL-1 EGF, 0.5 mg.mL-1  
hydrochortisone, 100 ng.mL-1  
Cholera toxin 
10 µg.mL-1  Insulin 
T47D RPMI 10% FBS  
ZR-751 RPMI 10% FBS  
SKBR3 McCoy’s 5A 
media 
10% FBS  
MDA MB231 RPMI 10% FBS  
MDA MB468 RPMI 10% FBS  
HCC1143 RPMI 10% FBS  
MCF7 RPMI 10% FBS  
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2.4.2 Cell Freezing 
Adherent cells were trypsinised and collected by centrifugation (Section 2.4.1). 
The resulting cell pellets were washed with PBS to remove residual trypsin and 
media; cells were further pelleted by centrifugation (3 minutes at 1300 rpm) 
before removing supernatant. Freezing media (90% FBS (v/v) and 10% DMSO 
(v/v)) was used to resuspend cell pellet before aliquoting into 1 mL cryovials. 
Cells were immediately stored at -80°C overnight before transferring to liquid 
nitrogen for long-term storage. 
 
2.5 Transfection of nucleic acids to 2D cultured cells 
2.5.1 Transfection of plasmid DNA with ViaFect™ 
Cells were plated a day prior to transfection and left to adhere overnight. DNA 
transfections were performed using ViaFect™ transfection reagent as per 
manufacturer’s instructions. ViaFect was added to Opti-MEM serum free 
medium to give a 3:1 ratio (μL of viafect to μg of plasmid DNA) and incubated 
for 5 minutes to allow lipid complexes to form. DNA is then added for a further 
20 minutes to allow for DNA:lipid complexes to form before adding to cells in 
antibiotic free medium. The following day media was changed to fresh medium 
with antibiotics and cells are analysed 48 hours post transfection. 
 
2.5.2 Transfection of siRNA with Dharmafect™ 
 For forward transfections cells are plated a day prior to transfection at 
appropriate cell density; reverse transfections are performed by adding 
transfection mix directly to wells prior to adding cell suspension. Unless 
otherwise stated, siRNA transfections were performed with either Dharmafect 
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1 or Dharmafect 2 transfection reagents. Transfection reagent was added to 
Opti-MEM serum free medium at an equal volume to siRNA (diluted to 20 μM) 
and incubated for 5 minutes. siRNA was added directly to transfection mixture 
and mixed by gentle pipetting before adding to cells in antibiotic free medium. 
The following day media was changed to fresh DMEM containing antibiotics 
and cells are analysed 72 hours post transfection. 
 
2.6 Lentirviral transduction to produce stable cell lines 
To produce lentivirus, HEK293T cells were transfected with lentiviral vector and 
second-generation packaging plasmids pHR’-CMV-8.2ΔR (packaging) and 
pMDG.2 (VSV-G envelope plasmid) at a ratio of 15:6:11 respectively.  
48 hours following transfection, viral media was harvested, centrifuged at 1500 
rpm for 3 minutes to remove cell debris and passed through 0.22 μM sterile 
filter before mixing with complete medium (50% v/v) and adding to cells to be 
transduced. Transduced cells were maintained in antibiotic containing medium 
at appropriate concentration for at least 10 days to select for successful 
transgene incorporation. To determine appropriate dose of antibiotic for 
selection, kill curves were performed for each experiment. Cells were plated at 
an appropriate density to be 50-60% confluency the following day, cells were 
treated with a varying dose of antibiotics for 72 hours before determining 
minimum dose required to kill all cells. 
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Figure 2.6: Puromycin kill curve. Representative image of puromycin kill curve. A549 
cells were treated with puromycin for 48 hours before imaging cells by bright field 
microscopy. Cells were then fixed in methanol overnight before staining with crystal 
violet. 
 
2.7.1 Analysis of cell proliferation using Incucyte 
Cells were grown and pretreated with doxycycline (25 ng.mL-1) in 2D monolayer 
and maintained in logarithmic growth phase prior to incucyte analysis. Cells 
were trypsinised and re-plated at 30,000 cells per well in 12-well plate. Once 
cells had adhered the plate was placed into incucyte with brightfield images 
taken every 6 hours for 7 days. Media was replaced with fresh complete media 
every 48 hours. Confluency masks were calculated for each well to account for 
plate surface coverage, results were presented as percentage confluency. 
 
2.7.2 Analysis of cell proliferation using Countess II cell counter 
A549-tet-shRNA lines were pretreated with doxycycline at 25 ng.mL-1 for 72 
hours prior to plating. On day of plating cells were detached as described in 
2.4.2 before being plated at a density of 30,000 cells per well in duplicate plates 
with one being placed immediately in 1% O2 and the other maintained in 
atmospheric oxygen. On days 1, 3, 5 and 7 cells were detached and re-
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suspended in a final volume of 1 mL of cell culture media. The resulting cell 
suspension was counted on Countess II cell counter.  
 
2.7.3 Clonogenic assays 
Inducible shRNA lines were treated with doxycycline at 25 ng.mL-1 for 72 hours 
before cells were detached from plate with trypsin and neutralising with 
complete medium. Cells were spun at 1300 rpm for 5 minutes before re-
suspending in 1 mL of complete medium before counting using TC20TM BioRad 
Cell Counter or Countess II (ThermoFisher) using Trypan blue to detect viable 
cells. Cells were plated at either 100 cells per well and immediately placed into 
hypoxia workstation or 21% O2 incubator for 10 days with regular media 
changes every 2-3 days. After 10 days and visible cell colonies formed, cells 
were washed three times in PBS before fixing in 100% methanol overnight. 
Fixed cells were stained with crystal violet solution (aq, 0.05% w/v) for 40 
minutes before being washed in distilled water. Colonies were counted 
manually on top of a white light box. 
 
2.7.4 Wound healing assay 
A549-tet-RNA cells were pre-treated with 25 ng.mL-1 for 72 hours prior to 
plating at a density to be a confluent monolayer the following day. Once cells 
had adhered and the cells reached a confluent monolayer wells were scratched 
with a P200 pipette to remove cells. Each well was washed three times with 
fresh complete DMEM with doxycycline to remove any floating cells. Scratches 
were imaged and photographed using a 4x objective, wound closure was 
measured 6 and 24 hours later. Wound closure was measured using the MRI 
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wound healing tool plug-in on ImageJ [192]. Wound closure percentage was 
calculated using formula below:  
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒
= 100 × (
(𝑆𝑡𝑎𝑟𝑡 𝑤𝑜𝑢𝑛𝑑 𝑠𝑖𝑧𝑒 − 𝐶𝑙𝑜𝑠𝑒𝑑 𝑤𝑜𝑢𝑛𝑑 𝑠𝑖𝑧𝑒)
𝑆𝑡𝑎𝑟𝑡 𝑤𝑜𝑢𝑛𝑑 𝑠𝑖𝑧𝑒
) 
 
2.8 Protein expression analysis 
2.8.1 Sample collection and protein quantification 
Cells were washed 3 times in ice cold PBS and lysed in RIPA buffer (150 mM 
NaCl, 1% (v/v) IGEPAL, 0.5% (w/v) Deoxycholic acid, 0.1% (w/v) SDS, 50 mM 
Tris) with added protease and phosphatase inhibitors (Roche). Cell lysate was 
scraped and transferred to a 1.5 mL Eppendorf tube before centrifugation at 
14000 rpm for 10 minutes to clear insoluble cellular debris. Supernatant is 
collected and stored at -80°C. Protein concentration was quantified using 
Pierce BCA protein assay kit as per manufacturer’s instructions 
(ThermoFisher). Samples were made up to the required concentration in 
sample buffer (250mM Tris-HCL ph 6.8, 50% (v/v) glycerol, 5% (v/v) SDS, 
0.05% Bromophenol Blue and β-mercaptoethanol) and boiled for 5 minutes at 
95°C to denature proteins. 
 
2.8.2 Western blot 
Samples were separated via electrophoresis on 6-12% gels (BioRad). Proteins 
were transferred onto PVDF membrane (activated with methanol and 
rehydrated with ddH2O) using either semi-dry transfer method (Trans-Blot, 
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BioRad) or wet transfer (Criterion, BioRad). Membranes were blocked in 5% 
skimmed milk solution (Sigma) in PBS-T (0.05% Tween-20) or 5% BSA solution 
(Sigma) in TBS-T (0.1% Tween-20). Membranes were incubated in primary 
antibody at 4°C overnight (see Table 2.8.2 for concentrations). The following 
day membranes were washed three times in PBS-T and incubated in 
secondary antibody for 1 hour at room temperature. Protein expression was 
detected using either Immobilon chemiluminescent HRP western blotting 
substrate (Millipore) or Pierce Enhanced chemiluminescence  (ECL) western 
blotting substrate (Thermo Fisher) and developed onto chemiluminescent 
detection film or using Amersham Imaging ChemiDoc 600 (GE Healthcare). 
Band densitometry was calculated using either ImageJ software. 
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Table 2.8.2: Antibodies used throughout the thesis and dilutions required for 
western blotting. 
Target  Supplier Dilution Target Supplier Dilution 
HIF-1α BD 
Trasnduction 
1:500 ACSS1 Proteintech 1:1000 
HIF-2α Novus 1:500 ACSS2 Proteintech 1:1000 
HIF-1β Cell Signalling 1:500 OGDH Proteintech 1:1000 
CoAsy 
(mAb) 
Abcam 1:1000 PDHA1 Abcam 1:1000 
CoAsy 
(pAb) 
Abcam 1:1000 LIMD1 Homemade 1:1500 
β-actin Sigma-aldrich 1:25,000 GST Cell Signalling 1:1000 
PHD2 Abcam 1:2000 GFP Roche 1:2000 
PD-L1 Cell signalling 1:1000 HA Cell Signalling 1:1000 
VHL BD 
Transduction 
1:1000 CoA Homemade 
(Prof. Ivan Gout) 
1:6000 
 
2.8.3 Immunoprecipitation assays 
Immunoprecipiration experiments were performed with the ImmunoCruz 
Optima IP Matrix system (Santa-Cruz biotech). IP matrix species was selected 
to correspond to the antibody used in IP. Tubes containing matrix were vortexed 
gently until homogenous bead slurry is formed before aliquoting 35 µL per 
reaction. Beads were re-suspended in a 500 µL of 2% BSA and 2 µg of primary 
antibody and left overnight at 4°C with gentle agitation. The following day beads 
were pelleted by centrifugation before being washed with RIPA lysis buffer. 
Input samples were taken from cleared lysate before adding the rest to IP 
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matrix. IP mixtures were incubated for 1 hour at room temperature with gentle 
agitation. Bead-IP-Protein complexes were pelleted by centrifugation before 
being washed 3x with RIPA lysis buffer. Complexes were eluted by boiling IP 
matrix in 35 µL of 5x protein sample buffer. Samples were analysed by western 
blot.  
 
2.8.4 Immunohistochemistry 
Staining of TMA was performed using Leica autostainer system and Novolink 
detection kit (Leica). Slides were heated to 60°C for 10 minutes to aid in section 
attachment to the slides before dewaxing and rehydrating on Leica autostainer 
(2 washes with Xylene, 3 washes with industrial methylated spirits and a final 
wash in water). Antigen was performed by boiling slides in citrate buffer (pH 
6.0) for 15 minutes in microwave. Slides were blocked using peroxidase block 
and protein block as per manufacturers instructions before being stained with 
α-CoAsy pAb (ab155551) at a concentration of 1:75 for 1 hour at room 
temperature. Post primary, polymer, haematoxylin and DAB solutions were 
added as per manufacturers instructures before dehydrating and clearing slides 
using Leica autostainer. Slides were mounted on to coverslips with DPX before 
leaving to dry overnight prior to downstream analysis. 
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2.9 siKinome Screen 
2.9.1 siKinome library 
The screening library was the siGENOME protein kinases set from Dharmacon. 
This library includes 720 SMARTpool siRNA (4 siRNA sequences per target 
gene) targeting all known kinases, pseudokinases and proteins with predicted 
kinase activity. The library is supplied as 5 μL aliquots of 2 μM stock in the inner 
wells of a 96 well plate. The edge wells were filled with 5 μL of 2 μM siRNA 
targeting HIF1A, HIF2A, PHD2 and scrambled control.  
 
2.9.2 siKinome screen protocol 
A549 HRE reporter cells were plated in an optimized cell density. After 24 hours 
cells were transfected with siRNA library in duplicate using INTERFERin 
(Polyplus) transfection reagent and optiMEM (Thermo Fisher) reduced serum 
media to a final concentration of 50 nM.  The following day, siRNA-containing 
media was replaced with fresh complete media. One set of library-transfected 
cells was placed into hypoxia 48 hours after transfection. 18 hours later cells 
were removed from hypoxia and resazurin solution was added to a final 
concentration of 0.4 mg.mL-1 to all transfected cells before incubating for 3 
hours at 37°C and cell viability was assessed by measuring fluorescence using 
Wallac 1420 Multilabel counter plate reader at 560Ex/590Em. Cells were 
subsequently washed 3x with PBS prior to lysing in 25 μL passive lysis buffer 
(PLB, Promega), before freezing at -80°C. Luciferase activity was measured 
using Luciferase assay substrate (Promega) as per manufacturers instructions.  
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2.9.3 siKinome screen analysis 
Luminescence values from luciferase activity were normalized to resazurin 
fluorescence values. Z-scores were calculated for each kinase, representing 
standard deviations from the mean, negative values represent knockdown of a 
positive regulator of HIF-activity or positive values represent knockdown of a 
negative regulator of HIF-activity. Z scores of ±2 were considered to be ‘hits’. 
 
2.10 Labelled glucose metabolomics sample preparation 
For labelled glucose experiments, A549 cells were treated with siRNA at 40 nM 
with 5 technical replicates in duplicate plates. 24 hours later the media was 
replaced with fresh DMEM and one plate placed into hypoxia. The following day 
media was changed to ‘heavy’ glucose media (1X DMEM with 10 mM 13C-
Glucose (Cambridge isotopes) and 2 mM Glutamax). 24 hours following cells 
were washed with 0.9% NaCl before being place immediately on to dry ice to 
halt metabolism. Cells were scraped into 50:50 mix of 0.05% beta-
hydroxytoluene (in methanol) and 1 µg.mL-1 d6-glutaric acid (in MilliQ filtered 
water). Samples were snap frozen and stored at -80°C prior to  
 
2.11 FDA approved drug library screen 
Prior to drug screen, tet-shRNA cells were treated with doxycycline at 25 ng.mL-
1. On day 0 cells were plated at optimum density before being left overnight to 
attach. The library contains 14 plates of drugs arrayed so that each well 
contains 2 µL of 10 mM solution in DMSO, this solution was dissolved in 
complete DMEM to achieve a final concentration of 200 µM. Control wells of 
DMSO alone and media alone were added to the surrounding wells on the 
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plate. On day 1 and 3, the culture medium on cells was moved and replaced 
with 95 µL of fresh medium (with doxycycline) before adding 5 µL of drug 
aliquot. On day 5 cell viability was measured using resazurin viability reagent 
as described previously. Fluorescence values were used to calculate modified 
Z-scores using the formula below: 
𝑍 𝑠𝑐𝑜𝑟𝑒 = 𝑋 −
𝑀𝑒𝑑𝑖𝑎𝑛 (𝑠𝑎𝑚𝑝𝑙𝑒)
𝑀𝐴𝐷 (𝑠𝑎𝑚𝑝𝑙𝑒)
 
𝑀𝐴𝐷 (𝑠𝑎𝑚𝑝𝑙𝑒) =  𝑚𝑒𝑑𝑖𝑎𝑛i(|𝑋i − 𝑚𝑒𝑑𝑖𝑎𝑛i(𝑋i)|) 
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Results Chapter One: 
 
RNAi kinome screen identifies Coenzyme A synthase 
as a negative regulator of HIFs 
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3.1 Chapter aims 
HIF transcriptional activity has been reported as a driver of tumourigenicity 
across multiple cancer types. Furthermore multiple regulators of HIFs have 
been identified that are mutated or deregulated in cancer, thereby driving 
tumour progression in a HIF dependent manner. We aim to identify novel 
regulators of HIF activity. We achieved this through development a reporter 
system that was screened with a library targeting the entire human kinome, 
followed by subsequent validation.  
 
To summarise we sought to: 
 Develop stable HIF-1 reporter cell line and validate isoform 
specificity 
 Optimise siRNA screen protocol to ensure result validity 
 Perform siRNA screen using siKinome library 
 Validate significant hits 
 
3.1.1 Generation of a stable HIF reporter cell line 
In order to develop a robust screening platform, lung adenocarcinoma A549 
cells were lentivirally transduced to stably express a construct expressing a 
synthetic HRE sequence (containing three canonical hypoxic responsive 
element motifs), promoting expression of a firefly luciferase and EGFP 
separated by a 2A cleavage site (Fig 3.1.1). The 2A cleavage site is a short 
peptide isolated from foot and mouth virus that allows for equimolar expression 
of two proteins from one promoter with minimal effect on protein function [193]. 
The construct was a kind gift from Dr. Tristan McKay, however Dr. Daniel Foxler 
added the Zeocin resistance gene to the vector by PCR amplifying the ZeoR 
gene from pcDNA4.1 vector with MluI restriction sites flanking gene promoter 
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and PolyA tail, before digesting and ligating into the vector.  This vector allows 
for HIF activity to be measured, as upon HIF DNA binding to the HRE 
sequences this will initiate transcription and subsequent translation of firefly 
luciferase (that can be measured through addition of appropriate luciferin 
substrate) and enhanced green fluorescent protein (eGFP) (Fig 3.1.1.1). 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1.1: Hypoxic responsive element driven firefly luciferase reporter. A) 
Schematic of reporter construct with synthetic HRE driving expression of firefly 
luciferase and eGFP separated by 2A motif. B) Diagram of transduced cells upon 
hypoxic activation of HIFs. Cells will produce eGFP and firefly luciferase as a surrogate 
marker of HIF activity. 
 
Following lentiviral transduction and selection for successful transgene 
incorporation with Zeocin, A549-HRE reporter cells were exposed to hypoxia 
across a time course before lysing, measuring luciferase activity and HIF-1α 
protein levels by western blot.  
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Figure 3.1.1.2: Hypoxic induction of A549-HRE cells. A) A549-HRE reporter cells 
were exposed to hypoxia before measuring firefly luciferase values. Results displayed 
are shown as fold induction over normoxia (n=3). B) Western blot analysis of HIF-1α 
protein in A549-HRE reporter cells over a hypoxic time course (representative image 
of n=3). Statistical analyses presented are student T-tests of indicated bar compared 
to 0 hour time point. * p<0.05, ** p<0.01, *** p<0.001 
 
Figure 3.1.1.2 shows A549-HRE cells following hypoxic exposure (1% O2) over 
a time course ending at 48 hours. HIF-1α transcriptional activity was measured 
using luciferase assay substrate (Fig. 3.1.1.2A) and normalized to total protein 
as measured by BCA assay; results are displayed as fold induction over cells 
at atmospheric oxygen (21%). HIF-1α protein levels were determined by 
western blot (Fig. 3.1.1.2B).  This figure shows a steady increase of HIF-1α 
transcriptional activity over 48 hours and a clear hypoxic induction of firefly 
luciferase activity. One key observation is that the protein levels do not reflect 
transcriptional activity. HIF-1α protein is stabilized after 4 hours of hypoxia, 
whereas firefly luciferase activity remains low, it is unclear whether this is due 
to a delay in translation of firefly luciferase mRNA into protein or if further post-
translational modifications of HIF are required for activity. Furthermore the 
luciferase will accumulate overtime resulting in larger activity at later time 
points. In order to determine a suitable time frame for performing the RNAi 
screen, it is important to consider a window where both positive and negative 
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regulators of HIF activity in hypoxia can be clearly identified. To this end, 18 
hours was selected as an appropriate time point as there is a significant 
increase in luciferase activity over normoxic levels (5.7 fold increase) but not 
as high as 48 hours which could lead to false negatives. 
 
In order to determine the HIFα isoform specificity, siRNA knockdown 
experiments were performed to determine which has an effect in reducing 
luciferase activity. 
 
Figure 3.1.1.3: HIF isoform specificity of hypoxic responsive element. A) A549-
HRE reporter cells were transfected with siRNA targeting HIF1A, HIF2A, PHD2 and 
Scrambled control at a concentration of 50 nM. Cells were exposed to hypoxia for 18 
hours before lysis and downstream analysis. B) Western blot to confirm knockdown 
efficiency in A549-HRE cells. N=3 * p<0.05, ** p<0.01, *** p<0.001 
 
Figure 3.1.1.3 shows that following partial knockdown of HIF-1α, there is a 
significant reduction in luciferase activity in hypoxia. However after treatment 
with siRNA against HIF-2α, there was no change in luciferase activity indicating 
that in A549 cells and at this time point. In normoxia there was no significant 
change in luciferase activity with siRNA against either HIF1A or HIF2A, this is 
to be expected, as HIFs will show minimal activity in normoxia. PHD2 siRNA 
was included as a positive control; as expected, knockdown of PHD2 resulted 
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in a large increase in luciferase activity in normoxia that coincides with 
stabilization of HIF-1α protein. Taken together this data suggests that this is 
indeed a HIF-1α specific reporter and is sensitive to siRNA-induced changes in 
protein expression in both normoxia and hypoxia. 
 
3.1.2 Optimisation of arrayed RNAi kinome screen 
3.1.2.1 Optimisation of transfection reagent 
Before performing RNAi screens it is important to select an appropriate 
transfection reagent, which is both effective and relatively non-toxic. To test 
this, Interferin and lipofectamine RNAi-Max transfection reagents were used to 
transfect water (mock transfection), non-targeting control siRNA and HIF-1α 
siRNA. Both transfection reagents showed reduction in luciferase activity 
following HIF-1α knockdown, but there was more cell death observed with cells 
transfected with lipofectamine, therefore interferin was used for RNAi screens. 
 
Figure 3.1.2.1: Optimisation of siRNA transfection reagent. Transfection reagent 
optimization. A549-HRE reporter cells were transfected with mock transfection (water), 
non-targeting siRNA, siRNA targeting HIF1A and media only with either interferin (A) 
or lipofectamine (B). 
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3.1.2.2 Optimisation of cell viability reagent 
As the screening platform is based around a stable reporter cell line, it is crucial 
to normalize firefly luciferase activity to a certain parameter. False positives 
may arise from RNAi knock down of essential kinases, as cell death would also 
result in a reduction of luciferase activity.  In order to differentiate true results 
from these false positives, firefly luciferase activity was normalized to cell 
viability.  Cell viability was measured using resazurin solution. Resazurin is the 
active compound in commercially available methods of measuring cell viability, 
such as Alamar Blue. Resazurin is a weakly fluorescent blue dye that is 
irreversibly reduced by viable cells to form a highly fluorescent compound 
called resorufin. In order to determine the correct concentration of resazurin to 
use, a titration of cell number was prepared and treated with two doses. Both 
doses showed strong positive linear correlations (Fig. 3.1.2.2A), but treatment 
of cells with 0.4 mg.mL-1 displayed a stronger correlation (R2 = 0.9918) than 
that observed with 1.0 mg.mL-1 treated cells (R2 = 0.9724). This method was 
compared with the commercially available alternative, Cell-titer Fluor (Fig. 
3.1.2.2B). Once again, resazurin showed a strong positive correlation (R2 = 
0.9803) as did Cell-titer Fluor (R2 = 0.9735); however in this assay, resazurin 
displayed a larger range of activity compared to cell-titer fluor (125,000 cells 
per well compared to 62,500 cells per well respectively). These results indicate 
that resazurin solution is a suitable method of determining cell viability. 
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Figure 3.1.2.2: Optimization of cell viability reagent. Optimization of Resazurin 
solution as a measure of cell viability. A) A549 reporter cells were plated out across a 
wide range of cell densities before incubating with Resazurin solution at either 1 mg/mL 
or 0.4 mg/mL and incubating for 3 hours at 37°C and measuring fluorescence. B) 
Resazurin solution was compared with Cell-titer Fluor cell viability reagent. 
 
3.1.3 Primary siRNA kinome screen 
The A549-HRE reporter cell line was for regulators of HIF1 transcriptional 
activity with an arrayed siRNA library targeting all known kinases, pseudo-
kinases and proteins with predicted kinase activity. The library used was the 
siGENOME library from Dharmacon, which contains SMARTpool siRNA (4 
distinct sequences per kinase mixed in a single well). The edge wells of the 
plate were lined with siRNA against HIF1A, HIF2A, PHD2 and a scrambled 
control to act as positive and negative controls for the reporter construct. Z-
scores were calculated for each well and hits were identified by selecting those 
with Z-scores ± 2.  
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Figure 3.1.3.1: Primary siKinome screen for HIF transcriptional activity. A-B) The 
control siRNA added to each plate for the hypoxia screen in both normoxia (A) and 
hypoxia (B). C-D) Waterfall plots of siRNA kinome screen in both normoxia (C) and 
hypoxia (D), each dot represents an individual kinase. Cells were tranfected with 
siRNA at a final concentration of 50 nM n=2. 
 
The controls from the screen show an increase in HIF transcriptional activity 
following knockdown of PHD2 compared to non-targeting control in normoxia, 
this is likely due to stabilization of HIFα protein (Fig. 3.1.3.1A). In hypoxia, 
transfection of HIF1A siRNA decreased HIF transcriptional activity compared 
to non-targeting control; this reduction was not observed following HIF2A (Fig. 
3.1.3.1B). The controls match previous results, thereby suggesting that the 
screen results can be considered valid and robust. Z-scores of ± 2 were 
selected as a cut off point to identify hits from the primary screen, with Z-scores 
over 2 representing a potential negative regulator of HIF activity and below 2 
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as a potential positive regulator of HIF activity. In total the screen identified a 
total of 45 hits, with 34 potential negative regulators of HIF activity and 11 
potential positive regulators of HIF activity (Fig. 3.1.3.1C-D).  Of these hits a 
few previously identified regulators of HIFs were identified such as CDK1 and 
LATS2 [166, 171], this further suggests that the screen is valid. In order to 
determine if any kinase pathways were identified in the screen, STRING 
analysis was performed [194]. Through this analysis a few common pathways 
were identified, including the TGF-β pathway (ACVR2A, ACVR2B and 
TGFBR3) (Fig. 3.1.3.2).  
 
 
Figure 3.1.3.2: String network of all the hits from primary siKinome screen.  
String analysis shows interaction of proteins based upon published literature, 
type of interaction highlighted in legend below. 
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3.1.4 Secondary validation siRNA screen 
A secondary validation screen was performed, targeting the 45 hits identified in 
the primary screen. The secondary screen was performed using an arrayed 
siRNA plate from Dharmacon (ON-TARGETplus cherry picked library) with 
SMARTpool siRNA as used in the primary screen. The screen was performed 
in both normoxia (21% O2) and hypoxia (1% O2); firefly luciferase activity was 
normalized to cell viability as before. Results are displayed as fold change over 
non-targeting control siRNA.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1.4: Significant hits from secondary screen. A549 reporter cells were 
transfected with siRNA targeting all previous hits from primary screen at final 
concentration of 50 nM. 48 hours later cells were either left in normoxia (A) or placed 
in hypoxia (B) for 18 hours. Only hits that were statistically significantly different from 
non-targeting control siRNA were included. Statistical analyses presented are student 
T-tests of indicated bar Non-targeting control siRNA. N=3. * p<0.05, ** p<0.01, *** 
p<0.001  
 
The results indicate that of these 45 hits, 9 kinases significantly influenced HIF1 
transcriptional activity in normoxia and 8 influenced transcriptional activity in 
hypoxia (Fig. 3.1.4). Of the previously reported hits identified in the primary 
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screen, knockdown of MAPK7 and CDK1 still showed significant reduction of 
HIF transcriptional activity in the secondary screen, which suggests that the 
screen is valid. Amongst these hits, some are regulators in both normoxia and 
hypoxia, such as COASY. COASY was identified as a negative regulator of HIF 
transcriptional activity and MAP3K3 and PRKAG3 as positive regulators. Many 
of the hits were novel and had not previously been reported as a regulator of 
HIF activity. One such hit/protein was CoAsy, which negatively regulates HIF 
activity in both normoxia and hypoxia. Due to no previous publications linking 
CoAsy and HIF signalling, and the fact that loss of CoAsy increased HIF-1 
activity irrespective of oxygen tension, it was decided to further investigate how 
CoAsy may regulate HIF. 
 
3.1.5 Coenzyme A synthase (CoAsy)  
Coenzyme A synthase (CoAsy) is a bifunctional enzyme that catalyzes the final 
two steps of Coenzyme A (CoA) biosynthesis from pantothenate (Vitamin B5) 
[195]. CoAsy contains two functional domains, dephospho-CoA Kinase domain 
(DPCK) and phosphopantetheine adenyltransferase domain (PPAT). The 
PPAT domain transfers an AMP moiety to 4’phosphopantetheine prior to 
phosphorylation at the 3’hydroxyl position on dephospho-CoA yielding mature 
CoA. This pathway is conserved from prokaryotes through to humans, however 
in prokaryotes the PPAT and DPCK enzymes are separate, in addition to this 
the PPAT domain in CoAsy does not have significant sequence homology with 
the prokaryote counterpart, which makes it an interesting anti-bacterial drug 
target. Coenzyme A itself is not membrane permeable, however intermediates 
in the pathway are, such as 4’phosphopantetheine [196]. Germline mutations 
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in COASY have been associated with a form neurodegeneration with brain iron 
accumulation (NBIA) called CoPan [197], other NBIA diseases have been 
associated with mutations in the CoA biosynthetic pathway such as PKAN 
(mutations in PANK2 gene) [198]. CoAsy is found anchored into the outer 
mitochondrial membrane facing into the cytoplasm; deletion of the amino acid 
residues 1-29 in CoAsy removes the mitochondrial localization and distributes 
CoAsy throughout the cytoplasm [199]. 
 
Figure 3.1.5: Schematic of CoAsy protein. Schematic of CoAsy protein with the 
functional domains highlighted. MLS = Mitochondria localization sequence, PPAT = 
phosphopantetheine adenyltransferase and DPCK = Dephospho-CoA kinase 
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3.1.6 Validation of CoAsy as a novel regulator of HIFs 
3.1.6.1 siRNA knockdown of CoAsy 
The previous screens have all been performed with SMARTpool siRNA, this 
contains 4 distinct sequences targeting each gene that ensures efficient 
knockdown, making it very effective for screening purposes, however there is 
an increased risk of off target effects and results could potentially be due to off 
target effects. To address this, knockdown experiments were performed with a 
different siRNA from a different supplier and a distinct sequence to those used 
in the SMARTpool siRNA (Table 3.1.6.1).  
 
Table 3.1.6.1: siRNA sequences against CoAsy 
siRNA Supplier Sequence 
siGenome_CoAsy1 Dharmacon GAACAGAUAUUCUCCAUAA 
siGenome_CoAsy2 Dharmacon GGCAGAACCUGGUCCAUGA 
siGenome_CoAsy3 Dharmacon GGCAGCAGCUUGUGGAACA 
siGenome_CoAsy4 Dharmacon AGAAGCAGCUGAAGAUACU 
   
Mission siRNA CoAsy Sigma-Aldrich UGGAGUCUGUAUGUCUCUUAC 
 
Knockdown experiments were performed in a number of cell lines (A549, 
U2OS, HEK293T and T47D). As a positive control, siPHD2 was included in 
experiments, as loss of PHD2 will result in decreased HIF degradation and 
stabilised protein. For these experiments cells were placed into hypoxia for 4 
or 8 hours or cultured at atmospheric oxygen.  
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Figure 3.1.6.1: Knockdown of CoAsy results in stabilized HIFα protein. 
Knockdown of CoAsy results in stabilized HIFα in multiple cell types. A549 (A), U2OS 
(B), HEK293T (C) and T47D (D) were treated with siRNA against COASY, PHD2 and 
non-targeting control at 40 nM for 72 hours. Cells were exposed to 1% O2 for 0, 4 or 8 
hours before lysis and analysis by western blot. Relative HIF-1α band densitometry of 
indicated blot was calculated and plotted on bar chart. A549 n=4, U2OS n=3, HEK293T 
n=3 and T47D n = 2. 
 
Figure 3.1.6.1 shows that A549, U2OS, HEK293T and T47D cells each show 
an increase in HIF-1α protein levels following siRNA mediated knockdown of 
CoAsy. In A549 and U2OS, longer exposures of the membrane stained with 
anti-HIF-1α antibody shows an increase in HIF-1α protein in normoxia as well 
as after 4 hours and 8 hours of 1% O2. Whilst there is an increase in HIF-1α in 
normoxia, it is not as large as observed following knockdown of PHD2.  
HEK293T and A549 lysates were probed for HIF-2α protein. In these lysates 
there was an increase in HIF-2α protein following knockdown of CoAsy at both 
4 hours and 8 hours of hypoxia. In A549 cells we also observed an increase in 
HIF-2α protein in normoxia, whereas HEK293T no HIF-2α was observed in 
normoxia, even following knockdown of PHD2. In T47D cells, there was no HIF-
1α protein detected in normoxia, apart from a feint band following loss of PHD2, 
it is unclear why this is occurring in this cell line however it suggests that the O2 
dependent turnover of HIF-1α is highly efficient in this cell line and less 
dependent on PHD2 as other cell line such as A549. As there is an increase in 
HIFα protein across a number of different cell types (A549 are lung 
adenocarcinoma, U2OS are osteosarcoma, T47D are Luminal A breast cancer 
and HEK293T are transformed embryonic kidney cells) it suggests that this 
mechanism is not restricted to only lung adenocarcinoma and instead, a 
fundamental mechanism across transformed cell types. It is important to note 
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that there was no significant change in HIF-1β expression following loss of 
CoAsy in any of the cell lines tested, suggesting that this effect is HIFα specific. 
 
3.1.6.2 Cloning of pLKO-tet-shRNA vector to target CoAsy 
In order to perform further knockdown experiments targeting CoAsy, the pLKO-
tet-Puro vector (Addgene number = 21915) was purchased and sequences 
yielding shRNA hairpins targeting CoAsy or a non-targeting control were 
inserted, such that shRNA hairpins were expressed upon tetracycline 
treatment. To identify suitable sequences for the constructs, sequences from 
MISSION shRNA (Sigma Aldrich) were used, specifically a shRNA sequence 
targeting the 5’ UTR of CoAsy mRNA was selected as this will allow future re-
expression experiments with CoAsy cDNA constructs (Fig. 3.1.6.2), 
furthermore this siRNA sequence was distinct from those found in the 
SmartPOOL siRNA or individual mission siRNA.  
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
Figure 3.1.6.2: Cloning of inducbile shRNA vector. The pLKO-tet-Puro was 
digested with AgeI and EcoRI-HF prior to ligating with annealed shRNA insert strands. 
Ligation was confirmed with XhoI digest and sequence verified by Sanger sequencing 
(Source Bioscience).  
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3.1.6.3 Validation and optimisation of tetracycline inducible shRNA 
knockdown of CoAsy 
In order to activate the TetR transgene and shRNA expression, Doxycycline 
was used instead of tetracycline due to increased stability in cell culture 
medium. Prior to performing experiments with doxycycline inducible shRNA 
lines it is important to determine an appropriate concentration to use to ensure 
that a suitable degree of mRNA knockdown is achieved with the minimal 
amount of doxycycline, this is crucial as excess doxycycline has been reported 
to induce changes in cellular metabolism and proliferation and may lead to 
incorrect interpretation of results [200]. 
 
Figure 3.1.6.3: Validation of tet-shRNA system. Validation of inducible shRNA 
system in A549 (A-B) and MCF10A (C-D) cell lines. Inducible shRNA lines were 
treated with doxycycline or vehicle only for 48 hours prior to lysis and analysis by qRT-
PCR (A-C) and western blot (B-D). n=1.  
 
100 
 
A549, T47D and the normal breast cell line MCF10A were transduced with 
lentivirus containing constructs made in 3.1.6.2 as described in section 2.6. In 
order to determine the correct concentration of doxycycline to use cells were 
treated with a serial dilution of doxycycline (ranging from 0.1-1000 ng.mL-1) for 
48 hours prior to cell lysis and analysis by western blot and qRT-PCR. For each 
cell line addition of doxycycline had no strong effect on CoAsy protein or RNA 
expression in the shScr line. In the shCoAsy lines addition of doxycycline 
induced knockdown of CoAsy RNA and protein across a broad range of doses. 
Western blot analysis shows that protein knockdown is achieved at 
concentrations at the bottom dose of 0.1 ng.mL-1 in A549 cell line and 1 ng.mL-
1 in MCF10A cell line; however both cell lines showed maximum protein 
knockdown at this dose of 1 ng.mL-1. CoAsy mRNA expression matched protein 
expression as 0.1 ng.mL-1 of doxycycline decreased CoAsy expression by 44% 
in the A549 cells. Treatment with doses of 1 ng.mL-1 or higher achieved a 
maximum decrease in CoAsy mRNA of 73%. Future experiments were 
performed at a concentration of 25 ng.mL-1; this concentration was selected as 
it will achieve a high degree of knockdown and is below doses that have been 
previously reported to alter cellular metabolism and proliferation [200]. 
 
3.1.6.4 shRNA mediated knockdown of CoAsy stabilizes HIFα protein 
To test whether CoAsy knockdown had the same effect of stabilising HIF-1α 
protein the A549 and T47D tet-shRNA lines were pretreated with doxycycline 
(25 ng.mL-1) to induce gene silencing before being exposed to hypoxia for 4 
and 8 hours. As the inducible shRNA system uses siRNA sequences distinct 
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from the mission siRNA, it will further support that the stabilization of HIF-1α is 
an on-target effect of CoAsy knockdown instead of an off target effect.   
 
 
Figure 3.1.6.4: shRNA mediated knockdown of CoAsy results in stabilized HIF-
1α. Knockdown of CoAsy using inducible shRNA system in A549 (A) and T47D (B) 
cells. Tet-shRNA inducible lines were plated before being treated with 25 ng.mL-1 
doxycycline for 72 hours. Cells were exposed to hypoxia for 0, 4 or 8 hours hypoxia 
before cell lysis and analysis by western blot. Representative blot from A549 (n = 3) 
and T47D (n = 2).  
 
Knockdown of CoAsy in A549 cells resulted in stabilized HIF-1α at both 21% 
O2 and following 4 hours of 1% O2 (Fig. 3.1.6.4A). Interestingly no stabilization 
was observed at 8 hours of hypoxia, however this result was inconsistent as 
other biological replicates showed a degree of stabilization at this time point 
(See appendix). There was a large decrease in HIF-1α protein expression 
between 4 and 8 hours of hypoxia for the A549 cell line, this is likely due to the 
adaptive response that occurs following exposure to hypoxia, where a negative 
feedback loop induces expression of proteins such as PHD2 and LIMD1 that 
negatively regulate HIF-1α expression. For the T47D cell line (Fig. 3.1.6.4B) 
there was no HIF-1α protein observed even after long exposures for the 
western blot. However at 8 hours there was a clear stabilization of HIF-1α 
following loss of CoAsy.  
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3.1.6.5 Loss of CoAsy does not alter HIF1A or HIF2A mRNA expression 
but upregulates a subset of HIF target genes 
So far results have indicated that loss of CoAsy upregulates HIF-1 activity in 
both normoxia and hypoxia using a synthetic reporter system and that loss of 
CoAsy results in increased protein levels in multiple cell lines. However it is 
important to test whether this increased HIF is active across a number of HIF 
target genes. HIF activity requires a number of co-activators that help dictate 
function such as CBP/P300. Furthermore HIF activity is further regulated by 
FIH mediated hydroxylation, as this hydroxylation event occurs at the C-
terminus there are a number of target genes that are affected by this and a 
subset that are insensitive to FIH inhibition. As it is unclear how CoAsy 
regulates HIF, analysis of target genes may provide clues as to FIH 
functionality. In addition to HIF target genes, analysis of HIF1A and HIF2A 
mRNA can determine whether loss of CoAsy is upregulating HIF protein at the 
transcriptional stage or whether this is occurring post-transcriptionally. This is 
an important clue in determining how CoAsy regulates HIF and can help dictate 
future experiments. In order to address these points, A549 tet-shRNA lines 
were treated with doxycycline for 72 hours before exposing to hypoxia for 0, 4 
and 8 hours prior to cell lysis, RNA extraction and analysis by qRT-PCR.  
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Figure 3.1.6.5: Analysis of HIF target gene expression in A549-tet-shRNA cell 
lines. qRT-PCR analysis of HIF target genes and HIF1A and HIF2A mRNA levels. 
A549 cells were treated with doxycycline (25 ng.mL-1) for 72 hours before being 
placed in hypoxia for 0 (A), 4 (B) or 8 (C) hours before cell lysis and analysis by qRT-
PCR. Results are mean ± SD. n=4. Statistical tests are multiple T-tests with Holm-
Sidak method. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
 
Figure 3.1.6.5 shows the qRT-PCR data from the knockdown experiments in 
the A549-tet-shRNA lines. Across each time point there was a significant 
reduction of COASY mRNA, indicating the shRNA system was working and 
achieving high levels of knockdown. At 0 and 4 hours of hypoxia there was no 
significant difference in either HIF1A or HIF2A mRNA. After 8 hours of hypoxia 
there was a significant increase in HIF1A mRNA but not HIF2A mRNA. As only 
the 8 hour time point displayed a significant increase in HIF1A mRNA level, it 
is unlikely that the increase in HIF-1α protein is a direct result of increased 
mRNA expression, especially as increased HIF protein expression is observed 
at 0 and 4 hours of hypoxia (section 3.1.6.4). Furthermore knockdown 
experiments with mission siRNA have shown that HIF-2α protein also increases 
and there was no significant increase in HIF2A mRNA, therefore this suggests 
that the stabilization of protein observed is occurring post-transcriptionally. The 
increase in HIF1A mRNA could be explained by positive feedback 
mechanisms, such as through NFκB p65 [201]. In normoxia (21% O2, Fig. 
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3.1.6.5A) the only HIF target gene that was statistically different following loss 
of CoAsy is ENO1. Other target genes did show increase in expression, 
however due to large variations in biological replicates there was no statistical 
significance (see appendix for alternative graphical representation). Following 
exposure to hypoxia, ENO1 no longer showed a significant increase in 
expression following loss of CoAsy. However both PHD2 and SLC2A1 did show 
a significant increase (Fig. 3.1.6.5B-C). Once again other target genes also 
showed increased expression, however due to large variations between the 
biological replicates, were not statistically significant. This datum shows that 
there is a small increase in HIF target gene expression, however due to large 
variations in results it is unclear as to the extent and biological significance of 
these differences. 
 
3.1.7 Summary 
This chapter sought to identify novel regulators of HIF transcriptional activity. 
Through a siRNA screen targeting the human kinome and secondary validation 
screen, the Coenzyme A biosynthesis enzyme CoAsy was highlighted as a 
novel negative regulator of HIF transcriptional activity. Knockdown experiments 
with siRNA and shRNA, each with distinct target sequences to those used in 
the primary screen, showed that knockdown of CoAsy resulted in increased 
HIF-1α and HIF-2α protein expression with no change in HIF-1β. Analysis of 
HIF1A and HIF2A mRNA showed there was no increase in expression 
suggesting that this change is due to post-transcriptional events occurring 
following loss of CoAsy. In the A549 inducible shRNA cell line there was a 
significant increase in a small subset of the HIF target genes tested, however 
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further experiments are required to confirm to what extent HIF activity is 
affected and additional cell lines should be tested. 
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Results Chapter Two: 
 
Elucidating the mechanism and functionality of 
CoAsy-mediated HIF regulation 
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4.1 Chapter aims 
In the previous chapter we identified Coenzyme A synthase (CoAsy) as a novel 
negative regulator of HIF-1 transcriptional activity and a negative regulator of 
both HIF-1α and HIF-2α protein levels, but had no effect on HIF1A or HIF2A 
mRNA expression. However it was unclear as to the mechanism behind this 
stabilization, addressing this is the first aim of this chapter. Secondly, we will 
determine the consequences of loss of CoAsy in cellular transformation. The 
role of HIFs in driving cancer has been characterized in multiple cancer types; 
therefore it stands to reason that the upregulation of HIF following loss of CoAsy 
may increase cellular transformation and aggressiveness.  
 
To summarise, we aim to:   
 Determine the mechanism behind the upregulation of HIF protein 
following loss of CoAsy 
 Assess changes in cellular transformation in vitro following loss of 
CoAsy 
 
4.2.1 Cloning of CoAsy-EGFP 
The previous chapter identified CoAsy as a negative regulator of HIFs through 
a siRNA screen. Subsequent validation experiments were performed also with 
RNAi techniques for knockdown of mRNA and consequently protein. We 
therefore asked if the converse may also be true, if CoAsy is overexpressed 
then HIFα protein levels may decrease as our hypothesis would predict. To test 
this an overexpression vector with fluorescently tagged CoAsy was made. 
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Figure 4.2.1: Cloning of CoAsy-EGFP. Cloning strategy to make CoAsy-EGFP over 
expression vector. CoAsy CDS was amplified from HEK293T cDNA (A) with the 
introduction of EcoRI and BamHI restriction sites and ligated into pEGFP-C1 vector 
(B). Successful cloning was confirmed by colony PCR (C) restriction digest (D), Sanger 
sequencing, western blotting and fluorescent microscopy (E). 
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To construct the CoAsy expression vector, the coding sequence of COASY was 
amplified from HEK293T cDNA with primers designed to add EcoRI and BamHI 
restriction sites to the 5’ and 3’ ends respectively (Fig. 4.2.1A). Both the PCR 
product and vector containing PI16-EGFP (an unrelated protein that was cloned 
in using the same restriction sites) were digested with EcoRI and BamHI before 
performing ligation (Fig. 4.2.1B).  As the CDS for COASY contains an internal 
EcoRI site there are two potential products from the ligation. Either the full 
length CoAsy CDS insert or a truncated form, lacking the 5’ half of the insert. 
To screen for successful insertion of the full length CoAsy cDNA, a colony PCR 
was performed. This technique utilizes PCR to selectively amplify only the full-
length insert with no amplification observed in clones featuring the truncated 
insertion; the full length PCR product was used as a positive control for the 
reaction (Fig. 4.2.1C).  Through this approach two positive clones were 
identified. Successful ligation was confirmed through EcoRI and BamHI digest 
and Sanger sequencing (Fig. 4.2.1D). HEK293T cells were transfected with 
plasmid and protein expression was confirmed by western blot and fluorescent 
microscopy (Fig. 4.2.1E). 
 
4.2.2 Overexpression of CoAsy-EGFP does not affect HIF-1α protein 
levels but overexpression of Pank1β negatively regulates HIFα protein 
levels 
To assess if overexpression of CoAsy can reduce HIFα protein levels as our 
hypothesis would predict, HEK293T cells were transfected with EGFP-vector 
only and CoAsy-EGFP before being exposed to 1% O2 for 0, 4 and 8 hours 
prior to cell lysis and analysis of protein expression by western blot.  
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Figure 4.2.2.1: Overexpression of CoAsy does not alter HIF-1α expression. 
Overexpression of CoAsy-EGFP does not change HIF-1α protein levels. A) HEK293T 
cells were transfected with EGFP or CoAsy-EGFP for 48 hours before being exposed 
to hypoxia (1% O2) for 0, 4 or 8 hours. Protein expression was analysed by western 
blot. B) Schematic of the Coenzyme A biosynthesis pathway. 
 
As can be seen in figure 4.2.2.1, overexpression of CoAsy does not change 
HIF-1α protein levels after 4 or 8 hours of hypoxia. The overexpression of 
CoAsy was confirmed by fluorescent microscopy and by western blot analysis 
(Fig. 4.2.2.1A). One possible explanation for this result is that overexpression 
of a kinase does not necessarily mean that there is increased activity as 
substrate or cofactor availability may be rate limiting in this case. Indeed 
analysis of the literature highlighted a crucial role of pantothenate kinase 
(PanK) in regulating the levels of intracellular Coenzyme A (Fig. 4.2.2.1B) 
[202].  
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To test if overexpression of PanK can regulate protein levels of HIFα, HEK293T 
cells stably expressing Pank1β, a splice variant of one of the three PanK 
isoforms, were exposed to hypoxia as well as wild-type (WT) HEK293T cell 
lines. The HEK293-Pank1β cells were a kind gift from Prof. Ivan Gout. 
Metabolomics experiments have shown that these cells display ~6x higher 
levels of Coenzyme A compared to wild type cells as well as significantly 
elevated levels of Coenzyme A derivatives such as acetyl-CoA and malonyl-
CoA (unpublished data from Prof. Ivan Gout). 
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Figure 4.2.2.2: Overexpression of Pank1β reduces HIFα protein expression. A) 
HEK293T and HEK293-Pank1β cells were plated and exposed to 1% O2 for 0, 4 and 
8 hours before cell lysis and western blot analysis. B) Relative HIF-1α, HIF-2α and 
HIF-1β band densitometry is shown. Statistical analysis is Two-way ANOVA with 
Sidak’s post hoc tests. Bar charts are represented as mean ± SD N=3. * p < 0.05, ** 
p<0.01, *** p<0.001.  
 
As can be seen in figure 4.2.2.2, the HEK293T cells with overexpressed 
Pank1β display significantly less HIF-1α and HIF-2α protein levels in both 4 and 
8 hours of hypoxia. Two-way ANOVA analysis shows that the difference in 
protein expression for HIF-1α and HIF-2α is clearly significant in hypoxia (HIF-
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1α p values are 4h = 0.0015, 8h = 0.0047, HIF-2α p values are p <0.0001 for 4 
and 8 hours) however there was no change observed in HIF-1β protein. No 
signal was observed for either HIF-1α or HIF-2α at atmospheric oxygen 
therefore it is unclear whether overexpression of Pank1β only regulates HIF 
expression in hypoxia and further experiments are required to confirm this. To 
assess the degree of PANK1 overexpression qRT-PCR analysis was 
performed. In addition to Pank1, two HIF target genes were also analyzed to 
give an indication whether this reduction of HIFα proteins results in reduced 
HIF-1/2 transcriptional activity. 
 
Figure 4.2.2.3: qRT-PCR analysis of HEK293-Pank1β cells and HEK293T WT. 
HEK293T and HEK293-Pank1β cells were plated and exposed to 1% O2 for 0, 4 and 
8 hours before cell lysis and qRT-PCR analysis of PANK1, PHD2 and PDK1. Statistical 
analysis is Two-way ANOVA with Sidak’s post hoc tests. Bar charts are represented 
as mean ± SD. N=3. * p < 0.05, ** p<0.01, *** p<0.001. 
 
The PANK1 overexpression in these cell lines is significantly higher than that 
observed in the WT HEK293T cells with ~100x higher expression observed in 
normoxia and hypoxia (Fig. 4.2.2.3A). There was a small increase of PANK1 
expression in hypoxia, which was observed in both the WT and Pank1β 
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overexpressing line. This suggests that HIF or an alternative HIF target gene 
may potentially transcriptionally regulate PANK1 mRNA expression; however 
further experiments are required to confirm this. The two HIF target genes 
assayed here (PHD2 and PDK1) did not show a significant difference between 
the lines (Fig. 4.2.2.3B-C). It is unclear why there is no reduction in expression 
of these target genes with the reduction in HIFα protein levels. One possible 
explanation is that following the reduction of HIFα; alternative transcriptional 
regulators of these proteins may be increased. An alternative explanation is 
that the increased levels of acetyl-CoA will increase the level of acetylation of 
HIF-2α resulting in increased affinity with HIF-1β and subsequent increase in 
activity [203]. Further experiments are required to fully determine why target 
gene expression is unaffected and additional target genes should also be 
tested to determine if this is a PHD2 or PDK1 specific effect.  
 
This data suggests that Pank1β overexpression reduces HIF protein, however 
the wild-type cell line used is not the most appropriate control as it is not the 
matched vector only control and has not been lentivirally transduced. To 
address this point and directly address if PanK1 regulates HIF protein levels, 
siRNA knockdown experiments were performed in both the WT and Pank1β 
expressing cell lines were performed. This allows for comparison of HIF 
expression following loss of Pank1 compared to the scrambled siRNA control. 
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Figure 4.2.2.4: siRNA knockdown of PANK1 stabilises HIF-1α. HEK293T and 
HEK293-Pank1β cells were treated with siRNA against PANK1 or scrambled control 
at 40 nM. 72 hours post transfection cells were exposed to hypoxia (1% O2) for 0, 4 or 
8 hours before cell lysis and analysis by western blot. n=3. 
 
Figure 4.2.2.4 shows that in both the WT and Pank1β overexpressing cell lines, 
knockdown of Pank1 with siRNA increases HIF-1α protein in normoxia as well 
as after 4 and 8 hours of hypoxia. As observed in figure 4.2.2.4, there was 
reduced expression of HIF-1α protein in the Pank1β cell lines compared to the 
WT HEK293T cells when treated with scrambled siRNA control. The primary 
antibody against Pank1 was not able to detect endogenous levels of Pank1 in 
the WT cell line, possibly due to low expression of the protein. The antibody did 
detect overexpressed Pank1 in the HEK293T-Pank1β cells and the siRNA 
knockdown was visible in these cells.  
 
To summarise this section, overexpression of CoAsy had no affect on HIF-1α 
protein levels however overexpression of Pank1β did significantly reduce both 
HIF-1α and HIF-2α. Knockdown of Pank1 resulted in stabilized HIF-1α as was 
observed following loss of CoAsy. Taken together this data suggests that the 
Coenzyme A biosynthesis pathway plays a role in regulating HIFα protein in a 
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post transcriptional manner. Potentially implicating Coenzyme A or a 
Coenzyme A derivative in negatively regulating HIF protein expression. 
 
4.2.3 Knockdown of enzymes that utilize CoA as a substrate 
Previous results indicate a role of the CoA biosynthesis pathway in regulating 
HIFα protein stability. However it is unclear whether this is as a result of CoA 
or a related CoA derivative, this is of important to note as the Pank1β cells 
express higher levels of CoA and derivatives such as acetyl-CoA (unpublished 
data from Prof. Ivan Gout). Furthermore, published work has shown that siRNA 
mediated knockdown of CoAsy resulted in significant reduction of CoA and 
acetyl-CoA to the same extent thereby suggesting the close relationship 
between CoA and derivatives [204]. There are a number of different pathways 
in which CoA is used however many metabolites such as malonyl-CoA and 
acyl-CoA utilize acetyl-CoA as a precursor instead of CoA. In an attempt to 
determine which CoA function negatively regulates HIF we next examined 
suitable targets to address this line of investigation. 
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Figure 4.2.3.1: Schematic of enzymatic processes involving CoA. Schematic 
diagram of enzymes that require Coenzyme A as a substrate. CoA is utilized in the 
TCA cycle where pyruvate dehydrogenase complex and α-ketogluturate 
dehydrogenase complex both require CoA as a substrate. Acetyl-CoA is produced 
from acetate and CoA in by ACSS1 and ACSS2 in the mitochondria and cytoplasm 
respectively. 
 
CoA is highly prevalent in the TCA cycle as the pyruvate dehydrogenase 
complex utilizes CoA to form acetyl-CoA that acts in 2-carbon metabolism. 
Another utilization of CoA in the TCA cycle is in the α-ketogluturate (αKG) 
dehydrogenase complex where αKG is converted to succinyl-CoA before being 
reduced to form succinate and thereby recycling CoA. To inhibit these steps 
smart pool siRNA targeting PDHA1 (pyruvate dehydrogenase complex subunit 
E1α) and OGDH (oxogluturate dehydrogenase complex E1) were purchased. 
The conversion of acetate to acetyl-CoA is compartmentalized due to the highly 
labile nature of the acetyl group and the membrane impermeability of acetyl-
CoA [205], in the mitochondria acetyl-CoA is produced via ACSS1 whereas in 
the cytoplasm this reaction is catalyzed by ACSS2. It is important to note that 
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following changes in oxygen tension, ACSS2 relocates to the nucleus to 
maintain histone acetylation [206]. Targeting these key enzymes may elucidate 
which CoA derivative regulates HIF protein stability. 
 
 
Figure 4.2.3.2: Knockdown of enzymes that utilize CoA in A549 cells. A549 cells 
were treated with siRNA against ACSS1, ACSS2, OGDH and PDHA1 at 40 nM. 
72 hours post transfection cells were placed into hypoxia (1% O2) for 4 hours 
or cultured at 21% O2 before cell lysis and analysis by western blot (A) 
densitometry was calculated for displayed western (B). Representative blot 
from n = 4.  
 
Wild-type A549 cells were treated with siRNA against ACSS1, ACSS2, OGDH 
and PDHA1  and analysed by western blot in Figure 4.2.3.2. In each case the 
western blot indicates that the proteins have been successfully knocked down 
by the siRNA. Knockdown of ACSS1 resulted in stabilized HIF-1α in both 
normoxia and hypoxia. ACSS1 produces acetyl-CoA from acetate and CoA 
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inside the mitochondria matrix, however it is unclear how this may regulate HIF-
1α stability. As HIF stabilization occurs in both normoxia and hypoxia as is 
observed following loss of CoAsy, they could potentially be occurring through a 
similar mechanism. Loss of ACSS2 resulted in stabilized HIF-1α in normoxia, 
however there was once again a decrease in protein levels in hypoxia; previous 
results indicate that ACSS2 is required for HIF-2 signaling, however little is 
known on the role of ACSS2 on HIF-1α stability. Knockdown of OGDH resulted 
in stabilized HIF-1α, which matches the literature that states loss of OGDH 
causes loss of prolyl-hydroxylase activity and subsequent stabilization of HIF-
1α. Interestingly the same stabilization was not observed in hypoxia instead 
there was a slight decrease in HIF-1α levels. The mechanism for this is unclear. 
Knockdown of PDHA1 resulted in an increase of HIF-1α in normoxia however 
this was not observed in hypoxia; as loss of CoAsy results in stabilized HIF-1α 
in both normoxia and hypoxia, we hypothesized that CoAsy may be regulating 
HIF through an alternative mechanism.  
 
 
The previous figure showed that knockdown of ACSS1 resulted in stabilized 
HIF-1α, however it is unclear if this is occurring by the same mechanism as 
CoAsy. To address this the same knockdown was performed in A549-tet-
shRNA lines, with the hypothesis being that if knockdown of ACSS1 regulation 
of HIF occurs through the same mechanism as CoAsy then there will only be a 
stabilization of HIF-1α in the shScr line and not in the shCoAsy line.  
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Figure 4.2.3.3 Knockdown of enzymes that utilize CoA in A549-tet-shRNA cells: 
A549-tet-shRNA cells were treated with doxycycline at 25 ng.mL-1 before treating with 
siRNA against ACSS1, ACSS2, OGDH and scrambled control. 72 hours after 
transfection cells were placed into hypoxia for 8 hours before lysis and analysis by 
western blot. Relative densitometry of HIF-1α band intensity of 1% O2 was calculated 
normalized to siScr for each line. n=3. 
 
Figure 4.2.3.3 shows that knockdown of ACSS1 results in an increase of HIF-
1α protein in the shScr lines in hypoxia but not in the shCoAsy lines. The bar 
chart (Fig. 4.2.3.3B) shows relative HIF-1α band intensity normalized to the 
siScr control; in the shScr line there is a 2-fold increase in HIF-1α protein 
compared to scrambled control whereas there is no increase in the shCoAsy 
line. Between the lines there was a large increase in HIF-1α protein as has 
been previously shown following loss of CoAsy. ACSS2 was included as a 
related negative control; once again there was a slight decrease in HIF-1α 
protein levels following siACSS2 compared to siScr. Knockdown of OGDH 
resulted in stabilized HIF-1α in the shScr line, this result matches previous 
reports in the literature, however in the shCoAsy line there was a reduction of 
HIF-1α protein. It is unclear why there is this opposing effect. It has been 
reported that OGDH knockdown results in inhibition of prolyl-hydroxylase 
function through L-2HG production (an enantiomer of α-ketogluturate) however 
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it is unclear how CoAsy or CoA may be affecting L-2HG production or indeed 
how active prolyl-hydroxylase enzymes are following loss of CoAsy [191].  
 
This data suggests that mitochondrial acetyl-CoA may be the CoA derivative 
responsible for negatively regulating HIFα, however these experiments have so 
far only assessed HIF-1α protein levels. It is important also to investigate HIF-
1 activity through the use of reporter assays; this is of particular importance as 
it has previously been reported that ACSS2 is required for acetylation of HIF-
2α thereby increasing transcriptional activity without altering protein stability but 
there have been no studies on the role of ACSS1 in regulating HIF activity.  
 
4.3 CoAsy negatively regulates HIF-1α post-transcriptionally at the 30-389 
and 390-462 amino acid domains. 
Taking an alternative and complimentary approach to identifying the 
mechanism as to how CoAsy regulates HIFα protein, a series of HA-tagged 
domains from HIF-1α were overexpressed in A549 cell lines knocked down for 
COASY and PHD2. These constructs each contain the same CMV promoter 
sequence and the same 3’ UTR each distinct from that of the HIF1A gene 
thereby negating any transcriptional or miRNA differences of expression, 
instead only differences in protein stability or translation will be observed.  This 
is of interest as no changes in HIF1A or HIF2A mRNA were observed following 
loss of CoAsy in normoxic conditions where HIF-1α and HIF-2α protein levels 
are both stabilized. This suggests that CoAsy does not affect HIF1A or HIF2A 
gene transcription.  
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Figure 4.3.1: Schematic of HA-EGFP tagged domains of HIF-1α. Schematic of the 
HIF segments used for overexpression experiments. 30-389 domain encompasses the 
bHLH domain and PAS domains, the ODDDD contains N-TAD as well as proline 
residues and lysine residue required for O2 dependent degradation of this subunit and 
the 630-826 contains C-TAD domain. 
 
These constructs were transfected in to A549 cells that had been previously 
treated with siRNA against COASY and PHD2. siPHD2 was included as a 
positive control as it has been well reported that loss of PHD2 would result in 
stabilized ODDD due to reduced prolyl-hydroxylation and inhibition of 
subsequent ubiquitination and degradation of ODDD domain via the 
proteasome. Through this approach it was confirmed that CoAsy regulates HIF 
post-transcriptionally and which domain or domains of HIF does CoAsy 
negatively regulate. 
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Figure 4.3.2: CoAsy negatively regulates 30-389 and the ODDD of HIF-1α. A549 
cells were treated with siRNA against COASY, PHD2 and scrambled control. The 
following day cells were transfected with HIF domains detailed in Fig. 4.3.1. 48 hours 
following transfection cells were lysed and analysed by western blot (B). Relative HA 
band densitometry of 30-389 domain was calculated for 3 biological replicates. Bar 
chart shows mean ± SD. Statistical analysis was Mann-Whitney U test. * p < 0.05. n=3. 
 
A549 cells were treated with siRNA against COASY, PHD2 and non-targeting 
control. Knockdown efficiency was confirmed by western blot and in each case 
the siRNA achieved high levels of protein knockdown. The 30-389 and ODDD 
domains both increase in expression following loss of CoAsy compared to 
scrambled siRNA control, this effect is specific for these domains as there was 
no change in the 630-826 domain thus suggesting that this effect is unlikely to 
be due to changes in transfection efficiency or translation efficiency. The ODDD 
domain was rapidly degraded in A549 cells treated with non-targeting siRNA 
however following loss of CoAsy this protein was stabilized and a faint band 
appears in the western blot; this increase is not as stark as that following loss 
of PHD2 which is a well-established regulator of the ODDD [60]. Loss of CoAsy 
also regulates the 30-389 domain of HIF-1α, calculating the changes in band 
densitometry reveals a significant difference between the siScr and siCoAsy 
treated samples (p = 0.031, Fig. 4.3.2B). The majority of the literature has 
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reported post-translational modifications at the ODDD or in the TAD of HIF-1α. 
To identify reported modifications of this domain the online server phosphosite 
was consulted [207]. This contains a database of reported post-translational 
modifications from high-throughput experiments, such as large-scale mass 
spectrometry of phosphorylated proteins, as well as papers with more focused 
approach and subsequent validation.  
 
Figure 4.3.3: Identified post translational modifications in HIF-1α. Schematic of 
reported post-translational modifications of HIF-1α. Figure is taken from phosphosite 
online server [207]. 
 
As can be seen in figure 4.3.3 the majority of reported post-modifications cluster 
towards the N-terminus (first 100 amino acids) and C-terminus (post residue 
450), however a number of post-translational modifications have been reported 
between the 30-389 region. The majority of these are ubiquitination events 
identified through mass-spectrometry experiments and were not subsequently 
validated. Of the reported post-translational modifications within this 30-389 
domain, two had been experimentally validated. One such event was the 
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phosphorylation of HIF-1α at Ser247 by casein kinase 1 [208], however this 
phosphorylation did not affect protein stability instead it inhibited interaction with 
HIF-1β and subsequent transcriptional activity. The second post-translational 
modification was protein kinase A (PKA) mediated phosphorylation of HIF-1α 
at Thr63 [209]. This phosphorylation event increases HIF-1α protein stability. 
Therefore it could be that loss of CoAsy may in some way alter PKA activity, 
however PKA also phosphorylates HIF-1α at Ser692 that also results in 
stabilization of HIF-1α independent of Thr63 phosphorylation. As loss of CoAsy 
does not affect stability of the 630-826 amino acid domain (which encompasses 
the Ser692 phosphosite) it is unlikely that this is the mechanism behind HIF 
stabilization following loss of CoAsy. 
 
To summarize this section, loss of CoAsy regulates HIF-1α at the post-
translational stage. This occurs at both the 30-389 and ODDD domains but not 
at the 630-826 domain. A number of post-translational modifications have been 
reported in the 30-389 domain however further experimental validation is 
required to determine how these are effected following loss of CoAsy (see 
future work). 
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4.4 Protein CoAlation  
Protein CoAlation is a recently identified protein modification that occurs in both 
prokaryotic and eukaryotic cells [210, 211]. This modification occurs at exposed 
cysteine residues as the free thiol of CoA forms a disulphide bond in a manner 
analogous to glutathionylation (Fig. 4.4). This protein modification is reversible 
and increased upon cellular stress. It was hypothesized that this protein 
modification may potentially play a role in regulating HIF; therefore when CoAsy 
is lost, CoA levels are reduced and subsequently CoAlation is diminished. 
Figure 4.4: Protein CoAlation. Schematic of protein CoAlation. The thiol group in 
Coenzyme A forms a disulphide bond with free cysteine residues in proteins. 
 
To assay the levels of protein CoAlation, a monoclonal antibody raised against 
CoA was prepared by Prof Ivan Gout. This mAb specifically detects CoA but 
not the biosynthetic precursors such as 3’-dephospho-CoA or 
4’phosphopantetheine [212]. Using this tool, Tsuchiya et al. identified extensive 
protein CoAlation both in cellulo and in vitro (H2O2 perfused rat hearts and the 
liver of starved rats) [210]. 
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 4.4.1 Protein CoAlation in hypoxia 
The role of protein CoAlation in hypoxia has not been studied. This is of 
particular interest as reactive oxygen species induces protein CoAlation in a 
dose dependent manner. It has been extensively reported that, rather 
paradoxically, ROS increases in hypoxia as a consequence of deficient electron 
transport train and aberrant functioning of complex III [213], therefore it could 
be assumed that CoAlation may increase in hypoxia as a result of elevated 
levels of ROS. However as mentioned previously, CoAlation occurs at free thiol 
groups however the hypoxic marker pimonidazole also works by binding to free 
thiol groups. If the ROS induced CoAlation is increased in hypoxia then it is 
possible that the free pimonidazole may not bind, thus CoAlation may not occur 
in low oxygen tensions. To address this, HEK293-Pank1β cells were exposed 
to 1% O2 for varying time points before being treated with the menadione or 
vehicle only to test the propensity for CoAlation to occur in hypoxia. 
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Figure 4.4.1: Menadione induced CoAlation in HEK293-Pank1β cells. Non-
reducing western blot analysis of Protein CoAlation in hypoxia following menadione 
treatment. HEK293-Pank1β cells were exposed to 1% O2 for varying time points before 
treating with 50 µM menadione for 30 minutes or DMSO for 30 minutes prior to cell 
lysis. n=3. 
 
Figure 4.4.1 shows large changes in protein CoAlation across the conditions 
tested. In the cells cultured at 21% O2 there was a large increase in CoAlation 
observed following treatment with 50 µM menadione. Interestingly, the cells 
cultured in hypoxia showed a large reduction in the menadione induced 
CoAlation even at the shortest time point of 4 hours. In contrast to the 
menadione induced CoAlation, endogenous CoAlation increases after 24 and 
48 hours of low oxygen tension. HIF-1α protein expression was further affected 
by the addition of menadione, this effect was more pronounced at later time 
points of hypoxic incubation (24 and 48 hours) at which point the adaptive 
response to hypoxia would be triggered. Together this shows that hypoxia 
changes the ability of menadione to induce CoAlation however endogenous 
CoAlation actually increases after longer time periods of reduced oxygen 
availability.  
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It is unclear as to why HIF-1α expression was reduced following menadione 
treatment, as menadione will not just effect CoAlation; instead a plethora of 
other cellular functions will be altered by increased ROS. Furthermore the 
decrease of CoAlation in hypoxia could potentially be a menadione specific 
effect; menadione induces ROS through redox cycling, which requires 
NAD(P)H-quinone oxidoreductase (NQOR) activity to produce ROS this in turn 
alters NADPH/NADP+ ratio that may also have an effect on CoAlation [214]. 
To remove potential non-ROS related effects from menadione treatment, H2O2 
was used as an alternative treatment to increase cellular ROS.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2: H2O2 induced CoAlation in HEK293-Pank1β cells: Non-reducing 
western blot analysis of Protein CoAlation in hypoxia following H2O2 treatment. 
HEK293-Pank1β cells were cultured in 1% O2 for 0, 4 and 8 hours before treating with 
500 µM of H2O2 for the final 30 minutes of incubation before cell lysis. n=3. 
 
The western blot in figure 4.4.2 once again shows an increase in protein 
CoAlation following addition of ROS inducing agent. In hypoxia the degree of 
H2O2-induced CoAlation is similar to that observed in normoxia, this result is in 
contrast to that observed following menadione treatment. There was a 
decrease in HIF-1α levels following treatment with H2O2 in hypoxic cells (see 
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appendix for other biological replicates), however in normoxia, treatment with 
H2O2 increased HIF-1α levels, this could potentially be due to oxidative 
dimerization of PHD2 [215]. It is difficult to draw comparisons between the two 
treatment methods, as the degree of ROS induction was not measured for 
either treatment and the samples were run on separate western blots. However 
these two figures do show that endogenous protein CoAlation is increased after 
24 hours of hypoxia and that ROS-inducing agents induce protein CoAlation 
and negatively regulate HIF-1α protein in hypoxia. 
 
4.4.2 Direct protein CoAlation of HIF-1α 
Due to the previously mentioned links between CoAlation, ROS and hypoxia, 
taking Occam’s razor approach it was hypothesized that HIF-1α may potentially 
be subject to CoAlation and this may negatively regulate protein stability. Hence 
in cells with deficient in CoA biosynthesis this will result in stabilized HIF-1α 
protein levels. 
 
4.4.3 Preparation of recombinant HIF-1α for in vitro CoAlation assays 
One method to test if proteins are directly CoAlated is through the use of in vitro 
CoAlation assays. These assays were used extensively by Tschuyia et al. to 
validate whether proteins are directly CoAlated in a system without other 
proteins or other potential interactors that may yield false positive results. Dr. 
Thomas Webb (previous member of Professor Tyson Sharp’s lab) subcloned 
HIF1A CDS into GST-tagged bacterial overexpression vector. In total, 4 
positive clones were generated and tested for expression levels. 
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Figure 4.4.3.1: Recombinant expression of GST-HIF-1α fusion from multiple DNA 
plasmid clones. Protein expression of GST-HIF-1α bacterial expression plasmids. 
DH5α competent cells were transformed with each GST-HIF-1α construct before 
inducing with IPTG to promote protein expression. Expression was measured by 
western blot. 
 
Each of the plasmid controls expressed HIF-1α, albeit to varying degrees. The 
western blot shows that clone 1 expressed a small amount of HIF-1α, as there 
was a band visible on the western blot corresponding to the correct size for 
GST-tagged HIF-1α (~140 kDa). Clone 2 showed the highest expression of 
GST-HIF-1α and was therefore used for subsequent expression studies. To 
express larger quantities of protein, the construct was retransformed in to 
Rosetta D3 cells. 3 colonies were picked, expanded to larger cultures and 
induced with IPTG.  
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Figure 4.4.3.2: Bacterial expression of recombinant HIF-1α GST fusion protein 
for in vitro CoAlation analysis. Protein expression was confirmed by SDS-PAGE 
and coomassie Blue staining, full-length fusion protein is marked with an asterisk (A) 
and by western blot (B) with α-GST and α-HIF-1α antibodies. 
 
Figure 4.4.3.2 shows that each of the colonies picked produced full length GST-
HIF-1α (Fig. 4.4.3.2A) with the band on coomassie gel corresponding to full-
length fusion protein marked with an asterisk. This band was confirmed to be 
the correct band by blotting with both α-GST and α-HIF-1α antibody (Fig. 
4.4.3.2B). The coomassie stained gel clearly shows multiple degradation 
products from the production of the fusion protein, which can be further 
visualized in both GST and HIF-1α western blot. Therefore when considering 
in vitro CoAlation assays only the band corresponding to full-length fusion 
protein (~140 kDa) should be focused on as a true readout of protein CoAlation. 
These samples were stored at -80°C before being given to Prof. Ivan Gout for 
in vitro CoAlation analysis. 
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4.4.4 Preparation of endogenous IP of HIF-1α for CoAlation analysis 
In addition to in vitro CoAlation assays, samples of endogenous HIF-1α 
immunoprecipitated (IP) from cell lysates were also prepared. This is an 
important condition to consider, because if protein CoAlation causes 
destabilization of HIF-1α protein and is responsible for the stabilization 
observed following loss of CoAsy then there must be sufficient basal levels of 
CoAlation prevalent in wild type cells without stimulation. IP conditions need to 
be adjusted for measuring CoAlation, as lysis buffer requires addition of n-
ethylmaleimide (NEM) to bind to free thiol groups to avoid non-specific 
CoAlation and proteins need to be eluted from beads in sample buffer without 
reducing agents to preserve the disulphide thiol linker. 
 
 
Figure 4.4.4.1: Optimisation of HIF-1α IP from HEK293T cells. HIF-1α was 
immunoprecipitated from HEK293T cells cultured in normoxia and hypoxia; IP was 
performed in both reducing (A) and non-reducing conditions (B). 
 
The IP from HEK293T in reducing conditions shows clear pull down of HIF-1α 
from lysates cultured in both 21% and 1% oxygen. This IP was specific for the 
HIF-1α antibody as the species matched IgG did not show any HIF-1α coming 
down (Fig. 4.4.4.1A). However following the addition of NEM in the lysis buffer 
and eluting in non-reducing sample buffer a number of non-specific bands 
appeared in both IgG IP as well as HIF-1α IP (Fig. 4.4.4.1B). It is unclear if the 
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non-specific bands are degradation of the IgG, this will run differently in non-
reducing conditions compared to reducing conditions. Instead of separating into 
light and heavy chains (bands running at ~50 kDa and ~25 kDa), the disulphide 
bonds will remain intact and appear at a higher molecular weight. To reduce 
non-specific bands the IP was repeated as before but with increased wash 
steps. 
 
Figure 4.4.4.2: Immunoprecipitation of HIF-1α from HEK293T cells. Three 
biological replicates of HIF-1α IP from HEK293T cells cultured in normoxia and 
hypoxia, protein was eluted and SDS-PAGE was performed in non-reducing 
conditions.  
 
The extra wash steps in the IP reduced the non-specific bands in the western 
blot. For each IP there is a specific pull down of HIF-1α protein in the cell lysate 
from hypoxic cells, however there is only a faint band observed in the normoxic 
lysate. Only a small proportion of the IP eluate was run on western blot, with 
the rest saved for assessing CoAlation, therefore loading more would show a 
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more intense band in the normoxic IP. The three repeats were submitted to 
Prof. Ivan Gout for CoAlation analysis. 
4.4.5 Analysis of potential CoAlation on HIF-1α 
The three clones of recombinant GST-HIF-1α and GST tag only along with 
three biological replicates of endogenous HIF-1α immunoprecipitated from 
HEK293T cells were submitted for in vitro CoAlation experiments and western 
blot analysis of endogenous CoAlation by Prof. Ivan Gout and his lab. These 
experiments will show if HIF-1α has the biophysical properties that allow for 
CoAlation as well as if this CoAlation occurs without stimulation in HEK293T 
cells.  
 
 
Figure 4.4.5: CoAlation analysis of HIF-1α samples.  Results from in vitro CoAlation 
assay of GST-HIF-1α and endogenous IP of HIF-1α, in vitro CoAlation of peroxiredoxin 
was used as positive control. Figure used with kind permission of Prof. Ivan Gout. 
 
kDa	
136 
 
The endogenous IP of HIF-1α showed no signal in either sample (IP from either 
normoxic or hypoxic cell lysates, lane 16 and 17 respectively), whereas the IgG 
control did show an unidentified CoAlated protein at ~150 kDa that is not 
specific for HIF-1α IP. Multiple conditions were tested for in vitro CoAlation of 
GST-HIF-1α; lane 10 is the in vitro CoAlation assay, with HIF-1α combined with 
CoA and producing a large smear on the western blot. No clear band is present 
at the correct size of ~150 kDa, however the western pattern appears to be 
specific for CoAlation as treatment with the reducing agent DTT completely 
reduces the signal observed (lane 11). Lane 12 is the reaction with GST-HIF-
1α and no CoA added, this control is included to ensure the CoAlation observed 
is due to the in vitro CoAlation and not from any CoAlation arising from the 
bacterial protein expression. Lane 10 and 12 display similar band profiles with 
neither showing a clear band at the predicted size for full-length GST-HIF-1α 
fusion protein. Taken together, this data suggests that HIF-1α is not CoAlated 
in cellulo or in vitro. The signal observed in the GST-HIF-1α samples could 
result from CoAlation of the GST tag, as CoA is a common molecule to both 
eukaryotes and prokaryotes there is potential for the GST tag to become 
CoAlated during bacterial protein production, analysis of the GST only 
recombinant protein would have determined if this is the case. 
 
4.4.6 CoAlation of members of the canonical pathway of HIF regulation 
The previous results indicated that HIF-1α is not directly CoAlated, however 
this is not to say that CoAlation does not play a role in regulating HIF-1α 
expression, as there are multiple regulators of HIF that may be subject to 
CoAlation. To test this multiple targets of the O2-dependent pathway of HIF 
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regulation (PHD, pVHL and LIMD1) were immunoprecipitated from HEK293-
Pank1β cell lysate cultured in atmospheric oxygen.  
 
Figure 4.4.6: IP to assess CoAlation of HIF-1α and O2-depdenedent regulators of 
HIF-1α: Immunoprecipitation of HIF-1α, PHD2, pVHL and LIMD1 from HEK293-
Pank1β cell lysate. IP and CoAlation was determined by western blot. n=2.  
 
Figure 4.4.6 shows successful IP of each target proteins. Despite this IP being 
performed in atmospheric oxygen conditions there was a clear band observed 
in the HIF-1α IP, the same band was also observed, albeit faintly in the PHD2 
Co-IP but no band of the same size in the IgG IP indicating that this interaction 
is specific, which is in concordance with the literature. IP of PHD2 revealed a 
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specific band with no band observed in Co-IP of other proteins. In this HEK293-
Pank1β cell line only the p19 isoform of pVHL was observed in either the input 
or IP. In the CoA western blot there is a degree of basal CoAlation observed in 
the input sample. The IgG control shows a number of strong non-specific bands 
thus making analysis of specific CoAlation difficult, for example the LIMD1 IP 
shows a strong band at ~75 kDa which may potentially indicate CoAlation of 
LIMD1 however due to the non-specific band in the IgG lane it remains 
inconclusive. No specific signal was observed at the correct size for pVHL or 
PHD2 IP. In the HIF-1α IP there was a band observed at the correct size as 
HIF-1α in the CoA blot indicating that contrary to previous results, HIF-1α may 
indeed be directly CoAlated. This band was not the same size as non-specifics 
in the IgG IP.  
 
It remains inconclusive as to whether HIF-1α is directly CoAlated or not. The in 
vitro assay and initial HIF-1α IP from HEK293T suggests that CoAlation does 
not occur, however subsequent IP from HEK293-Pank1β cells indicates a 
degree of CoAlation may occur. It is unclear why there is such discrepancy 
between results, one possible explanation may be as simple as sample storage 
in the initial analysis, as it is not known how stable the CoAlation modification 
is and may become cleaved in long term storage or subsequent freeze thaws. 
An alternative explanation is that the level of basal CoAlation in HEK293T cells 
may be so low that HIF-1α may not be CoAlated without overexpression of 
Pank1β and increased CoA levels, which casts doubts over the biological 
relevance of CoAlation in regulating HIF-1α in cancer. However, further studies 
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with appropriate controls are required to validate whether HIF-1α is CoAlated 
or not. 
 
 
4.5 Analysis of cell transformation following loss of CoAsy 
The second aim of this chapter was to determine the cellular consequences of 
losing CoAsy. Irrespective of how loss of CoAsy increases HIF-1 activity and 
stability, there will be multiple HIF dependent changes that can alter cell 
proliferation, motility and metabolism. However, CoA is crucial for many cellular 
processes such as TCA cycle therefore loss of CoAsy may impart proliferative 
defects to the cell. Therefore it is important to determine these cellular changes 
in vitro as it may highlight any pro-tumourigenic changes following loss of 
CoAsy. 
 
 
4.5.1 Loss of CoAsy does not change cell proliferation in A549 cells 
The first parameter tested was cell proliferation. Cancer is frequently 
considered a disease of uncontrolled cellular proliferation, thus it is an important 
consideration when looking at potential tumour suppressor genes. To 
determine cell proliferation rates, A549-tet-shRNA cells were pretreated with 
doxycycline before plating at low density. Cells were cultured at 21% O2 or 1% 
O2 for 7 days, proliferation was measured by counting cells at indicated 
timepoints.  
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Figure 4.5.1.1: Loss of Coasy does not alter cell proliferation in A549 cells. 
Growth curve of A549-tet-shRNA cell lines. Lines were pretreated with doxycycline to 
activate shRNA knockdown before plating on day 0 and placing into normoxia (21% 
O2) or hypoxia (1% O2). Cells were counted on day 1, 3, 5 and 7. Cell counts were 
presented as average cell counts (A) or normalized to day 1 (B). CoAsy knockdown 
was confirmed by western blot (C). Results are shown as SD. n=3.  
 
The plots in figure 4.5.1.1 indicate that there is no significant difference in cell 
proliferation following loss of CoAsy in A549 cells. When comparing average 
cell counts (Fig. Figure 4.5.1.1A) it appears in normoxia that there is a slight 
decrease in cell proliferation in 21% O2 following loss of CoAsy however this 
result is not statistically significant, instead this difference likely arises from 
plating errors at day 0 as normalizing results to day 1 accounts for this error 
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and the proliferation rates are equal between groups (Fig. Figure 4.5.1.1B). 
Proliferation was significantly reduced in hypoxia for the shScr and shCoAsy 
cell lines and there was no difference observed between the groups.  
 
There were no differences observed in cell proliferation between the A549 
shRNA lines whilst manually counting the cells. As an alternative readout of cell 
proliferation the Incucyte live cell analysis was used. This machine takes bright 
field images of live cells and measures percentage confluency, by tracking 
changes of percentage confluency across a time course it is possible to 
measure cell growth. The A549-tet-shRNA cells were pretreated with 
doxycycline before plating and being placed into incucyte.  
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Figure 4.5.1.2: Analysis of cell proliferation of A549-tet-shRNA cells using 
incucyte: Growth curve of A549-tet-shRNA. Line represents average percentage 
confluency at time point indicated. A549 cells were pretreated with doxycycline (dark 
blue or red lines) or grown in media without doxycycline (pink or pale blue lines) before 
being replated and placed in the incucyte for analysis. n=1. 
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The incucyte data once again shows that there is no difference in proliferation 
following loss of CoAsy in these cell lines. The lines were cultured in the 
presence or absence of doxycycline, for both the shScr and shCoAsy lines 
there is no difference between the doxycycline treatment and media alone. This 
confirms that the dose of doxycycline used in the experiments is not sufficient 
to cause changes in cell proliferation. Furthermore this result shows that 
activation of the shRNA system does not further effect cell proliferation. As both 
the incucyte analysis and manual cell counts data shows no differences 
between the two lines it can be said that loss of CoAsy has no effect on cell 
proliferation in A549 cells.  
 
4.5.3 Loss of CoAsy does not affect wound closure in A549 cells 
In vitro wound healing assays are a well-established technique for measuring 
2D migration of cancer cells. This technique involves growing cells to a 
complete monolayer before ‘scratching’ the plates to remove cells. The cells 
are then allowed to migrate and proliferate towards the free space provided by 
the scratch. A549-tet-shRNA cells were pretreated with doxycycline before 
plating and performing wound healing assay.  
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Figure 4.5.3: Loss of CoAsy does not affect wound healing in A549 cells. Wound 
healing assay in A549-tet-shRNA cells. A549 cells were pre-treated with doxycycline 
before replating in triplicate. Cells were left to adhere prior to scratching plates to 
remove cells. Wound closure was measured 6 and 24 hours later. N=3.  
 
This wound closure assay shows that loss of CoAsy does not affect wound 
closure. As this assay was not performed in serum free media or after inhibition 
of cell proliferation, this assay does not solely measure changes in migration 
instead changes in proliferation will have an effect. However due to the previous 
observation that cell growth is not affected it is unlikely to alter the results in this 
assay. As the bar chart shows (Fig. 4.5.3A) there was no difference in wound 
closure between the cell lines after 6 hours or 24 hours of wound closure. 
Successful knockdown was confirmed by western blot (Fig. 4.5.3B), the 
western blot was also probed for HIF-1α, in concordance with previous results, 
there was increased HIF-1α expression. This data suggests that the elevated 
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HIF-1α following loss of CoAsy is not sufficient to increase cell migration in this 
cell type.  
 
4.5.4 Loss of CoAsy does not affect clonogenic potential of A549 cells 
Clonogenic assays are another well-established in vitro technique that assays 
the ability of a cell to survive and grow from a single cell, which acts as a marker 
for increased cell survival and proliferation. Cells are plated at an equal number 
and left to grow, before fixing, staining and counting the colonies. Increased 
colony number is associated with increased tumourigenicity. A549-tet-shRNA 
cells were pretreated with doxycycline to induce knockdown before plating at 
100 cells and culturing for 10 days either in 21% O2 or 1% O2.  
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Figure 4.5.4: CoAsy does not alter clonogenic potential of A549 cells. Colony 
assay of A549-tet-shRNA cell lines. A549-tet-shRNA cells were pretreated with 
doxycycline before replating at 100 cells per well in 6 well plates before culturing for 
10 days in 21% O2 or 1% O2. Colonies were fixed stained and counted. A) Bar chart 
of relative number of colonies, normalized to 21% O2 shScr. B) Representative image 
of colonies. Statistical analysis performed is two-way ANOVA with Sidak’s Post Hoc 
test. n=3.  
 
Figure 4.5.1 shows that loss of CoAsy does not affect colony number in A549 
cells. For both cells cultured at 21% O2 and 1% O2 there was no significant 
difference in number of colonies between shScr and shCoAsy cell lines. Two-
way ANOVA indicates that there was a significant decrease in number of 
colonies between normoxic and hypoxic cells (p<0.0001, Fig. 4.5.1A) in 
addition to reduced number the colonies were also smaller in size as they 
contained fewer cells (Fig. 4.5.4B). This result is in keeping with earlier results 
indicating that in A549 cells there is no change in cell proliferation or fitness 
following loss of CoAsy. 
 
 
 
 
A B 
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4.5.5 Loss of CoAsy increases clonogenic potential of T47D cells 
As there were no changes in cell proliferation, wound closure or clonogenic 
potential in A549 cells lacking CoAsy other lines were tested to ensure that this 
isn’t specific to A549 cells. Therefore the clonogenic assays were repeated with 
T47D-tet-shRNA lines. 
 
Figure 4.5.5: Loss of CoAsy increases clonogenic potential of T47D cells: Colony 
assay of T47D-tet-shRNA cell lines. T47D-tet-shRNA cells were pretreated with 
doxycycline before replating at 100 cells per well in 6 well plates before culturing for 
10 days in 21% O2 or 1% O2. Colonies were fixed stained and counted. A) 
Representative bar chart of number of colonies. B) Representative image of colonies. 
Bar charts from other two biological replicates can be found in appendix. Statistical 
analysis performed is two-way ANOVA with Sidak’s Post Hoc test. n=3.  
 
The clonogenic assay in T47D shows a stark difference to that in A549 cells, 
as loss of CoAsy shows a significant increase in number of colonies in cells 
grown at 21% O2 (p = 0.0065). Cells cultured in hypoxia showed a slight 
increase in colony number however this result was not statistically significant 
(p = 0.175). As in A549 cells there is a significant decrease in colony number 
in the cells cultured in hypoxia compared to normoxia. This increase in 
clonogenic potential suggests that loss of CoAsy in T47D cells may confer a 
A B 
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fitness advantage that allows cells to grow from a single cell. Furthermore this 
highlights a difference between the role of CoAsy loss between A549 and T47D 
cells. 
 
4.6 Summary 
This chapter sought to identify how loss of CoAsy drives HIFα expression. 
Whilst the mechanism is still unclear, the data suggests that CoA or a CoA 
derivative negatively regulates HIFα. The data further points to HIFα being 
regulated at the post-translational stage, with both the 30-389 and ODDD 
amino acid domains of HIF-1α being affected. Finally the chapter showed that 
in A549 cells there was no difference in proliferation, wound closure or 
clonogenic potential however there was an increase in clonogenic potential in 
the luminal A breast cancer cell line T47D. The biological consequences of this 
are unclear and further lines will need to be tested, however this may highlight 
a difference in the role of CoAsy as a tumour suppressor in lung and breast 
cancer.  
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Results Chapter Three: 
 
Analysis of CoAsy expression in lung and 
breast cancer 
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5.1 CoAsy expression in non-small cell lung cancer (NSCLC) 
5.1.1 Analysis of CoAsy copy number from TCGA data 
The previous results chapters have shown that CoAsy is a novel negative 
regulator of HIF transcriptional activity and protein stability in a number of cell 
types in vitro. However it is important to confirm that this regulation is relevant 
in patients; specifically, We hypothesise that CoAsy may be lost in lung cancer 
and ask the whether CoAsy expression can predict patient morbidity. As the 
siKinome screen and subsequent validation was performed in lung 
adenocarcinoma cells (A549), CoAsy expression in non-small cell lung cancer 
was investigated.  
 
To first investigate COASY expression, gene copy number analysis data from 
TCGA was analysed using the open source platform cbioportal. This platform 
allows analysis of a wide variety of datasets including TCGA provisional 
datasets.  
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Figure 5.1.1.1: Copy number analysis of COASY  in lung cancer: Copy number 
analysis of COASY in Lung adenocarcinoma (TCGA provisional) and lung squamous 
cell carcinoma (TCGA provisional). Plots show frequency of copy number status. 
 
Copy number analysis of COASY in lung cancer TCGA data reveals distinct 
trends between adenocarcinoma and squamous cell carcinoma. This is likely 
due to the differing cell types of origin for these cancers. In the lung 
adenocarcinoma patient cohort (Fig 5.1.1.1A), no patients had deep deletion 
of the COASY gene and only 7.4% had shallow deletion. Over half the patients 
were diploid for COASY and a further 212 (41.4%) had a gain in copy number. 
In the lung squamous cell carcinoma cohort, deep deletions and amplifications 
were rare occurring in 2 patients each. However shallow deletions were more 
frequent than observed in the adenocarcinoma cohort (22% of patients). Most 
patients were diploid for COASY and there was still a large amount of patients 
with gain in copy number for COASY. In addition to the copy number analysis 
for this cohort, mRNA-seq data has been performed quantifying COASY 
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expression, plotting this against copy number shows that the copy number 
analysis correlates with mRNA expression thereby allowing conclusions on 
gene expression to be drawn from the copy number analysis data. Taken 
together this data suggests that a degree of CoAsy loss does occur in lung 
cancer, however this is not in the majority of cases and appears to be more 
frequent in squamous cell carcinoma. 
 
Figure 5.1.1.2: COASY copy number correlates with mRNA expression:  Box and 
whiskers plot (Tukey) of COASY copy number analysis plotted against CoAsy mRNA 
expression measured by RNA-seq (RNA-seq V2 RSEM). Data is from TCGA 
provisional datasets obtained from cbioportal server. 
 
 
5.1.2 Analysis of CoAsy mRNA expression as a prognostic marker in 
NSCLC 
In addition to determining the extent of CoAsy loss in lung cancer, the effect of 
CoAsy expression on survival was also investigated. To this end, Dr. Jun Wang 
performed univariate analysis of CoAsy expression from TCGA data correlating 
with overall survival. 
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Figure 5.1.2: COASY expression does not correlate with patient survival in lung 
TCGA datasets. Kaplan-Meier plots of patient overall survival stratified by COASY 
expression for both lung adenocarcinoma (A) and squamous cell carcinoma (B). 
Graphs were prepared by Dr. Jun Wang and the data is from the provisional TCGA 
dataset. Results show that COASY expression is not an independent predictor of 
patient outcome for either squamous cell carcinoma or adenocarcinoma 
 
Figure 5.1.2 shows that CoAsy expression data from TCGA does not serve as 
a significant prognostic marker for either lung adenocarcinoma or squamous 
cell carcinoma. In lung adenocarcinoma the hazard ratio (HR) is 1.31 indicating 
that higher CoAsy mRNA expression indicates a less favourable patient 
outcome and reduced survival, however this is not statistically significant as the 
P-value is 0.129. Conversely, the HR in lung squamous cell carcinoma data set 
is 0.79 suggesting that low CoAsy confers poor patient outcome however once 
again this is not significant (p = 0.223). As neither LUAD nor LUSC datasets 
show a significant correlation with patient outcome it can be said that CoAsy 
mRNA expression is not an independent indicator of patient outcome. However 
further multivariate analysis with other patient stratification such as patient age, 
stage or even co-expression with other hypoxic markers may reveal statistically 
significant trends in patient outcome. Despite neither dataset revealing 
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significant correlation, the difference in hazard ratios between the lung 
adenocarcinoma and squamous cell carcinoma is interesting nonetheless.  
 
5.1.3 Analysis of CoAsy mRNA expression as a prognostic marker using 
KMplot server 
KMplot [216] is an online portal that contains relapse free and overall survival 
data from a curated database of samples from TCGA, EGA and GEO sources. 
This allows the user to split patient samples into two groups based upon 
expression of biomarker of interest. This was performed twice for COASY, once 
with the cut off point adjusted to achieve maximum significance and again with 
patients separated by median COASY expression.  
 
 
 
 
 
 
For the probe used in the analysis (Affymetrix probe = 201913_s_at) there was 
a total of 1926 patients. When separating patients by the median COASY 
A
 
B
 
Figure 5.1.3: High COASY expression correlates with poor patient outcome in lung 
cancer.  Kaplan-Meier plots of lung cancer patient overall survival stratified by COASY 
expression. Patients were either stratified by median (A) or by a margin to create optimal 
statistical significance (B).  
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expression there was no significant difference in patient prognosis with a HR of 
1.03 and a logRank P value of 0.68. With the option to stratify patients in such 
a way to maximize the statistical significance, there is a significant difference in 
patient prognosis with high COASY expression correlating with poor outcome. 
The HR is 1.18 and the logRank P value is 0.021 suggesting a small difference 
similar to that that observed in the adenocarcinoma TCGA data. This dataset 
contains a mixture of both adenocarcinoma and squamous cell carcinoma 
patients as well as other undefined lung cancer patients.  
 
Considering survival data from both TCGA and the larger cohort of lung cancer 
patients on the KMplot server, it can be said that in lung cancer COASY mRNA 
expression does not act as an independent prognostic marker. 
 
5.1.4 Optimisation of antibody to detect CoAsy in formalin fixed paraffin 
embedded tissue microarrays.  
As the lung data for COASY mRNA data did not show statistically significant 
results, it does not mean that CoAsy protein expression is not relevant in 
cancer. There are numerous reports highlighting the poor correlation between 
mRNA expression and protein expression, this is also true in hypoxia with 
alternative translation machinery resulting in reduced correlation between 
mRNA expression and the resulting protein. Thereby suggesting that mRNA is 
a poor indicator of protein expression in cancer. To measure CoAsy protein in 
lung cancer, a TMA containing a mixture of adenocarcinoma and squamous 
cell carcinoma patients was stained for CoAsy protein expression. However 
prior to staining and analysis the antibody requires optimization to minimize 
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background staining. One commercially available antibody has previously been 
optimized for immunohistochemistry with antigen retrieval techniques 
optimized therefore this was used for staining. To identify an appropriate 
concentration of primary antibody for staining, multiple dilutions were used.  
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Figure 5.1.4: Optimisation of anti-CoAsy antibody for IHC.   The rabbit polyclonal anti-
CoAsy (ab155551) was used at 1:50, 1:200 and 1:500 on a test lung TMA to determine 
appropriate dilution for subsequent staining. 
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Across the dilutions used there was a wide variety of staining intensity 
observed. The negative control, staining without primary antibody, showed no 
staining at all indicating any colour from the DAB detection agent is as a result 
of reactivity with the primary antibody. To ensure scoring is accurate and robust, 
the primary antibody concentration should be adjusted such that the range in 
staining intensities is as broad as possible. Primary antibody dilution of 1:500 
resulted in no visible staining at all. Dilutions of 1:200 showed a degree of 
staining however across the slide there was not a large range in staining 
intensities. The staining observed with primary antibody at 1:50 resulted in 
intense staining as well as some regions of no visible staining and no visible 
staining in the surrounding stromal tissue. However the majority of cores across 
the TMA had high levels of staining making it difficult to differentiate between 
high and middle levels of CoAsy expression. Therefore the staining of the TMA 
was performed with primary antibody at 1:75. 
 
5.1.5 High CoAsy expression in lung cancer results in poor patient 
prognosis and correlates with high HIF expression and VEGF expression. 
Following staining of the lung TMA, cores were scored by Dr. Ian Spendlove 
(University of Nottingham). The scoring analysis used was H-score analysis, 
this is performed by defining staining intensities as high, medium and low which 
are given a numerical value (+3, +2 and +1 respectively). H-score is calculated 
by multiplying the percentage of cells that fit into each category for each core. 
This results in a number between 0-300. Frequency of H-score is plotted to 
check for normal distribution and discriminatory cut off is determined to 
determine which samples are ‘CoAsy High’ or ‘CoAsy Low’.  
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Figure 5.1.5.1: H-scores from CoAsy stained lung TMA:  A) Scores plot of H-score 
scoring of CoAsy staining in the lung cancer TMA, the plot shows a bimodal distribution 
with two peaks at 100 and 200. B) Representative cores for low, medium and high 
intensity staining intensity used for scoring TMA. 
 
Figure 5.1.5.1 shows representative cores of staining intensities. The staining 
observed was cytoplasmic with no nuclear staining observed. This matches the 
literature as CoAsy is found anchored in the mitochondrial membrane facing 
into the cytoplasm. One interesting feature observed was intense staining in 
infiltrating lymphocytes when present in the cores; the biological consequence 
of this is unclear at this date. The plot of scores forms a bimodal distribution 
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with two peaks at 100 and 200. A cut off point of 142 was used to define CoAsy 
high or low patients. Dr. Ian Spendlove performed statistical analysis on this 
cohort.  
 
 
 
 
 
Figure 5.1.5.2 shows the resulting Kaplan-Meier plot from the lung TMA stained 
for CoAsy expression. The line in blue represents low CoAsy expression and 
the line in green is high CoAsy expression. The graph shows that patients with 
Figure 5.1.5.2: Kaplan-Meier plot of lung cancer patient survival stratified by 
CoAsy protein expression. Patients with low CoAsy expression are in blue whereas 
patients with high CoAsy expression are in green. Results show that patients with high 
CoAsy expression have a significantly poorer outcome than low expression (p = 
0.024). 
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high CoAsy expression have a poorer prognosis compared to those with low 
CoAsy expression. The Log Rank (Mantel-Cox) confirms that the difference 
between the groups is statistically significant (p=0.024). This result is surprising 
as the in vitro work suggests that loss of CoAsy upregulates the known 
oncoproteins HIF-1α and HIF-2α, which would suggest that loss of CoAsy 
would result in poor patient outcome as tumours with high HIFα in general have 
a poorer outcome. This TMA has also previously been stained for HIF-1α 
expression and the HIF target gene, VEGF. With these additional datasets it is 
possible to determine if there is a correlation between CoAsy expression and 
HIF-1α and VEGF. HIF-1α and VEGF staining and statistical analysis was 
performed by Dr. Ian Spendlove. 
CoAsy HiLo vs HIF1α _two_cats Crosstabulation 
Count   
 HIF1A_two_cats Total 
low high 
CoAsy_HiLo 
1=low 78 9 87 
= hi 53 17 70 
Total 131 26 157 
Table 5.1.5.1: Counts of intact cores from both CoAsy and HIF-1α staining 
 
 
Table 5.1.5.1 shows the number of intact cores common across for each 
stained TMA. During the process of sectioning slides from the block, cores may 
become damaged or lost. Furthermore during the staining process and 
subsequent washes others may fall off therefore subsequent correlation 
analysis can only consider cores common between both datasets. 
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Chi-Square Tests 
 Value df Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.456a 1 .020   
Continuity Correctionb 4.493 1 .034   
Likelihood Ratio 5.458 1 .019   
Fisher's Exact Test    .030 .017 
Linear-by-Linear 
Association 
5.421 1 .020   
N of Valid Cases 157     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count 
is 11.59. 
b. Computed only for a 2x2 table 
 
Table 5.1.5.2: Chi-square tests of table above comparing likelihood of CoAsy 
expression to be related to HIF-1α expression 
 
 
Table  5.1.5.2 shows the Chi-square tests for this dataset, this statistical test 
measures the ‘goodness of fit’ for a dataset therefore acts as a readout for 
correlation between two variables. Table 5.1.5.2 shows an exact significance 
(2-sided) of p = 0.030 which shows that there is a statistically significant 
relationship between the two datasets. Comparing the groups in first table it 
indicates that the correlation is a positive relationship suggesting that in his the 
cohort the patients with high CoAsy expression are more likely to have high 
HIF-1α expression.  
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CoAsy_HiLo * vegf_two_cats Crosstabulation 
Count   
 vegf_two_cats Total 
low high 
CoAsy_HiLo 
1=low 25 64 89 
= hi 8 63 71 
Total 33 127 160 
 
Table 5.1.5.3: Counts of intact cores from both CoAsy and VEGF staining 
 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 6.827a 1 .009   
Continuity Correctionb 5.838 1 .016   
Likelihood Ratio 7.172 1 .007   
Fisher's Exact Test    .010 .007 
Linear-by-Linear 
Association 
6.784 1 .009   
N of Valid Cases 160     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 
14.64. 
b. Computed only for a 2x2 table 
 
Table 5.1.5.4: Chi-square tests of table above comparing likelihood of CoAsy 
expression to be related to VEGF expression 
 
 
The analysis was repeated as before with VEGF staining, in this cohort once 
again the Pearson’s Chi-square test shows that the relationship between 
CoAsy and VEGF is significant and therefore did not happen by chance. Once 
again this is a positive relationship suggesting that in this cohort patients with 
low CoAsy expression are more likely to have low VEGF expression and vice 
versa. 
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5.1.6 Summary 
Taken together this data shows that there is a small proportion of patients with 
reduced COASY mRNA expression and loss of copy number in both 
adenocarcinoma and squamous cell carcinoma. However when looking at 
survival analysis of TCGA data there was no significant difference. Analysis of 
a small lung TMA showed that high CoAsy expression correlated with poor 
patient outcome. Interestingly there was also a positive correlation with CoAsy 
and both HIF-1α and the target gene VEGF. This result is in contrast to the in 
vitro data where high HIF-1α was observed with low levels of CoAsy, which 
may suggest why the trend observed with CoAsy expression and overall 
survival did not match the original hypothesis in this cohort. 
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5.2 CoAsy expression in breast cancer 
In addition to analysing CoAsy expression in lung cancer, we further examined 
CoAsy expression in breast cancer. This was important as the in vitro data 
showed that loss of CoAsy resulted in stabilized HIF-1α and HIF-2α in T47D 
cells, which are luminal A breast cancer cells.  
 
5.2.1 Analysis of COASY and PANK1 in an in-house dataset of breast 
cancer patients 
COASY expression was analysed in an in-house cohort of breast cancer 
patients, in addition to CoAsy, PANK1 expression was also assessed, as there 
may be other defects across the CoA biosynthesis pathway. The in-house 
cohort is a small well annotated cohort (n = 19) with proteomics, phospho-
proteomics and RNA-seq data from each sample. In addition to the RNA-seq 
data, tissue sections also collected and patients have been stratified by 
receptor status. Each patient is still alive therefore no survival data can be 
collected. However serial samples were collected from tumour, adjacent tissue 
(2.5 cm2 from primary tumour) and surrounding tissue (between 5-10 cm2 from 
primary tumour), this data allows comparisons to be made in gene expression 
in tumour compared to matched adjacent normal tissue.  
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The RNA-seq data from the in-house cohort shows a significant reduction in 
COASY expression in tumour compared to the adjacent and surrounding tissue 
(p = 0.00160 and p = 0.00217 respectively). In contrast to this, one of the 
enzymes catalyzing the first step in CoA biosynthesis, PANK1 shows the 
opposite result with increased expression in tumour compared to the 
surrounding tissue (p = 0.0381 and p = 0.00681 respectively). The biological 
consequence of this is not entirely clear, as expression of PanK isoforms 
generally dictates the amount of CoA. However reduced expression of CoAsy 
could also reduce flux through the pathway and thereby inhibit CoA production. 
In order to best test this direct metabolomics should be performed to measure 
CoA and levels of intermediates in the CoA pathway (such as 
Figure 5.2.1.1: RNA-seq data of COASY and PANK1 :  RNA-seq data showing 
expression of COASY (A) and PANK1 (B) in the in-house cohort of breast cancer. 
Samples were taken from primary tumour or adjacent (2.5 cm from primary tumour) 
and surrounding tissue (over 5 cm from primary tumour). Statistical analysis is two 
tailed paired T-tests. 
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4’phosphopantetheine, the substrate for CoAsy). This cohort has also been 
stained for the three important receptors in breast cancer (ER, HER2 and PR) 
that allows for further analysis and stratification of patients by receptor status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.1.2: COASY expression from in-house cohort stratified by receptor 
status.  RNA-seq data showing expression of COASY in the in-house cohort. Patients 
were stratified by receptor status (ER, PR and HER2) as determined by IHC. 
 
As can be seen in figure 5.2.1.2, low COASY mRNA expression was observed 
in ER and PR negative patients. There appears to be a trend towards lower 
expression in HER2 negative patients, however due to the small sample size 
(2 patients with HER2 positive), it is not possible to perform statistical analysis 
on this dataset. The reduced COASY expression in the receptor negative 
patients is of particular interest as triple negative breast cancer (patients lacking 
all three receptors) remains an area of unmet clinical need and lacks efficient 
targeted therapies. Following on from this result, further investigation was 
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performed in to the correlation between CoAsy expression and receptor status 
in breast cancer. 
 
5.2.2 CPTAC proteomics database reveals low CoAsy protein expression 
in ER and PR negative tumours 
Due to the small sample size in the in house cohort and thus limited, larger 
datasets were analyzed to test the correlation between low CoAsy expression 
and lack of ER and PR receptors in breast cancer. To this end, data from the 
national cancer institute’s Clinical Proteomic Tumour Analysis Consortium 
(CPTAC) was used. This dataset contains integrated proteomics and 
complimentary genomics/RNA-seq data that is all made publically available and 
added to the TCGA (provisional) dataset. Using the online portal, cbioportal, 
CoAsy protein levels were correlated against both ER and PR receptor status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.2: CoAsy protein expression from CPTAC data stratified by ER and 
PR status:  Tukey plot of CoAsy protein expression (from CPTAC database) in breast 
cancer patients stratified by PR and ER status.  Data was obtained from cbioportal. 
Statistical test performed was unpaired two tailed T-test. 
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The data from CPTAC confirms the findings observed in Figure 5.2.1.2 and 
further suggests that low CoAsy expression is observed in patients lacking ER 
and PR receptor possibly implicating CoAsy protein level as a biomarker for 
patients with triple negative breast cancer. There were numerous metrics for 
HER2 expression within this dataset, however due to the poor consensus 
between different methods of measuring HER2 and lack of binary system as 
employed in figure 5.2.1.2, this data has not been included. 
 
5.2.3 Triple negative breast cancer cell lines express low levels of CoAsy 
protein 
A panel of breast cell lines were analysed for CoAsy protein expression as well 
as HIF-1α. In addition to this RNA was also collected and COASY mRNA was 
measured by qRT-PCR. The panel included 3 ER positive cell lines, a HER2 
positive and three triple negative breast cancer cell lines. 
 
Figure 5.2.3: CoAsy protein and mRNA expression in breast cancer cell lines.  
CoAsy protein (A) and mRNA (B) expression in a panel of breast cancer cell lines. 
Western blot is representative image from n = 3 biological replicates. qRT-PCR of 
COASY mRNA is 3 biological replicates ± SD. 
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Western blot analysis (Fig. 5.2.3) shows a correlation between CoAsy 
expression and HIF-1α protein levels in the three ER positive samples tested, 
with the MCF7 cells showing the lowest CoAsy expression and stabilized HIF-
1α even though samples were cultured at 21% O2. The triple negative cell lines 
(MDA-MB468, MDA-MB231 and HCC1143) show reduced CoAsy expression 
compared to the receptor positive lines. The qPCR data shows the T47D and 
ZR-751 expressing high levels of COASY mRNA reflecting the high protein 
levels observed in the western blot. Interestingly the mRNA levels observed in 
triple negative patients were not lower than the HER2 positive or MCF7 cells 
which is contrast to the protein levels. This highlights that in cancer mRNA 
levels do not always reflect protein expression [217]. Considering the in-house 
cohort, proteomics data and the results from the cell lines, it can be said that 
CoAsy is lost in breast cancer patients compared to surrounding tissue and loss 
of CoAsy is more frequently observed in triple negative breast cancer patients. 
 
5.2.4 Correlation of COASY mRNA and HIF target genes from TCGA data 
The in vitro data showed that loss of CoAsy resulted in increased HIFα protein 
levels and activity observed with both synthetic reporters as well as 
endogenous target genes. Whilst causality cannot be determined in patient 
datasets, correlation and trends in HIF target genes can be measured. To this 
end COASY mRNA was correlated with mRNA expression of HIF target genes. 
Target genes were selected from Dayan et al., 2006 and Briggs et al., 2016 [81, 
88]. These lists were selected due to encompass both FIH-dependent and 
independent targets (from Dayan et al.) and Briggs et al. identified a signature 
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of hypoxic responsive genes that were upregulated in triple-negative breast 
cancer. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5.2.4: Correlation of COASY mRNA expression and HIF target genes. 
Scatter plots showing correlation of HIF target genes with COASY expression in breast 
cancer patients. Data was taken from TCGA (provisional) accessed on cbioportal.  
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Table 5.2.4: Correlation coefficients and significance from TCGA (provisional) RNA-
seq data of COASY and a number of HIF-target genes. Correlation analysis was 
performed using Graphpad Prism 7. 
 
Across a number of HIF target genes (9/10 analysed) there was a statistically 
significant negative correlation between COASY expression and HIF target 
gene. The P-value was p < 0.0001 for the majority of targets analysed indicating 
these results were highly significant. However this is likely due to the large 
sample number present (n = 1100). It is important to consider the correlation 
coefficient. Negative values represent a negative correlation and higher 
negative values, up to -1, indicates a stronger negative correlation. For HIF 
target genes such as PDK1 and SOD2 the Spearman’s correlation coefficient 
was below -0.3 indicating that this is a strong correlation however other genes 
such as LDHA are less strongly correlated. Interestingly ANKRD3 expression 
did not correlate with COASY expression, as Spearman’s correlation coefficient 
was -0.01743 and p value was 0.5636. This suggests that not all HIF target 
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genes are affected by COASY expression and this may be a tissue or tumour 
type specific effect. There was no clear trend when comparing HIF target genes 
that have been reported to be FIH sensitive or insensitive. LDHA has been 
reported to be a gene that is inhibited by FIH whereas PGK1 has been reported 
to be insensitive to FIH activity, these two genes express similar correlation 
coefficients when compared to COASY expression in this dataset. The 
biological significance of both FIH dependent and independent targets is 
unclear as each could be derived from different regions across the tumour and 
oxygen tensions will vary greatly, therefore it is unclear whether FIH will be 
active in the tumours from which the samples were derived. Taken together 
these data shows that in patient RNA-seq data there is a small but consistent 
negative correlation between COASY expression and a number of target 
genes, which strongly supports the in vitro data presented earlier where loss of 
CoAsy resulted in increased HIFα, although it is important to note that this 
datum is a correlation and cannot determine causality.  
 
5.2.5 COASY expression is an independent prognostic biomarker in 
breast cancer 
The previous results have shown that there is a loss of COASY expression in 
breast cancer and this correlates with both the triple negative breast cancer 
subtype and high expression of HIF target genes. As triple negative breast 
cancer patients often have poor prognosis compared to receptor positive 
patients and high HIF expression has been associated with poor prognosis we 
hypothesized that COASY might act as an independent marker for patient 
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outcome. To this end COASY expression was used to stratify patients on the 
KMplot server.  
 
 
Figure 5.2.5: COASY mRNA expression correlates with poor patient outcome. 
Kaplan-Meier plots generated on KMplot server showing overall survival with patients 
stratified by COASY expression. Patients were stratified by median COASY 
expression (A) or with a cut off designed to achieve maximum significance (B).  
 
 
The Kaplan-Meier plots were prepared with varying methods for stratifying 
patients. The first plot (Fig. 5.2.5A) was prepared by separating the two patient 
groups by COASY expression by the median with the second plot (Fig. 5.2.5B) 
prepared to select the cut-off point to achieve maximum significance between 
the two patient groups. Both methods result in a statistically significant 
difference in patient survival based upon COASY expression with low COASY 
expression resulting in poor patient outcome. Separating the patients by 
median results in a subtle difference between the two populations as can be 
seen on the graph with the lines on the Kaplan-Meier plot close resulting in a 
hazard ratio of 0.85. However when separating the patients to achieve 
maximum significance the lines separate slightly which results in a lower hazard 
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ratio of 0.78 and increased significance. Taken together these results indicate 
that in breast cancer COASY acts as a prognostic biomarker and may implicate 
CoAsy as a novel tumour suppressor in breast cancer. 
 
 
5.2.6 Investigating the mechanism of COASY loss in breast cancer 
Previous results have shown that COASY is lost in breast cancer, but quite how 
this occurs is not clear. Previous data shows that there was a reduction in 
COASY mRNA expression in the tumour compared to surrounding tissue, 
however this can occur by multiple different means. This section will interrogate 
copy number loss and promoter methylation as two potential mechanisms. 
 
5.2.6.1 Analysis of COASY copy number in TCGA provisional dataset 
Genetic alterations are frequent in cancers with wide range of aneuploidy 
observed in every cancer type. Further rearrangements also occur as a 
consequence of chromosomal instability in a wide variety of cancer types. To 
investigate the copy number variations of COASY, TCGA breast (provisional) 
data was analysed on the cbioportal server. Prior to drawing any conclusions 
from this dataset it is important to establish if the copy number reflects mRNA 
expression. This is crucial as for genes that are tightly regulated by a specific 
transcription factor, gene copy number will be a less important indicator of 
expression than this hypothetical transcription factor activity.  To address this 
copy number was plotted against mRNA expression for matched samples taken 
from this cohort. 
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Figure 5.2.6.1.1: COASY copy number correlates with mRNA expression: A) 
Tukey plot showing COASY mRNA expression against gene copy number annotation. 
B) Collated data showing COASY mRNA expression against pooled data from patients 
with increased or decreased COASY copy number. Data is from TCGA (provisional) 
accessed on cbioportal. Statistical tests performed are Mann-Whitney T-tests. 
 
 
The Tukey plot in figure 5.2.6.1.1 shows that COASY copy number is an 
indicator of mRNA expression. Separating patients into copy number analysis 
shows that patients with loss of COASY (deep and shallow deletions) have 
reduced COASY expression compared to diploid patients (Fig. 5.2.6.1.1A). 
Within this dataset there was a subset of patients that had gain and 
amplification of COASY gene. These patients had an increased level of COASY 
mRNA compared to diploid patients; this is confirmed statistically when pooling 
together these patients as Mann-Whitney T-tests shows each group had 
significantly different levels of COASY mRNA expression compared to the 
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diploid patients. Therefore subsequent tests can assume that COASY copy 
number is an indicator of expression in this dataset. 
 
Figure 5.2.6.1.2: COASY is deleted in over 33% of breast cancer patients. A) 
Frequency of COASY copy number alterations in breast cancer. Data taken from 
TCGA (provisional) accessed on cbioportal. B) Percentage of copy number alterations 
for COASY and another of reported tumour suppressor genes in breast cancer. 
 
 
This large patient cohort allows us to determine how frequent loss of COASY 
is in breast cancer patients. Of the total 996 patients, 2 showed deep deletion 
of COASY with 341 patients with shallow deletion. In total this group represents 
over a third of breast cancer patients (34.4% of total) with loss of COASY. Less 
than 20% of patients had gain or amplifications in COASY copy number (19.5%) 
indicating that loss of COASY is a more frequent event. In addition to COASY 
copy number, a number of other reported tumour suppressors were analysed 
(Fig. 5.2.6.1.2B). The figure shows that across the tumour suppressors 
analysed, deep deletions are not frequent events with the highest observed for 
PTEN. The gene with the highest frequency of loss is TP53, a well-established 
tumour suppressor gene in multiple cancer types. It is clear that the copy 
number profile for COASY is comparable to that of the other classical breast 
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cancer tumour suppressors such as BRCA1 and CHEK2. Interestingly there 
was a higher degree of loss in COASY than observed with PTEN in this cohort. 
Taken together this data suggests that COASY copy number is an indicator of 
mRNA expression and that over a third of patients have loss of COASY which 
is in line with other classical breast cancer tumour suppressors such as CHEK2. 
 
5.2.6.2 Promoter methylation as an alternative mechanism for loss of 
gene expression  
An alternative mechanism for regulating gene expression is through DNA 
methylation. The majority of DNA methylation occurs at regions of DNA termed 
CpG islands, named as they contain multiple CG bases linked with the 
phosphodiester bond. The general consensus is that promoter methylation in 
these CpG islands corresponds with inhibited gene transcription and therefore 
reduced expression. To investigate the potential for COASY expression to be 
diminished by promoter methylation, the online server MethHC was utilized 
[218]. This server contains gene expression and methylation data from the 
TCGA. Analysis was also performed on TWIST1, a gene that has previously 
been reported to be hypermethylated in breast cancer [219]. 
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Figure 5.2.6.2: The promoter of COASY gene is hypermethylated in cancer. 
Promoter methylation status for COASY (A) and TWIST1 (B) and TNRC6A (C). Data 
is TCGA data accessed on MethHC online server. Results show a significant increase 
in promoter methylation in tumour samples compared to normal tissue in both COASY 
and TWIST1. Statistical test performed was Mann-Whitney T-test 
 
The Tukey plot in figure 5.2.6.2 shows a significant increase in COASY 
promoter methylation from tumour samples compared to that observed in 
normal healthy tissue (p = 0.0001). In the same dataset, the TWIST1 promoter 
also showed a significant increase in promoter methylation for the tumour 
samples compared to the normal (p < 0.0001). TNRC6A was included as a 
negative control, and no significant difference in methylation was observed 
between normal and tumour samples, furthermore the levels of methylation 
were all below 0.1 for each sample indicating that the promoter is not heavily 
methylated. Between the normal and tumour COASY promoter methylation 
datasets there is a small difference in the median values (0.1272 for normal 
and 0.1367 for tumour) that implies there is not a large difference between the 
two groups, however there are a large number of outliers with increased 
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methylation, which is why the difference between the groups is statistically 
significant. In contrast there is a large shift in median for the TWIST1 promoter 
(0.2091 and 0.3069 for normal and tumour respectively). The difference in 
normal and tumour promoter methylation is clear for both genes however this 
does not mean there is any biological significance, instead correlation between 
gene expression and promoter methylation needs to be compared. This dataset 
also contains RNA-seq gene expression data for matched methylation data, 
therefore to assess if the promoter methylation inhibits gene transcription this 
data was plotted in a scatter plot. 
 
 
 
 
 
The scatter plots in figure 5.2.6.3 show two distinct patterns between promoter 
methylation and gene mRNA expression. Pearson’s correlation analysis 
reveals no significant correlation between TWIST1 methylation and mRNA 
expression (p = 0.3004, Pearson’s correlation coefficient = 0.03883), this is in 
concordance with the literature as it has previously been shown that TWIST1 
CpG island methylation levels do not correlate with RNA or protein expression 
[220].  In this cohort there was a statistically significant correlation between 
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Figure 5.2.6.3: COASY mRNA expression correlates with promoter methylation. 
Scatter plots showing gene expression plotted against promoter methylation for 
COASY (A) and TWIST1 (B). Pearson’s correlation coefficient shows a significant 
correlation between COASY promoter methylation and mRNA expression. No 
significant correlation was observed for TWIST1. 
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COASY mRNA expression and promoter methylation (p < 0.0001, Pearson 
coefficient = -0.1830). Whilst the correlation is not strong it is highly significant, 
likely as a consequence of the large cohort size. Examining the scatter plot it is 
clear that no samples with methylation over 0.2 had high COASY expression 
thereby suggesting that promoter methylation may have an effect on COASY 
mRNA expression however further functional validation studies are required.  
 
In order to test if promoter methylation regulates COASY expression in vitro, a 
pair of triple negative breast cancer cell lines with low COASY expression were 
treated with the DNMT1 inhibitor 5’aza-2’-deoxycytidine. DNMT1 is the enzyme 
responsible for maintaining methylation patterns following cell division; therefor 
inhibiting this enzyme will block global DNA methylation as cells proliferate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.6.4: 5’-Azadeoxycytidine reduces COASY expression in MDA-MB231 
and HCC1143 cells: Bar chart showing COASY mRNA expression in two triple 
negative breast cancer cell liens following treatment with demethylating agent 5’-
azadeoxycytidine for 48 hours. Bar chart is representative image from n=2. 
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Figure 5.2.6.4 shows MDA-MB231 and HCC1143 cells treated with 5’-
azadeoxycytidine for 48 hours before collecting RNA and analyzing COASY 
expression by qPCR. As can be seen in the bar graph treatment with 5’-
azadeoxycytidine reduces COASY mRNA expression in MDA-MB231 cells 
(~40% reduction compared to vehicle only) whereas the HCC1143 cells 
displayed ~25% reduction in expression compared to vehicle. These results are 
in contrast to the initial hypothesis that demethylating agents will increase 
COASY expression. One important caveat from this experiment is that 5’-
Azadeoxycytidine acts as a global demethylating agent therefore other 
transcription factors or potential transcriptional repressors may also be 
affected. Another important point to consider is the basal levels of methylation 
in these cell lines, to address this the CCLE database was consulted. This 
database contains gene expression and methylation data for a wide array of 
cell lines. A number of breast cancer cell lines were taken from this database 
and plotted in a scatter plot to assess the degree of COASY promoter 
methylation in the cell lines used for the demethylation experiments.  
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Figure 5.2.6.5: COASY promoter methylation in breast cancer cell lines. Scatter 
plot of COASY mRNA expression plotted against promoter methylation from a number 
of breast cancer cell lines. Data obtained from CCLE database. Datapoints highlighted 
in red are the two cell lines used for 5’-azadeoxycytidine treatments  
 
The scatter plot in figure 5.2.6.5 shows that the methylation of COASY promoter 
is low in the two cell lines used in the in vitro experiments with MDA-MB231 
showing methylation status of 0.0074 and HCC1143 with 0.0037. This low level 
of methylation may explain why no increase in COASY expression was 
observed following treatment with 5’-azadeoxycytidine, instead alternative cell 
lines such as MDA-MB468 (in green) would be more appropriate to use due to 
the high methylation status observed in this cell line. Taken together, this data 
suggests that methylation is increased in tumour samples compared to normal 
tissue and correlates with COASY expression however further studies are 
required to define the causality between promoter methylation and COASY 
expression.  
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5.3 Conclusion 
This chapter sought to determine the expression levels of CoAsy protein and 
mRNA in breast and lung cancer patients and to further determine if this 
correlates with patient survival. In large datasets of lung cancer (both 
squamous and adenocarcinoma), a small proportion of patients displayed loss 
of copy number however in the same datasets there was no significant 
correlation with patient survival for either adenocarcinoma or squamous cell 
carcinoma. In a small lung cancer TMA CoAsy protein expression was 
analysed, in this TMA high CoAsy expression was associated with poor patient 
outcome and there was a positive correlation observed with HIF-1α and the 
target gene VEGF. This is in contrast to the in vitro data observed in the lung 
adenocarcinoma cell line A549 where knockdown of CoAsy resulted in 
stabilized HIF-1α.  
 
In contrast to the lung data, there was a larger proportion of copy number loss 
(over 34%) in breast cancer patients. In a small cohort of breast cancer tumours 
with matched adjacent tissue there was a significant reduction of COASY 
expression in the primary tumour compared to adjacent suggesting that 
COASY is lost in breast cancer. Further stratifying patients by receptor status 
shows that reduced CoAsy expression is correlated with lack of hormone 
receptors, this trend was further observed in larger cohorts (proteomic analysis) 
and in cultured cell lines. Further bioinformatics analysis shows that low 
COASY expression is associated with poor outcome. It is currently unclear as 
to the mechanism behind loss of CoAsy in breast cancer, however promoter 
methylation may play a role. Taken together it can be said that CoAsy is lost in 
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breast cancer and may potentially act as a tumour suppressor gene, particularly 
in triple negative breast cancer. 
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Results Chapter Four: 
 
Exploiting the concept synethic lethality to 
target CoAsy deficient cells 
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6.1 Chapter aims 
Previous chapters have identified CoAsy as a novel negative regulator of HIF 
transcriptional activity and protein stability.  Further analysis has shown that 
CoAsy is lost in over 34% of breast cancer patients and is correlated with poor 
patient prognosis. Due to this clear loss of CoAsy in breast cancer we sought 
to identify a targeted therapy against CoAsy negative cancers.  To identify such 
an inhibitor, the concept of synthetic lethality was be exploited whereby a drug 
will selectively kill cells lacking in CoAsy but will spare healthy cells with normal 
levels of CoAsy expression (Fig. 6.1).  
 
 
Figure 6.1: Synthetic lethality: Schematic diagram showing the concept of synthetic 
lethality 
 
To summarise the aims for this chapter: 
 To screen a library of compounds in inducible shRNA lines to 
identify a compound that selectively kills CoAsy knockdown cells 
 To validate identified hits across a dose response to determine 
change in Sf50 
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6.1.1 Optimisation of cell viability reagent 
For the arrayed drug library screen, the final readout for the assay is cell 
viability. Previous drug screens performed by collaborators with the same 
library used Cell Titer-Glo (Promega) as a viability reagent, however previous 
experiments in this project utilized the resazurin for cell viability. In order to 
determine the differences between the two reagents dose response curves 
were generated and treated with both reagents. As resazurin is a non-lytic 
reagent it is possible to perform the experiments in tandem on the same sample 
to allow for direct comparison. 
 
Figure 6.1.1: Optimisation of cell viability reagent for drug screen. T47D-tet-
shRNA cells were treated with doxycycline (25 ng.mL-1) for 72 hours prior to plating 
and treating with gemcitabine across a wide dose range. Cells were dosed on day 1 
and 3 of assay before reading cell viability with Cell Titer-Glo (A) and resazurin (B). 
n=1. 
 
T47D tet-shRNA cells were pretreated with doxycycline for 3 days prior to 
plating and treated with a dose range of gemcitabine. Gemcitabine was 
arbitrarily picked as an agent to induce cell death to test validity of viability 
reagents. Both shScr and shCoAsy cell lines were tested with viability agents 
as these have differing mechanisms of actions (Cell Titer-Glo measures cellular 
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ATP whereas resazurin requires functioning mitochondrial NADPH 
dehydrogenase) that may be altered by loss of CoAsy. As can be seen by the 
dose response curves there is no significant difference between the two viability 
reagents. There was a slight increase in variability with the luminescence 
readings from Cell Titer-Glo compared to the fluorescent readout from 
resazurin, however error bars are small for each viability reagent. This assay 
also shows that loss of CoAsy does not alter sensitivity to gemcitabine in T47D 
cells. 
 
6.1.2 FDA library drug screen in inducible shRNA cell lines  
To identify an inhibitor that selectively targets CoAsy deficient cells, three pairs 
of inducible shRNA lines were used (A549, MCF10A and T47D). These lines 
were selected as HIF stabilization following loss of CoAsy has been observed 
in both the A549 and T47D cell lines. The MCF10A-tet-shRNA pair were also 
included as these represent a ‘normal’ cell type, however it is important to note 
that these cells are naturally immortalized and had undergone EMT prior to 
lentiviral transduction, therefore a degree of cellular transformation has already 
occurred and cannot be considered a true primary cell line. Nevertheless the 
MCF10A pair still represents an isogenic pair of breast cells with or without 
CoAsy.  
 
The drug library used was an arrayed library containing 1177 FDA approved 
compounds; this library encompasses a wide range of inhibitors with 
chemotherapy agents, hypertensive agents and other compounds such as Talc 
included in the library. The advantage of this FDA approved library is that 
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significant pre and post clinical work has been performed on the compounds, 
with drug pharmacokinetics and mechanism of action (including off-target 
effects) being well established for the majority of compounds. The drug screen 
was performed at a dose of 10 µM per compound with two doses performed 
per replicate; a schematic of the drug protocol is below:  
 
Figure 6.1.2.1: protocol for FDA-approved library screen. Schematic of drug 
screen dose schedule. Cells were pretreated with doxycycline (25 ng.mL-1) for 72 prior 
to plating on day 0. Cells were treated with library at 10 µM at day 1 and day 3 with 
fresh doxycycline media added each time. Cell viability was measured at the end point 
of day 5 with resazurin viability reagent.  
 
Drug screen was performed as described above in the A549-tet-shRNA pair (2 
biological replicates), T47D-tet-shRNA pair (2 biological replicates) and in the 
MCF10A-tet-shRNA pair (1 biological replicate). After measuring cell viability 
the modified Z-score was used to determine statistical outliers, each 
representing a ‘hit’ from the screen.  
190 
 
 
Figure 6.1.2.2: Drug screen of FDA approved compounds. A) Scatter plot of 5 
biological replicates in the primary drug screen. T47D (n = 2), A549 (n = 2) and 
MCF10A (n = 1) tet-shRNA lines were screened with FDA approved library as 
described in Fig 6.1.2.1. B) Δ-Z scores were calculated from two biological replicates 
of the T47D shRNA screen and plotted in increasing Z-score. Results are presented 
as mean ± SD. 
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The scatter plot in figure 6.1.2.1A displays a broad distribution of Z-scores for 
the tested compounds, this shows that there is a wide range of effects from 
drug treatment with some inhibitors being very toxic. However, examining the 
spread of data in figure 6.1.2.1A shows the majority of the compounds did not 
greatly alter cell viability; this is important as it allows the Z-score statistical 
approach to be valid, as it is a measure to determine outliers, the assumption 
is based on the majority of results having no effect. Figure 6.1.2B shows a plot 
of Δ Z-score, which represents the change in viability between shCoAsy and 
shScr cell lines. Therefore the negative values on the screen means the 
inhibitor selectively targets CoAsy deficient cells whereas the positive suggest 
that loss of CoAsy confers some resistance to this drug. The error bars in this 
figure are large across the entire dataset; this could be a result of the 
degradation of the drug stock or through pipetting errors. The large error bars 
means that simply analyzing the average ΔZ-score will be an inefficient way of 
identifying hits as there will likely be a large number of false positive and 
negative hits and other more systematic approaches will be more applicable.    
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6.2 Validation of hits from drug screen 
6.2.1 Quarternary ammonium compounds 
To identify hits the first approach was to look at each cell line individually and 
compare the hits with the largest differences between shScr and shCoAsy lines. 
The first line tested was the MCF10A-tet-shRNA pair. 
 
Figure 6.2.1: Top 10 hits from drug screen in MCF10A-tet-shRNA cells. Drugs 
underlined in red represent drugs from the quaternary ammonium class of 
antimicrobial agents. 
 
Analysis of the top hits of this screen revealed a number of molecules that 
belong to the same class with each containing a quaternary ammonium cation. 
These compounds are all broad-spectrum microbiocidal compounds that are 
used in many antiseptics [221]. It is important to note that each of these 
compounds were across different plates and different locations across plates, 
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therefore it is unlikely that the effect observed in the screen occurred due to 
technical errors during manual pipetting. 
 
 
Figure 6.2.2: Quaternary ammonium compounds. Structures of the quaternary 
ammonium compounds identified during the drug screen. Each compound contains 
the positive nitrogen cation that is covalently bonded to 4 alkyl side groups (or double 
bonds as part of an aromatic ring) highlighted here in blue. 
 
Two of these quaternary ammonium compounds were purchased and the 
A549, T47D and MCF10A tet-shRNA cell lines were treated using the same 
protocol as that from the primary screen across a wider dose range. The two 
selected were benzothenium chloride and domiphen bromide. Domiphen 
bromide was selected as in the drug screen it showed the highest degree of 
selectivity whereas benzothenium chloride was selected as it is a related 
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compound, however is formulated with a different salt anion. Therefore testing 
this compound will help determine if the salt anion is important for activity.  
 
 
Figure 6.2.3: Dose response curves for quarternary ammonium compounds in 
inducible shRNA lines. A-C) Dose response of Benzothenium chloride in MCF10A 
(A), A549 (B) and T47D (C). D-E) Dose response of Benzothenium chloride in 
MCF10A (D), A549 (E) and T47D (F).  Experiments were performed using the same 
protocol as initial drug screen. N=1 
 
The dose response curves in figure 6.2.3 show that in A549 and T47D there is 
no difference in selectivity between the shScr and the shCoAsy for either 
domiphen bromide or benzothenium chloride. This is to be expected as neither 
hit showed significant selectivity in these lines in the initial drug screen. In the 
MCF10A lines there was a slight degree of selectivity in for each drug as Sf50 
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values were shScr = 1.507 µM and shCoAsy 1.865 µM for benzothenium 
chloride and shScr = 0.845 µM and shCoAsy = 2.05 µM for domiphen bromide, 
this selectivity is different to that observed in the screen where treating MCF10A 
inducible lines with 10 µM of each drug resulted in selectivity for the CoAsy 
deficient cell line. It is unclear as to why this class appeared to be selective in 
the primary screen but failed to reproduce across a dose range. Therefore 
these drugs were not taken forward for further experiments. 
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6.3 Nicardipine HCl 
Taking an alternative approach to identify hits, the screen was re-analysed to 
select compounds that showed a degree of selectivity in each cell line tested. 
Furthermore the hits with very large Z-scores were excluded from analysis as 
these results often skew the analysis and results in increased false positives. 
Through this approach nicardipine HCl was identified. Nicardipine HCl is a 
potent calcium channel blocker that is used in the treatment of hypertension 
[222].  
 
 
Figure 6.3.1: Nicardipine HCl was selective for CoAsy deficient cells in primary 
screen. A) Bar chart showing the Z-scores for T47D, A549 and MCF10A inducible 
shRNA lines treated with 10 µM nicardipine HCl in primary screen. B) Chemical 
structure of nicardipine HCl. 
 
As can be seen in figure 6.3, nicardipine HCl appears to be selective against 
CoAsy deficient cells in T47D and MCF10A at a dose of 10 µM, the error bars 
are large for the A549 experiments therefore it is hard to determine if there is 
any selectivity in this cell line. The drug is toxic in T47D cells as there is a large 
amount of cell death in both the shScr and shCoAsy cell lines, this is in contrast 
to the A549 and MCF10A cells where no significant cell death was observed in 
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the shScr cell lines. To further validate nicardipine, A549-tet-shRNA cells were 
treated with nicardipine across a wide dose range. 
 
Figure 6.3.2: Loss of CoAsy sensitizes A549 cells to Nicardipine HCl. A549-tet-
shRNA cells were pretreated with doxycycline for 72 hours before plating and treated 
with nicardipine HCl across a dose range. Cells were treated as in the primary drug 
screen. N=1.  
 
The initial validation of nicardipine HCl in the A549 cell line showed promising 
results, as loss of CoAsy sensitized the cells to treatment with nicardipine HCl. 
The Sf50 values were shScr = 9.89 µM and shCoAsy = 3.26 µM, indicating a 
threefold reduction in drug required to kill half of the cells. Subsequent repeats 
were performed to confirm this result in the A549-tet-shRNA cell lines. 
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Figure 6.3.3: Nicardipine HCl treatment of A549-tet-shRNA cells. A549-tet-shRNA 
cells were pretreated with doxycycline for 72 hours before plating and treated with 
nicardipine HCl across a dose range. Cells were treated as in the primary drug screen. 
N=2.  
 
As can be seen in figure 6.3.3 the further repeats of nicardipine HCl treatment 
differed greatly to the first repeat. There is still a degree of selectivity for the 
CoAsy deficient cells with a reduction in Sf50 of 2.μM, however it is to a lesser 
extent as seen in figure 6.3.2. In both the shScr and shCoAsy lines there is an 
increase in Sf50 values (shScr = 19.5 µM and shCoAsy = 17.1 µM) compared 
to figure 6.3.2 and a decreased sensitivity for Nicardipine in these lines. This 
decrease in drug efficacy led to the hypothesis that there has been degradation 
of the drug after multiple freeze-thaw cycles. To negate this effect fresh drug 
was purchased from multiple suppliers and the experiments were repeated 
again. 
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Figure 6.3.4: Treatment of A549-tet-shRNA cells with Nicardipine HCl from two 
different suppliers. A549-tet-shRNA cells were pretreated with doxycycline for 72 
hours before plating and treated with nicardipine HCl purchased from Sigma-Aldrich 
(A) and Abcam (B). Cells were treated as in primary drug screen. n=2.  
 
Treatment of A549 tet-shRNA lines with fresh aliquots of nicardipine HCl from 
either supplier failed to display the selectivity observed in Figure 6.3.4. The Sf50 
values were shScr = 17.21 μM and shCoAsy = 16.17 μM for the drug purchased 
from Sigma-Aldrich and shScr = 13.08 μM and shCoAsy 12.88 μM. As there 
was no observed selectivity for either batch of drug it was decided to not 
continue any further experiments with nicardipine HCl and the initial repeat with 
the observed selectivity was dismissed as a false positive.  
 
6.4 Future drug validation experiments 
Due to the previous inhibitors not validating, an alternative approach to identify 
hits to validate was performed. The previous chapter identified loss of CoAsy 
in breast cancer that correlated with poor prognosis, whereas in lung cancer 
low CoAsy correlated with better patient prognosis, therefore the lung 
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adenocarcinoma cell line (A549 tet-shRNA pair) was discounted from the 
screen. Furthermore to simplify analysis of hits, the MCF10A inducible shRNA 
pair were discounted from analysis, as these are untransformed cells (albeit 
having undergone EMT prior to lentiviral transduction) they will be significantly 
different from the transformed cell line T47D. Therefore the top hits from T47D 
were compiled as potential candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Top hits from T47D screen. The Z-scores from the two biological 
replicates were manually screened to identify an inhibitor with increased cell death in 
the shCoAsy line compared to the shScr. Bar chart shows Z-scores from the top hits. 
Bars are average ± SD. N=2. 
 
From these compiled hits from the screen in T47D-tet-shRNA lines, two 
inhibitors shared a mechanism of action, as both 2-thiouracil and aminothiazole 
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are used in the treatment of hyperthyroidism through inhibition of thyroid 
peroxidase [223]. Axitinib is a tyrosine kinase inhibitor that targets VEGFR, c-
KIT and PDGFR, which in turn, inhibits angiogenesis [105]. Currently there is 
market authorization for treatment of renal cell carcinoma with axitinib. Future 
experiments will test these inhibitors across a wide dose range to determine if 
these compounds are truly selective against CoAsy deficient cells.  
 
6.5 Summary  
In this chapter we sought to identify an inhibitor that selectively targets CoAsy 
deficient cells. To achieve this A549, T47D and MCF10A inducible shRNA cell 
lines were screened against a library of 1177 FDA approved compounds and 
cell viability was measured. Attempts to validate some of the inhibitors are thus 
far unsuccessful, however there are a number of promising candidates that still 
require validation. Whilst the screen has highlighted a number of inhibitors with 
common mechanisms, it is unclear whether there are any pathways that are 
altered through loss of CoAsy. This is in part due to the high concentration of 
inhibitor used during the primary screen, which increases the likelihood of off-
target drug effects from occurring. Once a hit from the screen has been 
validated, this opens up the exciting prospect of preclinical studies for a novel 
targeted therapy against CoAsy deficient cancers. 
 
 
 
 
 
202 
 
 
 
 
 
Discussion and future work 
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7.1 CoAsy is a negative regulator of HIF-1 transcriptional activity 
The initial aim of the project was to identify novel regulators of HIFs. Taking an 
unbiased approach, an arrayed library of siRNA targeting all known human 
kinases, pseudo-kinases and proteins with predicted kinase activity was 
screened against A549 cells stably expressing HIF-1 HRE driven firefly 
luciferase. Through this primary screen and secondary validation screen, the 
Coenzyme A biosynthesis enzyme, CoAsy, was identified as a negative 
regulator of HIF-1 transcriptional activity in both normoxia and hypoxia. siRNA 
mediated knockdown experiments in multiple transformed cell lines indicated 
that loss of CoAsy results in stabilised HIF-1α and HIF-2α protein levels. This 
was an unexpected finding as there have been no previous reports linking the 
CoA biosynthesis pathway to HIF signaling.  
 
A number of non-canonical functions of CoAsy have been reported, as it has 
been shown that CoAsy binds to the P-body component EDC4 and ribosomal 
protein S6 kinase 1 (S6K1) [224, 225]. It has been shown that the EDC4:CoAsy 
interaction results in reduced CoAsy kinase activity however it is not known 
what function this interaction has in regulating EDC4 mRNA decapping ability, 
furthermore whether this interaction can have an effect on HIF signaling. 
Inhibition of S6K1 results in reduced rates of HIF-1α protein as a consequence 
of reduces HIF1A mRNA translation rates. However, the CoAsy:S6K1 
interaction has not been shown to affect either CoAsy or S6K1 activity, indeed 
this interaction has yet to be validated at the endogenous level or without serum 
starvation. Therefore it is unlikely that the previously identified non-canonical 
functions of CoAsy are responsible for the increased HIF activity. Interactions 
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between CoAsy and proteins unrelated to CoA biosynthesis highlight a potential 
role for CoAsy to function as scaffold protein where a protein can bring together 
two interactors to focus enzymatic activity. Future experiments to identify 
binding partners of CoAsy may provide hints to the mechanism behind the role 
of CoAsy in HIF signaling. Preliminary experiments were performed to test if 
PHD2 or HIF-1α interacted with overexpressed CoAsy-EGFP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: IP of CoAsy-EGFP and EGFP in HEK293T. HEK293T cells were transiently 
transfected with either EGFP-vector only or CoAsy-EGFP. 48 hours post transfection cells were 
lysed and immunoprecipitated with α-GFP prior to analysis by western blot. N=1. 
 
This IP indicates that CoAsy does not interact with either HIF-1α or PHD2. Both 
the EGFP vector only and CoAsy-EGFP display an enrichment of protein during 
the IP that indicates the IP was successful. However in the co-IP, no HIF-1α or 
PHD2 protein was detected. It is possible that this result is a false negative, as 
no positive control was assayed. Therefore future experiments should include 
a previously identified interacting protein such as S6K1. Furthermore the co-IP 
panel should be expanded to encompass other proteins that are known to 
regulate HIF such as pVHL.  
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Alternative approaches to identify if CoAsy is acting as a scaffold can also be 
used such as immunofluorescence (IFA) to detect if proteins co-localise or 
alternatively proximity ligation assay (PLA) to detect if they directly interact 
(within 30-40 nm).  
 
7.2 Coenzyme A or a Coenzyme A derivative negatively regulates HIFα 
protein stability 
Overexpression of CoAsy had no effect on HIF-1α protein levels, however 
overexpression of Pank1β, an isoform of Pank1, did result in a significant 
decrease of both HIF-1α and HIF-2α protein levels with no changes observed 
in HIF-1β. RNAi mediated silencing of Pank1 resulted in stabilised HIF-1α 
regardless of oxygen tension, as was observed following knockdown of CoAsy. 
This suggests a role of the CoA biosynthesis pathway in regulating HIF, 
however it is unclear whether this is as a result of CoA or other derivatives. To 
address this a number of enzymes that utilize CoA as a cofactor were knocked 
down in both wild type and inducible shCoAsy A549 cells. This highlighted 
ACSS1 as a potential mediator of this pathway, which means that the 
conversion of acetate and CoA to acetyl-CoA in the mitochondria is the reaction 
required to negatively regulate HIF. However further experiments were required 
to test this further. This was repeated with a reporter assay to test if HIF activity 
was still increased following loss of ACSS1. 
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Figure 7.2.1: Reporter assay of HIF activity in A549-tet-shRNA cells following 
knockdown of ACSS1, ACSS2 and OGDH. Cells were plated out and treated with 
doxycycline (25 ng.mL-1) before being treated with siRNA against ACSS1, ACSS2, 
OGDH and non-targeting control (40 nM). 48 hours post transfection cells were 
transfected with HRE driven nano-luciferase vector and firefly luciferase normalization 
vector before being placed into hypoxia overnight. Luciferase activity was measured 
(A) and knockdown was confirmed by western blot (B). Bar chart represents mean ± 
SD from 6 technical replicates. N=1. 
 
The reporter shows that loss of CoAsy increases the HRE reporter activity as 
the shCoAsy line showed higher relative luciferase activity compared to the 
shScr line once treated with non-targeting control siRNA. The previous data 
indicated that loss of ACSS1 increased HIF-1α protein levels, which appeared 
to be in a CoAsy dependent manner. However the reporter results showed that 
this stabilised HIF does not activate the HRE reporter, as loss of ACSS1 in the 
shScr line did not show increased luciferase activity. This result is in contrast to 
the reporter data following loss of CoAsy that shows an increase in reporter 
activity. Whilst further repeats are required to confirm this result, it suggests 
that loss of CoAsy may not regulate HIF through this enzyme. 
 
CoA is not membrane permeable; therefore simply supplementing cell culture 
medium with CoA will not directly increase intracellular CoA. Instead CoA will 
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be converted to 4’phosphopantetheine and converted to CoA by CoAsy [196], 
which is important as this means CoA supplementation will not restore CoAsy 
deficiency.  However a number of lipid based transfection reagents are capable 
of delivering small molecules to cells, therefore using this approach it is possible 
to transfect cells with CoA and other CoA derivatives and assess changes to 
HIF signaling. As a proof of concept experiment, this was performed with CoA 
in the A549-tet-shRNA cell lines. 
 
Figure 7.2.2: Transfection of A549-tet-shRNA cells with Coenzyme-A. A549-tet-
shRNA cells were treated with doxycycline (25 ng.mL-1) for 72 hours before being 
transfected with 30 µM CoA or equivalent volume of water using Lipofectamine 
transfection reagent. 2 hours post transfection cells were exposed to hypoxia for 4 
hours before lysis and analysis by western blot (A). HIF-1α band intensity was 
calculated and normalized to β-actin and plotted in bar chart (B). N=1. 
 
As can be seen in Figure 7.2.2 transfecting cells with CoA reduced HIF-1α 
protein expression in both the shScr and shCoAsy cell lines. The dose of 30 
µM was used, as this is double the intracellular concentration of CoA in HeLa 
cells. No information was available as to the concentration of CoA in A549 cells 
at the time of this experiment. This suggests that it is possible to transfect CoA 
to cells, therefore future experiments will be performed with the addition of 
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acetyl-CoA as well as other precursors such as 4’pantetheine as a negative 
control.  However in addition to this assay, a key future experiment is to develop 
a reliable method for determining CoA and CoA derivative concentrations in cell 
samples. This will confirm that the transfection reagent is successfully 
delivering the desired metabolite to cells. 
 
7.2.1 Acetyl-CoA and HIF-1α 
The main function of acetyl-CoA in cells is to act as an acetyl-carrier. The acetyl 
group is a labile subgroup that has been reported in many proteins. A number 
of acetylation events have been reported in HIF-1α. One such event is ARD1 
mediated acetylation of HIF-1α at K532; this acetylation event was reported to 
destabilize HIF-1α through increased association with pVHL and subsequent 
increased turnover [226], therefore it stands to reason that loss of CoAsy may 
reduce this acetylation event and result in stabilised HIF-1α. However this result 
has been debated as further research has shown that only a specific splice 
variant of mouse ARD1 is able to acetylate HIF-1α whereas no such activity 
was observed with human ARD1 [227, 228]. HIF-1α is further acetylated at the 
N-terminus which acts to stabilize the protein post-translation [158]. This 
suggests that loss of CoAsy could regulate HIF through altered acetylation, 
however studies in A549 cells have shown that despite reduction of both CoA 
and acetyl-CoA following CoAsy knockdown, there is no significant changes in 
acetylation [204]. Instead certain proteins actually displayed increased 
acetylation, however HIF-1α was not reported to have differential acetylation in 
this dataset.  Future experiments should directly assay HIF-1α acetylation 
following loss of CoAsy, as it is unclear whether this will increase or decrease 
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acetylation. This can be achieved through Immunoprecipitation of HIF-1α and 
western blot with an α-acetyl-lysine antibody.  
 
7.3 The role of CoA and CoAsy in the TCA cycle and metabolic regulators 
of HIFs 
CoA plays a major role in TCA cycle function as highlighted in figure 4.2.3.1. 
TCA cycle is impaired during low oxygen tension, indeed it is widely reported 
that not only is there a reduction of flux through the pathway, various 
metabolites accumulate during hypoxia such as succinate. Furthermore some 
of these metabolites have been reported to regulate HIF stability, often through 
inhibition of prolyl-hydroxylase function. This complex interplay between CoA, 
TCA cycle and HIF activity suggests an interesting biological relationship that 
may help explain how CoAsy regulates HIF. In addition to this, the glycolytic 
switch is a known occurrence in cancer; loss of CoAsy may also be a potential 
driver of this change in metabolism. Initial tracer analysis was performed with 
labeled glucose; this analysis involves growing cells with a metabolite labeled 
with a ‘heavy’ isotope, in this case all 6 carbons labeled with 13C, followed by 
analysis of metabolites by mass spectrometry. Through this approach it is 
possible to quantify the total level of metabolites in cells as well as the 
contribution of the starting metabolite to that pool, which makes it possible to 
obtain an idea of how metabolites move through various pathways.  
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Figure 7.3.1: Steady state levels of metabolites from A549 cells. A549 cells were 
treated with siRNA targeting COASY or scrambled control for 24 hours before placing 
into hypoxia for 48 hours. ‘Heavy’ glucose media was added for final 24 hours before 
lysis and sent to Dr. Daniel Tennant for analysis. Full data set in appendix 
 
The steady state levels of metabolites show a partial phenocopy of the hypoxia 
following loss of CoAsy in 21% O2, this is highlighted in the levels of α-
ketogluturate (αKG), malate and to a lesser extent citrate. Alanine also showed 
this trend, the majority of cellular alanine production occurs through 
transamination of pyruvate. Through analysis of the distribution of isotopomers, 
it is possible to determine the contribution of labeled glucose to each pool, 
which suggests how metabolic pathways are utilized following loss of CoAsy. 
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Figure 7.3.2: Mass isotopomer peaks for indicated metabolite as measured by 
mass spectrometry. Experiment was performed as previously described. Full dataset 
in appendix. 
 
Through analysis of the labeled mass isotopomer ratio it can be seen that 
despite the increase in levels of glycerol 3-phosphate there is no significant 
change in the production, with the majority still being produced from glucose. 
However there is still a large proportion of unlabeled glycerol-3-phosphate from 
each condition (M+0 peak). Two metabolites in the TCA cycle have been 
highlighted here, analysis of citrate shows the M+2 peak shows a reduction in 
labeled glucose following treatment with siCoAsy, as this peak corresponds to 
citrate derived from acetyl-CoA feeding in from pyruvate dehydrogenase it 
212 
 
implies the 2 carbon metabolism is hindered. Comparison of the siScr 
conditions in normoxia and hypoxia reveals an even greater decrease in 
labeled glucose, this is to be expected as it has been well reported the HIF-
mediated upregulation of PDK1 will result in increased phosphorylation of 
PDHA1 and subsequent inhibition of the dehydrogenase complex activity. In 
hypoxia the siRNA against CoAsy displays further reduction in labeling 
suggesting increased impairment of PDH complex activity beyond normally 
observed in hypoxia. Similar results were observed for malate. This leads to 
the question of what is the cellular fate of pyruvate? 
 
Figure 7.3.3: The contribution of glucose to alanine and pyruvate pools in A549 
cells following loss of CoAsy. Mass isotopomer peaks for Pyruvate (A) and Alanine 
(B) as measured by mass spectrometry. Experiment was performed as previously 
described. Full dataset in appendix. 
 
As can be seen in Fig 7.3.3A the majority of pyruvate comes from the labeled 
glucose. There is a small decrease in the glucose derived pyruvate pool 
following exposure to hypoxia, which is further increased with loss of CoA. The 
converse is true of alanine, where the majority of alanine remained unlabeled 
whereas the small labeled proportion indicates an increase of the M+3 
population following loss of CoAsy, which is further increased following 
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exposure to hypoxia thereby suggesting an increased rate of transamination of 
pyruvate. It is important to note that the majority of TCA cycle intermediates 
displayed low levels of labeling with the majority of peaks from M+0 pool, which 
suggests that these cells rely heavily on glutamine as a carbon source. Whilst 
these results give a clue as to the metabolic flux following loss of CoAsy, further 
experiments should be repeated in an alternative cell line and with labeled 
glutamine experiments to compliment these findings. This is of particular 
importance due to the high levels of glutamine dependency observed in 
cultured cancer cells. 
 
One interesting observation in this dataset is the reduction of steady-state 
levels of αKG.  Prolyl-hydroxylase enzymes (PHDs) require αKG as well as O2 
for activity; therefore it stands to reason that this reduction of αKG may result 
in reduced PHD activity and subsequently stabilised HIFα. There is a 
commercially available antibody that specifically recognizes the hydroxylated 
proline residue in HIF-1α (P564), which acts as surrogate readout of PHD 
activity.  
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Figure 7.3.4: Loss of CoAsy does not alter HIF-1α hydroxylation. HeLa cells were 
treated with siRNA against COASY, PHD2 and non-targeting control (40 nM). 72 hours 
post transfection cells were exposed to hypoxia (1% O2) for 0, 4 and 8 hours before 
cell lysis and analysis by western blot (A). Densitometry of hydroxylated HIF-1α was 
quantified using ImageJ and normalysed to HIF-1α band densitometry. N=1. 
 
In HeLa cells loss of CoAsy results in stabilised HIF-1α in both 4 and 8 hours 
of hypoxia as observed in other cell lines (Fig. 7.3.4A). Interestingly, the 
hydroxylated HIF-1α blot also shows increased in the siCoAsy treated cells in 
hypoxia, normalizing the hydroxylated HIF densitometry to total shows that in 
4h (B) of hypoxia there is increased levels compared to scrambled control and 
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no change in 8 hours of hypoxia (C). For this assay the cells were lysed in RIPA 
buffer with EDTA free protease inhibitors, this buffer will completely lyse the 
cells and block protein degradation however some enzymatic activity may 
remain. Therefore the hydroxylation HIF is likely to have occurred post cell lysis 
and reoxygenation of samples whilst samples were being prepared for western 
blot.  Despite this, it is still possible to determine whether hydroxylation is 
inhibited, as knockdown of PHD2 results in a large decrease of P564 
hydroxylation (Fig. 7.3.4B-C). Therefore this datum suggests that loss of 
CoAsy does not impair prolyl hydroxylase activity, despite the reduction in αKG. 
Further experiments are required to test this such as MG132 chase and in vitro 
hydroxylation assays.  
 
7.4 CoAsy regulates HIF-1α stability at the 30-389 and oxygen dependent 
degradation domain (ODDD) 
Analysis of HIF1A and HIF2A mRNA did not show a significant increase 
following loss of CoAsy, therefore it was postulated that the increase in HIF 
protein occurs post transcription. Following this segments of HIF-1α were 
transfected in to A549 cells that had been treated with siRNA against COASY, 
PHD2 and non-targeting control. Following loss of CoAsy there was a 
stabilization of the 30-389 and ODDD domains of HIF-1α with no change 
observed in the C-terminal domain (630-826). Little is known as to how the 30-
389 domain is regulated, such novel findings could present different 
mechanisms of HIF degradation and alternative therapeutic options to target 
HIF signaling. The advantage of these overexpression segments of HIF is that 
they each contain the same promoter and 3’ UTR, thereby ensuring the same 
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transcription and translation initiation occurs for each construct in conditions 
tested. The 30-389 domain contains a number of ubiquitinated residues that 
have been identified via unbiased screening for post-translational 
modifications. However no functional validation has been performed for these. 
Future experiments in determining whether these ubiquitination events are 
altered following loss of CoAsy are key to determining if these are the reason 
for the HIF regulation. The initial experiments to be performed will be 
immunoprecipitation of each segment in cell lines with CoAsy knocked down 
and western blot with α-ubiquitin antibody. Once changes have been 
characterized following loss of CoAsy mutation of each residue will allow for 
mapping of the specific residue or residues affected. This potential mechanism 
opens up potential for targeted therapies; as if there is an associated 
deubiquitinase (DUB) enzyme for these ubiquitination sites that is effected 
following loss of CoAsy, then this DUB poses an attractive candidate for drug 
inhibition.  
 
7.5 Global CoAlation in hypoxia and specific CoAlation of HIF-1α 
Protein CoAlation is a recently identified protein post-translational modification 
that is increased upon redox stress. Due to the previous literature surrounding 
hypoxia and this projects interest in CoA, the impact of hypoxia on CoAlation 
was analysed both basal levels and following redox stress. Treatment with 
menadione and H2O2 greatly increased protein CoAlation in normoxia, however 
exposure to hypoxia reduced protein CoAlation induced by menadione. This 
effect was not observed following treatment with H2O2, indicating that this 
decrease is perhaps a menadione specific effect. However the induction 
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observed following H2O2 treatment was not equal to that observed with 
menadione making cross comparisons difficult between these two treatments 
(see figures 4.4.1-2). Conversely basal levels of CoAlation increased following 
exposure to hypoxia, it has long been established that ROS levels increase 
following exposure to hypoxia therefore it stands to reason this could explain 
the increase in CoAlation. Attempts to identify direct CoAlation of HIF-1α were 
inconclusive. In vitro CoAlation assays showed reactivity with the α-CoA 
antibody, however this could be in part due to the GST tag. IP of endogenous 
HIF-1α from HEK293T cells did not show any signs of specific CoAlation, 
however the basal levels of CoAlation are low within these cells. IP of HIF-1α 
in HEK293-Pank1β cells showed a signal that potentially corresponds to 
CoAlated HIF-1α, however further validation is required. The functional 
consequence of CoAlation is yet to be determined, previous studies have 
shown recombinant enzymes show a reduction of activity following CoAlation 
in in vitro assays, however how this may alter HIF-1α is unclear. CoAlation 
occurs at free thiol groups of cysteine residues, of which a number have been 
identified in the PAS domains of mouse HIF-1α (which share near complete 
amino acid sequence homology) (Fig. 7.5). Therefore it stands to reason that 
HIF-1α could be subject to protein CoAlation, yet the biological significance of 
this is unclear. 
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Figure 7.5: HIF-1α contains exposed cysteine residues in the 30-389 region. 
Crystal structure of mouse HIF-1α (red), HIF-1β (blue) and HRE sequence of DNA 
(brown and blue). Exposed free cysteine Cys169 is highlighted in black. Crystal 
structure PDB number: 4ZPR [229]. Image was prepared using Chimera. 
 
7.6 The role of CoAsy in suppressing tumour aggressiveness  
HIF signaling is a known driver of tumourigenesis across multiple cancer types 
and has been shown to increase tumour burden, cell proliferation, metastasis 
and drug resistance [230-232]. Therefore it stands to reason that increased HIF 
as a consequence of loss of CoAsy will recapitulate this phenotype. In vitro 
assays in A549-tet-shRNA inducible lines showed no difference between the 
shScr and the shCoAsy knockdown lines suggesting that loss of CoAsy and 
subsequent HIF stabilization did not affect tumourigenicity, however increased 
colony formation was observed in T47D cell inducible cell lines. It is unclear 
why this is the case, highlighting differences between both CoAsy and HIF 
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biology between in these cancer lines. In the A549-tet-shRNA there was only a 
modest increase in HIF target genes following loss of CoAsy suggesting that 
this stabilised HIF-1α, whilst this panel needs to be expanded and there was 
large variability in this assay, it indicates that in this cell line the increased HIF 
may not be as active on endogenous genes as on synthetic reporters. This 
could potentially explain why no changes were observed in proliferation or 
clonogenic potential following loss of CoAsy. However the increased 
clonogenic potential observed in T47D cells may not be through HIF activity, 
therefore the experiment should be repeated with knockdown of HIF1A, HIF2A 
or ARNT in order to determine if HIF activity is required and if there is any 
isoform specificity driving this phenotype. Furthermore qRT-PCR analysis of 
HIF target genes following loss of CoAsy in T47D cells should be performed, 
this will show if the stabilised HIF-1α is active in this cell line and if the in vitro 
data corroborates and implies causality to the breast cancer patient data where 
low COASY mRNA expression correlates with increased HIF target gene 
expression.  
 
In addition to the proliferation based assays, wound healing assays were 
performed in the A549-tet-shRNA lines. Once again, no significant differences 
were observed between the two lines. This 2D wound closure assay can 
indicate differences in migration, however the coated plastic plates used for 
standard cell culture does not accurately mimic the extracellular matrix and 
poorly represents true metastasis. To address this transwell migration assays 
were performed whereby cells are plated on top of a thin layer of matrigel in a 
transwell insert (Fig. 7.6A1) and placing in high serum medium (Fig. 7.6A2). 
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Cells then migrate through matrigel (Fig. 7.6A3) before being stained with 
crystal violet and manually counted. 
 
Figure 7.6: Loss of CoAsy increases cell migration through matrigel. A) 
Schematic diagram of transwell matrigel assay, cells are plated on top of a thin layer 
of matrigel (A1) before being placed in to high serum media (A2) to stimulate migration 
(A3). B) Transwell migration assay of A549 and T47D-tet-shRNA lines. Lines were 
pretreated with doxycycline (25 ng.mL-1) for 72 hours before plating and performing 
assay. Bar chart is mean of technical replicates ± SD. Experiment was performed by 
Dr. Miguel Hermida. N=1.   
 
The matrigel invasion assay differs from the 2D assay in that before the cells 
invade through the matrigel the solid matrix must be degraded and space 
created for cells to invade through. In this preliminary experiment, loss of CoAsy 
increases cell invasion through matrigel in both the A549 and T47D lines. Whilst 
further repeats are required to confirm this result, this data indicates that CoAsy 
may curtail cell invasion and metastasis. It is unclear whether this is a result of 
increased HIF signaling; therefore this experiment should be repeated with 
knockdown of HIF1A, HIF2A and ARNT. 
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7.7 CoAsy expression in cancer 
Through various bioinformatics approaches and analysis of CoAsy protein in 
lung tissue it was clear that high CoAsy expression correlated with poor patient 
outcome in lung cancer. There was a difference observed in overall survival 
between the lung adenocarcinoma (LUAD) cohort and lung squamous cell 
carcinoma (LUSC) cohort, whilst neither result was significant, when stratifying 
patients by COASY expression the hazard ratio was 0.79 for LUSC whereas it 
was 1.31 for LUAD. It is unclear why this may be the case; the cell type of origin 
for squamous cell carcinoma is still much debated with tumours postulated to 
arise from the squamous cells lining the proximal airway however LUSC arises 
from neuroendocrine cells. This highlights the importance of cellular context in 
considering CoAsy biology, indeed analysis of transcriptomes of 
adenocarcionmas and squamous cell carcinomas across multiple organ sites 
indicated that the histology represented gene expression variation more than 
organ site [233].  
 
In breast cancer patients there was reduced COASY mRNA expression in 
primary tumour compared to adjacent and surrounding. Furthermore, stratifying 
patients by receptor patients revealed that CoAsy expression (both mRNA and 
protein) correlated with receptor status. In addition to this, low CoAsy 
expression correlated with poor patient outcome. Triple negative breast cancer 
(TNBC) remains an area of unmet need, with chemotherapy used as current 
standard first line treatment. Whilst a number of TNBC patients respond well to 
chemotherapy and appear to display increased sensitivity compared to other 
molecular subtypes of breast cancer, there is still a large subset of patients that 
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do not respond well and have limited therapeutic options [234]. Therefore 
identifying novel targets are of utmost importance. It has been reported that 
TNBC display an increased hypoxic signature, with elevated levels of HIF target 
gene expression [88]. Analysis of TCGA RNA-seq data displayed a significant 
negative correlation between COASY expression and a number of HIF target 
genes. It is unclear as to the relationship between CoAsy expression and HIF 
in TNBC as the only breast cancer cell line with CoAsy levels modified thus far 
has been T47D, which is an ER/PR positive cell line. As most of the TNBC cell 
lines assessed thus far have displayed low basal levels of CoAsy, future work 
should be performed to see if re-expression of CoAsy can reduce the HIF target 
gene expression and pseudo-hypoxic phenotype observed in these cell lines. 
In addition to this, the results show a reduction of COASY mRNA compared to 
adjacent tissue, however it is unclear whether this is observed at the protein 
level or not. The emerging role of protein translation in cancer is becoming 
increasingly well understood; therefore the levels of mRNA may not always 
reflect the protein levels. To address this future experiments should be 
performed to stain for CoAsy in breast TMA containing malignant tissue and 
matched normal tissue to determine if the RNA-seq data from the in-house 
cohort holds true for larger cohorts at the protein level.  
 
So far this work has addressed CoAsy expression in lung and breast cancer, 
however targeting of hypoxic sensitive pathways is of significant interest in 
other cancers such as renal cell carcinoma. A defining event in clear cell renal 
cell carcinoma (ccRCC) is the early loss of chromosome 3p.2, in particular the 
VHL gene [235]; this results in stabilised HIF-1α and HIF-2 protein, interestingly 
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later stage disease also presents with loss of chromosome 14q and the 
subsequent deletion of HIF1A gene and it has been postulated that HIF1A acts 
as a tumour suppressor gene in this cancer [94, 235]. As CoAsy regulates HIF 
through the 30-389 region as well as the ODDD it is unlikely that this occurs in 
a VHL dependent manner as this is known to regulate ubiquitilyation at Lys674 
therefore CoAsy may act as an alternative regulator of HIF in ccRCC.  
 
Figure 7.7: COASY and CoA is lost in ccRCC: A) COASY mRNA expression in 
clear cell renal cell carcinoma patients (ccRCC) taken from TCGA provisional data 
accessed via firebrowse server. B) Log2 of the fold change of concentration of the 
indicated metabolite in tumour vs normal adjacent tissue from clear cell renal cell 
carcinoma patients. 
 
Analysis of RNA-seq data from TCGA provisional dataset from ccRCC patients 
displays a significant reduction of COASY expression in the tumour compared 
to adjacent normal tissue (Fig. 7.7A). Furthermore, published direct 
metabolomics analysis from 20 ccRCC patients and matched adjacent tissue 
displays a significant reduction of CoA levels (~75% reduction) in the tumour 
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samples, suggesting errors in CoA biosynthesis are impaired in tumour (Fig. 
7.7B).  Validation is required to test if CoAsy acts as a negative regulator of HIF 
in ccRCC cell lines however the patient data suggests that this disease is an 
interesting model with significant clinical potential for novel HIF-related targeted 
therapies.  
7.8 Targeting loss of CoAsy in cancer cells 
In order to identify an inhibitor that selectively targets CoAsy deficient cells, a 
library of 1170 FDA approved compounds was screened against A549, T47D 
and MCF10A inducible shRNA lines. The library encompasses a wide array of 
compounds, all of which contain a significant amount of preclinical data. One 
hit identified from the screen was the calcium channel blocker nicardipine HCl, 
which selectively targets the CaV1.2 isoform and is currently approved for 
treatment of hypertension. The first repeat showed ~3 fold selectivity for the 
CoAsy deficient A549 cells, the IC50 for this result was 3.26 µM, whilst the 
affinity of nicardipine HCl for the calcium channel receptor is in the sub 
micromolar range [236], furthermore the free available concentration in plasma 
achieved in patients following administration of 20 mg of nicardipine was ~100 
nM [237], well below that required to kill A549 shCoAsy cells. Therefore 
nicardipine HCl would serve as a poor treatment option in targeting CoAsy 
deficient disease, however the high IC50 implies that the cell death observed is 
occurring by an off target mechanism and suggests that nicardipine may act as 
a tool compound in determining the off-target effect and a more appropriate 
inhibitor can be used. Whilst the subsequent data suggests this was a false 
positive, further cell lines with loss of CoAsy should be tested before fully 
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dismissing this result as false, particularly as selectivity was observed across 
each tested line in the primary drug screen.   
7.9 The role of CoAsy in regulating immune checkpoint blockade 
The field of immunotherapy has grown significantly over recent years with 
successful clinical trials performed across multiple cancer types. The bulk of 
current therapies target the PD-1/PD-L1 axis. Programmed death receptor 1 
(PD-1) is a receptor expressed on activated T-cells which will initiate cell killing 
of neoplastic cells, however many cancers upregulate programmed death 
ligangd 1 (PD-L1) which renders these cells ‘invisble’ to the T-cells upon binding 
of the ligand to the receptor. Thereby inhibiting this interaction through either 
targeting of the receptor or ligand has proven to be successful in treating 
patients. There has been controversy regarding this as recent studies have 
shown that PD-L1 is a poor biomarker for anti-PD1 therapy suggesting 
alternative pathways are at play, however further understanding as to the 
mechanism behind the upregulation of these immune checkpoints is of 
significant interest. It has been reported that CD274, the gene that encodes 
PD-L1, is a hypoxic responsive gene. Therefore it stands to reason that loss of 
a negative regulator of HIF may induce increased PD-L1 expression. Analysis 
of TCGA (provisional) breast cancer dataset displays a significant negative 
correlation between COASY and CD274 (Spearman’s correlation = -0.1948, p< 
0.0001), furthermore a significant correlation was also observed between 
COASY and CTLA4 (Spearmean’s correlation = -0.2279, p < 0.0001), an 
alternative immune checkpoint regulator (Fig 7.9.1A-B). 
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Figure 7.9.1: CoAsy may immune checkpoint blockade: A-B) Correlation of 
COASY with CD274 (A) and CTLA4 (B) mRNA levels. Data taken from TCGA 
provisional breast cancer dataset. C) A549-tet-shRNA cells were treated with 
doxycycline (25 ng.mL-1) for 72 hours before being placed into hypoxia for 8 hours and 
cell lysis. N=1. D) A549 cells stably expressing Cas9 were transfected with crRNA 
against CoAsy or non-tareting control. Clones were selected and analysed by western 
blot. N=1. 
 
To test directly if loss of CoAsy regulates PD-L1 protein expression, A549-tet-
shRNA lines were treated with doxycycline to induce knockdown and cultured 
in normoxia or hypoxia (Fig. 7.9.1A). In addition to this a number of A549 lines 
that were edited with CRISPR/Cas9 to produce a hypermorphic form of CoAsy 
that is expressed at significantly lower levels were tested in normoxia (Fig. 
7.9.1B). In both cases loss of CoAsy resulted in increased levels of PD-L1 
protein. It is unclear if this is a HIF-dependent increase in protein. As patient 
data shows a negative correlation between COASY and CD274 mRNA, the 
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upregulation is likely to occur at the transcriptional level and may be via HIF 
activity however direct validation is required to test this. Furthermore this 
requires validating in a wider range of cell types and an increased repertoire of 
immune checkpoint regulators such as CTLA-4 and IDO.  Nevertheless, this 
initial finding offers up the exciting prospect of a novel regulator of immune 
checkpoint in tumour cells. 
 
Figure 7.9.2: CoAsy expression is higher in infiltrating lymphocytes. 
Representative cores from lung TMA stained with anti-CoAsy pAb. A) Core shows 
weakly stained tumour cells surrounded by lymphocytes, highlighted region on the left 
and tumour cells on the right. B) Core shows weakly stained tumour cells from 
infiltrating lymphocytes displaying increased staining intensity. Scale bars indicate 250 
μM. 
 
Staining of the lung TMA showed increased CoAsy protein present in infiltrating 
lymphocytes (Fig. 7.9.2A). It was not possible to determine the lineage of these 
infiltrating cells as no counterstain was performed for specific markers, however 
in cores where the immune cells did not invade the tumour cells the staining 
was less intense (Fig. 7.9.2B). There are multiple possible explanations for this 
change. One possibility is the requirement for increased cellular CoA in 
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infiltrating and activated immune cells, as increased CoAsy may shift CoA 
homeostasis in these cells. Another possibility is the role of CoA in controlling 
macrophage polarization. Recent studies have identified that the 
cardiovascular drug etoxomir inhibits macrophage polarization (by IL-4) at high 
concentrations as a direct consequence of depleting intracellular CoA levels. 
The authors did not fully determine the molecular mechanism behind how CoA 
regulates macrophage polarization, however there is potential for this to occur 
through a HIF dependent pathway as HIF signaling has been shown to be 
crucial for both M1 and M2 macrophage activation. 
 
7.10 Concluding remarks 
Through this work we have identified CoAsy as a novel negative regulator of 
HIF-1α and HIF-2α at the post-translational stage. Whilst the mechanism 
behind this regulation is not known as of yet, the regions of HIF most affected 
have been identified, one of which contains a number of uncharacterized post-
translational modifications. The datum further suggests that this occurs through 
depletion of CoA or CoA derivatives; whilst a number of metabolites have been 
identified as regulators of HIFs there has been no reports of CoA homeostasis 
being linked to hypoxic signaling. Analysis of patient samples highlighted loss 
of CoAsy in breast cancer, particularly in triple negative breast cancer. 
Furthermore, the in vitro experiments showed that CoAsy can regulate HIF in 
multiple cancer types which suggests that this biology may extend to other 
cancer types, indeed we have further shown that COASY is lost in ccRCC 
tumours compared to adjacent normal tissue. Furthermore we have performed 
a drug screen to identify an inhibitor that selectively targets CoAsy deficient 
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cells; whilst no specific inhibitor has been validated yet, a number show 
potential in developing a targeted therapy against CoAsy deficient cancers. 
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8. Appendix 
8.1 Alternative biological replicate for A549-tet-shRNA KD 
 
 
Figure 8.1: Knockdown of CoAsy in A549-tet-shRNA cells. A549-tet-shRNA 
inducible lines were plated before being treated with 25 ng.mL-1 doxycycline for 72 
hours. Cells were exposed to hypoxia for 0, 4 or 8 hours hypoxia before cell lysis and 
analysis by western blot. 
 
 
 
 
8.2 Alternative graphical representation of qRT-PCR data from figure 
3.1.6.5 
 
 
 
Figure 8.2: qRT-PCR analysis of HIF target genes and HIF1A and HIF2A mRNA 
levels. A549 cells were treated with doxycycline (25 ng.mL-1) for 72 hours before being 
placed in hypoxia for 0 (A), 4 (B) or 8 (C) hours before cell lysis and analysis by qRT-
PCR. Results are mean ± SD. n=4. Statistical tests are multiple T-tests with Holm-
Sidak method. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
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8.3 Alternative biological replicate of HEK293-Pank1β treated with H2O2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3: Alternative biological replicate of HEK293-Pank1β treated with H2O2. 
Non-reducing western blot analysis of Protein CoAlation in hypoxia following H2O2 
treatment. HEK293-Pank1β cells were cultured in 1% O2 for 0, 4 and 8 hours before 
treating with 500 µM of H2O2 for the final 30 minutes of incubation before cell lysis. 
 
8.4 Remaining two biological replicates for T47D clonogenic assay 
 
Figure 8.4: Colony assay of T47D-tet-shRNA cell lines. T47D-tet-shRNA cells were 
pretreated with doxycycline before replating at 100 cells per well in 6 well plates before 
culturing for 10 days in 21% O2 or 1% O2. Colonies were fixed stained and counted. A 
and B represent individual biological replicates to accompany figure 4.5.5 
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8.5 Full data set from 13C Glucose tracer experiments 
 
 
Figure 8.5.1: Steady state levels of metabolites from A549 cells. A549 cells were 
treated with siRNA targeting COASY or scrambled control for 24 hours before placing 
into hypoxia for 48 hours. ‘Heavy’ glucose media was added for final 24 hours before 
lysis and sent to Dr. Daniel Tennant for analysis 
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Figure 8.5.2: Mass isotopomer peaks for indicated metabolite as measured by 
mass spectrometry. Experiment was performed as previously described. 
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